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Screening women aged 65 years or over for abdominal
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Background: Abdominal aortic aneurysm (AAA) screening programmes have been established for men in
the UK to reduce deaths from AAA rupture. Whether or not screening should be extended to women
is uncertain.
Objective: To evaluate the cost-effectiveness of population screening for AAAs in women and compare a
range of screening options.
Design: A discrete event simulation (DES) model was developed to provide a clinically realistic model of
screening, surveillance, and elective and emergency AAA repair operations. Input parameters specifically
for women were employed. The model was run for 10 million women, with parameter uncertainty
addressed by probabilistic and deterministic sensitivity analyses.
Setting: Population screening in the UK.
Participants: Women aged ≥ 65 years, followed up to the age of 95 years.
Interventions: Invitation to ultrasound screening, followed by surveillance for small AAAs and elective
surgical repair for large AAAs.
Main outcome measures: Number of operations undertaken, AAA-related mortality, quality-adjusted
life-years (QALYs), NHS costs and cost-effectiveness with annual discounting.
Data sources: AAA surveillance data, National Vascular Registry, Hospital Episode Statistics, trials of
elective and emergency AAA surgery, and the NHS Abdominal Aortic Aneurysm Screening
Programme (NAAASP).
Review methods: Systematic reviews of AAA prevalence and, for elective operations, suitability for
endovascular aneurysm repair, non-intervention rates, operative mortality and literature reviews for
other parameters.
Results: The prevalence of AAAs (aortic diameter of ≥ 3.0 cm) was estimated as 0.43% in women aged
65 years and 1.15% at age 75 years. The corresponding attendance rates following invitation to screening
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were estimated as 73% and 62%, respectively. The base-case model adopted the same age at screening
(65 years), definition of an AAA (diameter of ≥ 3.0 cm), surveillance intervals (1 year for AAAs with
diameter of 3.0–4.4 cm, 3 months for AAAs with diameter of 4.5–5.4 cm) and AAA diameter for
consideration of surgery (5.5 cm) as in NAAASP for men. Per woman invited to screening, the estimated
gain in QALYs was 0.00110, and the incremental cost was £33.99. This gave an incremental cost-
effectiveness ratio (ICER) of £31,000 per QALY gained. The corresponding incremental net monetary
benefit at a threshold of £20,000 per QALY gained was –£12.03 (95% uncertainty interval –£27.88 to
£22.12). Almost no sensitivity analyses brought the ICER below £20,000 per QALY gained; an exception
was doubling the AAA prevalence to 0.86%, which resulted in an ICER of £13,000. Alternative screening
options (increasing the screening age to 70 years, lowering the threshold for considering surgery to
diameters of 5.0 cm or 4.5 cm, lowering the diameter defining an AAA in women to 2.5 cm and
lengthening the surveillance intervals for the smallest AAAs) did not bring the ICER below £20,000 per
QALY gained when considered either singly or in combination.
Limitations: The model for women was not directly validated against empirical data. Some parameters
were poorly estimated, potentially lacking relevance or unavailable for women.
Conclusion: The accepted criteria for a population-based AAA screening programme in women are not
currently met.
Future work: A large-scale study is needed of the exact aortic size distribution for women screened at
relevant ages. The DES model can be adapted to evaluate screening options in men.
Study registration: This study is registered as PROSPERO CRD42015020444 and CRD42016043227.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Abdominal aortic aneurysms (AAAs) are bulges in the main blood vessel in the abdomen. An AAA thatgets too large can burst (rupture), an event that is usually fatal. Although AAAs do not usually cause
any symptoms and are unlikely to cause problems until they burst, they can be easily diagnosed by simple
ultrasound screening. In the UK, men aged 65 years are offered ultrasound to look for an AAA, and just
over 1 in 100 men who are screened are found to have an AAA. If the AAA is large, men are offered
an operation to prevent the aneurysm bursting; if it is small, they are offered regular scans to monitor
their AAA.
Women are not currently screened for AAAs, mainly because they are less likely than men to have AAAs.
Currently, there is no information on whether or not screening women for AAAs would save lives by
preventing AAA rupture, or if such a screening programe would be cost-effective for the NHS. In this
research, we have gathered together a wide range of available information about AAAs in women to find
out if screening women for AAAs might be effective. We have developed a computer program to analyse
all of this information and simulate what would happen if women were screened for AAAs.
Our research showed that offering women the same screening as men would have a very minor effect on
the overall life expectancy of women, resulting in an average of just over 1 extra day of life for each woman
invited to screening. Although there is considerable uncertainty, we estimate that around 4100 women
would need to be invited to screening to prevent one death from AAAs, and that each death prevented by
screening women for AAAs would cost the NHS £150,000.
Based on our findings, a national AAA screening programme for women would not be cost-effective for
the NHS.
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Scientific summary
Background
The NHS Abdominal Aortic Aneurysm Screening Programme (NAAASP) was initiated for men in England
and later extended to all of the UK following the large Multicentre Aneurysm Screening Study (MASS)
randomised trial in men and subsequent health economic modelling. For women, there has been only
one small randomised trial of abdominal aortic aneurysm (AAA) screening. AAA screening in women
has not been considered worthwhile because the prevalence of AAAs (aortic diameter of ≥ 3.0 cm) in
women is substantially lower than in men. However, modelling suggests that NAAASP would still be
cost-effective for women at a threshold of £20,000 per quality-adjusted life-year (QALY) even down to
an AAA prevalence of 0.35%. Moreover, one-third of deaths from AAA in the UK are now in women.
Hence, the cost-effectiveness of AAA screening in women needs to be formally assessed.
Objectives
The scientific objectives of this project were to:
1. adapt a previous multistate model of AAA screening in men to create a more flexible discrete event
simulation (DES) model
2. obtain information from published literature, where possible, on input parameters for this model
relevant to women rather than men
3. seek other information or data sources on input parameters for women that are not available in the
published literature
4. run the model for women to estimate life-years gained, incremental costs and incremental
cost-effectiveness for a population-based AAA ultrasound screening programme in women, and assess
the impact of parameter uncertainty on the conclusions using probabilistic and deterministic
sensitivity analyses
5. assess modifications that might make a screening programme more appropriate and cost-effective
for women.
Methods
A DES model was developed using the R programming language (The R Foundation for Statistical
Computing, Vienna, Austria) to provide a clinically realistic model of screening, surveillance, AAA growth
and rupture, elective and emergency AAA repair operations, and deaths from AAAs and non-AAA causes.
This was validated for men against the MASS trial. Input parameters specifically for women were then
employed. To obtain sufficient precision, the model was run for 10 million women. Parameter uncertainty
was addressed by sensitivity analyses, both probabilistic (1000 runs of 500,000 women) and deterministic
(runs of 10 million women).
Systematic reviews were undertaken, following Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines, for key parameters in women. These included AAA prevalence at
different ages and parameters related to elective surgery [proportion suitable for endovascular aneurysm
repair (EVAR), non-intervention rate and operative mortality following endovascular and open AAA repair].
We also carried out literature reviews of attendance rates following invitation to attend screening, of
non-intervention rates and of outcomes for emergency surgery for ruptured AAAs.
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Rates of aortic diameter expansion and AAA rupture were estimated using individual data from an
international collaboration of AAA surveillance, using multilevel and joint modelling, respectively.
Anonymised individual data from the UK National Vascular Registry (NVR) were analysed to estimate
parameters related to elective and emergency AAA operations in women (proportion receiving
endovascular repair and operative mortality rates) and how these depended on age and AAA diameter.
Summarised tabular data from the English Hospital Episode Statistics (HES) database were used to
cross-check estimates from the NVR, and provide up-to-date information on hospital length of stay
(LOS) for AAA operations. Data from the endovascular aneurysm repair trial 1 (EVAR-1) and Immediate
Management of Patients with Ruptured aneurysm: Open versus Endovascular Repair (IMPROVE) trial were
used to provide estimates of long-term AAA mortality and reintervention rates after AAA surgery.
Costs were considered from a NHS perspective. Those related to screening and surveillance were obtained
from NAAASP. Costs related to surgery and reinterventions were derived from the individual patient data
in the EVAR-1 and IMPROVE trials, supplemented by hospital LOS data from HES. Costs were adjusted to
2014–15 prices. Utility adjustments for quality of life (QoL) were based on age alone.
Models were run for women aged ≥ 65 years, up to age 95 years. Discounting at 3.5% per year was
applied to costs and life-years. The base-case model adopted the same age at screening (65 years),
definition of AAA (diameter of ≥ 3.0 cm), surveillance intervals (1 year for AAAs with a diameter of
3.0–4.4 cm, 3 months for AAAs with a diameter of 4.5–5.4 cm) and AAA diameter for consideration
of surgery (5.5 cm) as in NAAASP for men, and used surgical parameters based on the overall estimates
from the NVR. Other options for a screening programme were also investigated to try to improve
cost-effectiveness.
Results
The DES model had a similar structure to a previous multistate Markov model for AAA screening based
on the MASS trial, but was much more sophisticated. It modelled individuals in continuous time, aortic size
was considered as a continuous variable and the model allowed the flexibility to change screening options
such as the intervention threshold. The model validated as well against the MASS data as the original
Markov model in terms of numbers of key events and yielded an incremental cost-effectiveness ratio
(ICER) estimate for men in NAAASP of £6400 per QALY gained as compared with £7400 from the
Markov model.
The prevalence of AAAs (aortic diameter of ≥ 3.0 cm) was estimated from the first systematic review as
0.43% [95% confidence interval (CI) 0.23% to 0.80%] in women aged 65 years and 1.15% (95% CI
0.59% to 2.24%) at age 75 years. The corresponding attendance rates following invitation to screening
were estimated as 73% and 62%, respectively. In the systematic reviews for elective operations, women
were shown to fare worse than men in all respects: the proportion suitable for EVAR was 34% (95% CI
25% to 44%), lower than in men (54%); the non-intervention rate was 34% (95% CI 28% to 40%),
higher than in men (19%); and 30-day mortality was 2.2% (95% CI 1.9% to 2.7%) following EVAR and
5.4% (95% CI 4.2% to 6.9%) following open AAA repair, both of which are higher than in men
(1.3% and 2.8%, respectively).
Based on the international AAA surveillance data, aortic diameters in women were estimated to increase
on average by 5.3% per year, with a standard deviation (SD) between individuals of 3.8%. Rupture rates
were 4.3 times higher in women than in men, and increased by 31% for each 5% increase in AAA
diameter, being 0.17 and 4.6 per 100 woman-years at 3.0 cm and 5.5 cm, respectively.
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Based on women in the NVR, for elective operations, the proportion receiving EVAR increased greatly with
age but decreased somewhat with AAA diameter, and open AAA repair mortality increased with age.
For emergency operations of ruptured AAAs, operative mortality increased with age for both endovascular
and open repair. The cost of elective operations was higher in women than men owing to a longer
hospital LOS.
For the base-case model, invitation to screening increased elective operations by 21%, lowered emergency
operations by 4% and decreased AAA deaths by 3%. Per one woman invited to screening, the estimated
gain in life-years was 0.00285, the gain in discounted QALYs was 0.00110 and the discounted incremental
cost was £33.99. This gave an ICER of £31,000 per QALY gained. The corresponding incremental net
monetary benefit (INMB) at a threshold of £20,000 per QALY was –£12.03 (95% uncertainty interval
–£27.88 to £22.12).
The deterministic sensitivity analyses halved or doubled the AAA prevalence, halved or doubled the rates of
dropout from surveillance and incidental AAA detection, included the dependence of surgical parameters
on age and AAA diameter, based surgical parameters on the literature reviews, and altered the unit costs
of screening and operations downwards by 20% or upwards by 25%. None of these analyses brought the
ICER below £20,000 per QALY gained, except when modifying the distribution of aortic diameters at
screening; for example, doubling the AAA prevalence to 0.86% gave an ICER of £13,000.
In the investigation of alternative screening options, increasing the age at screening to 70 years gave an
ICER of £24,000 per QALY gained. Lowering the threshold for considering surgery to a diameter of 5.0 cm
or 4.5 cm gave ICERs of £28,000 and £27,000 per QALY gained, respectively. Lowering the diameter
defining an AAA in women to 2.5 cm, together with 5-year surveillance intervals for the 2.5- to 2.9-cm
group, gave an ICER of £25,000 per QALY gained. Putting together the options of screening at age 70
years, considering surgery at a diameter of 5.0 cm, and including the 2.5- to 2.9-cm group in surveillance,
gave an ICER of £23,000 per QALY gained. The corresponding INMB at a threshold of £20,000 per QALY
was –£5.08 (95% uncertainty interval –£31.53 to £69.98).
Conclusions
The conclusion of our analyses is that the accepted criteria for a cost-effective AAA screening programme
in women are not currently met. We did not find any combination of screening options for women that
would make population AAA screening cost-effective at a willingness-to-pay threshold of £20,000 per
QALY. This is in marked contrast to previous findings in men.
The DES model developed for this project was novel in a number of respects. First, because it considered
individuals rather than groups, aortic diameter expansion could be more precisely represented, allowing
for the substantial heterogeneity between people in growth rates. Moreover, and importantly in the
context of investigating AAA screening for women, it allowed the modelling of different screening options,
which would not be feasible in a single multistate model. The downside of individual modelling is the
computational requirements, as millions of individuals have to be modelled to ensure that the results
obtained are reliable.
The systematic review of AAA prevalence was of key importance to this project. However, the available data
in women were rather limited and complicated by studies having been undertaken in different calendar years
that used different screening approaches and ultrasound measurement techniques. In addition, individual
data on aortic size distribution were available from only two modestly sized studies: (1) a Swedish study of
5140 women aged 70 years and (2) a Danish study of 570 women aged 67 years; this limited the exact
description of the aortic diameter distribution in women. As revealed by a sensitivity analysis using the
Swedish data, this may have a considerable impact on the cost-effectiveness estimates.
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Based on the international AAA surveillance data, the AAA rupture rate in women increased by about
30-fold when the AAA diameter increased from 3.0 cm to 5.5 cm, and the AAA rupture risk in women
was about fourfold that of men at the same AAA diameter. This might lead one to propose that the
threshold for surgery for women should be lowered to a diameter of 4.5 cm, as this might give a similar
balance of risk and benefit as the 5.5-cm diameter threshold for men. However, because of the worse
elective surgery outcomes in women, the cost-effectiveness based on 4.5-, 5.0- or 5.5-cm diameter
thresholds for women were very similar.
The analysis of the individual data for women in the NVR was important in a number of respects. First, it
substantiated in recent UK data the overall higher mortalities in women than men for elective operations,
as found in the systematic review. Second, it showed that the proportion of patients actually receiving
elective EVAR was lower in women than men, which paralleled the difference in the proportion suitable
for EVAR found in the systematic review. Third, it provided reliable estimates of these parameters for
emergency surgery for ruptured AAAs, while the literature review undertaken for emergency surgery was
less detailed. Fourth, it allowed the modelling to include dependence of these parameters on age and AAA
diameter for elective operations, and on age for emergency operations.
The base-case cost-effectiveness analysis showed that the average number of life-years gained per woman
invited was very small: 0.00285 life-years or 1.04 life-days. A small average life-years gain is expected in
population screening as the vast majority of those screened have normal aortic diameter and no change
in life expectancy. Nevertheless, this very small gain in life-years is the main reason for the unfavourable
cost-effectiveness results. Using National Institute for Health and Care Excellence (NICE) recommended
discounting for costs and life-years, the ICER per QALY gained was estimated as £31,000. This is above the
threshold of £20,000 generally used by NICE as a basis for approving health interventions for use in the
NHS. The sensitivity analyses did not change this conclusion, but also underlined the pivotal role of AAA
prevalence in determining the ICER. When the AAA prevalence was doubled, from 0.43% to 0.86%,
the ICER fell below £20,000 per QALY gained. Moreover, the uncertainty indicated by the probabilistic
sensitivity analysis was considerable.
Screening women for AAA might become more cost-effective if one moved away from the options
adopted in NAAASP for men. Screening became more cost-effective if offered at age 70 years. Lowering
the threshold for defining an AAA to a diameter of 2.5 cm, lengthening surveillance intervals somewhat
for the smallest AAAs, or lowering the threshold for considering elective surgery made AAA screening for
women slightly more cost-effective, but these changes considered individually did not bring the ICER down
below £20,000 per QALY gained. Even when the best options were combined, the estimated ICER was
£23,000 per QALY gained.
The study undertaken had a number of strengths:
l the use of individual simulation modelling, which allowed evaluation of multiple screening options
l modelling aortic diameter as a continuous variable
l the use of women-specific parameters wherever possible
l systematic reviews undertaken for key parameters
l extensive re-analysis of data sources.
The study also had some limitations:
l lack of validation of the model against empirical data for women
l the problem that some parameters were poorly estimated or not specifically available for women
l the relevance of some parameter values to current women in the UK was uncertain.
SCIENTIFIC SUMMARY
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Our main recommendations for future research are:
1. Undertake a large-scale empirical study of the current attendance rate at screening, AAA prevalence
and exact aortic size distribution for women screened at relevant ages. This could include the
investigation of whether or not AAA screening, and positive or negative results, influence QoL.
2. Capitalise on the development of the DES model by evaluating screening options in men, to assess
whether or not NAAASP could be improved.
Study registration
This study is registered as PROSPERO CRD42015020444 and CRD42016043227.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and aims
In the UK, ultrasonographic screening for abdominal aortic aneurysms (AAAs) is currently offered to menaged 65 years but not to women. Until recently, the prevalence of AAAs in women was substantially
lower than that for men.1 However, women now account for 34% of all deaths due to ruptured AAA.2
AAA ruptures are fatal in about 80% of cases and women with a small AAA have been found to have a
fourfold higher risk of rupture than men.3 Moreover, the prevalence of smoking has been rising in younger
women, and so, in the future, AAAs may become even more common in women.
Thus, research is needed to assess the cost-effectiveness of screening women for AAAs. Only one study,4
published in 2006, has attempted to address this question; this modelling study was based on a prevalence
of AAA in women of 1.1% and suggested that screening may be cost-effective at US$6000 per life-year
gained. However, more data are now available to inform such modelling, and a more sophisticated and
realistic model can be used to provide more reliable results. One of the conclusions of the literature review
undertaken by LeFevre and the US Preventive Services Task Force5 was that high-quality modelling studies
need to be conducted to determine whether or not AAA screening is beneficial in women. An international
consensus group6 also identified that targeted AAA screening of women is an area for future development
to reduce deaths from AAAs. Furthermore, there is international debate regarding the optimal clinical
management strategy for women who have been diagnosed with an AAA.7
Population-based screening for abdominal aortic aneurysms
Screening men for abdominal aortic aneurysms
The NHS Abdominal Aortic Aneurysm Screening Programme (NAAASP)8 for men aged 65 years was
launched in England in 2009, and similar programmes have subsequently been introduced to other parts
of the UK. In NAAASP, an aortic diameter of ≥ 3.0 cm, as measured by ultrasound, is used as a diagnosis of
an AAA. Men with smaller aortic diameters are reassured and not followed up further. Men with AAAs of
3.0- to 4.4-cm diameter enter a surveillance programme with annual follow-up scans, while those with
AAAs of diameter 4.5–5.4 cm have follow-up scans every 3 months. Men with AAAs whose diameter is
initially ≥ 5.5 cm, or which expand to that diameter during surveillance, are referred for consideration of
elective surgery.
The scientific evidence supporting the implementation of NAAASP came from the results of four randomised
trials9 of AAA screening that almost exclusively recruited men. These trials showed that AAA-related mortality
in men could be halved by offering AAA screening along with appropriate clinical follow-up that included
elective surgery when an AAA reached a threshold size. Long-term modelling based on the largest of these
trials, the Multicentre Aneurysm Screening Study (MASS),10 showed that AAA screening in men aged 65 years
was extremely cost-effective, with an estimated cost of £3000 per quality-adjusted life-year (QALY) gained.11
This cost-effectiveness estimate came under scrutiny later, because initial data from NAAASP8 showed an
AAA prevalence of 1.5% in men aged 65 years, rather than 4.9% as observed in the MASS trial.10 Revision
of the long-term model to reflect this lower prevalence as well as the attendance rates observed in
NAAASP and updated cost estimates increased the cost per QALY. Nevertheless, NAAASP was still
estimated to be highly cost-effective, at £7400 per QALY gained.12 Indeed, provided the AAA prevalence
was above 0.35%, it was estimated that screening would be cost-effective at a willingness to pay (WTP) of
£20,000 per QALY. This could imply that screening women for AAAs might also be cost-effective.
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Screening women for abdominal aortic aneurysms
The prevalence of AAAs in women aged 65 or 70 years may be around 0.5%.13–15 Moreover, it is known
that women have an AAA rupture rate about fourfold of that in men for a given AAA diameter,3 although
their AAA growth rates are similar.16 Women may also have worse outcomes after AAA surgery than
men,17,18 for example, because of their typically shorter aneurysm necks.19 A higher proportion of women
are turned down for both elective and emergency surgery.20 Some of these differences between women
and men would probably favour systematic AAA screening in women, whereas others would not.
There are a number of reasons why the design of an optimal AAA screening programme for women might
differ from that currently adopted for men. The prevalence of AAA increases with age, and women have
a greater life expectancy than men, so screening women at age 70 years might be more beneficial than
screening them at age 65 years. The diameter of the aorta ss typically smaller aortic in women than in
men,21 and the aortic diameter that define an aneurysm could be lowered from the conventional 3.0 cm.
Because AAA rupture rates are higher in women, it may be advisable to reduce the diameter threshold for
considering elective surgery below the usual 5.5 cm.
There is no prospect of being able to undertake a randomised trial to answer these questions in women.
First, such a trial would have to be an order of magnitude bigger than the MASS trial10 of 68,000 men and
with a similar length of follow-up (13 years).22 Second, a single trial could not address the relative merits
of different designs of a screening and intervention programme. The best practical way in which these
questions can be addressed is by undertaking a detailed modelling exercise, which is described here.
Aims and objectives
The overall aim is to estimate the cost-effectiveness of systematic population-based AAA screening for
women. Offering ultrasound screening for AAAs to women is compared with a policy of no systematic
screening. Outcomes are in terms of AAA-related mortality, life expectancy, elective AAA operations,
emergency AAA operations, costs and cost-effectiveness. Cost-effectiveness is expressed as cost per
life-year gained and, using age-dependent quality-of-life (QoL) norms, cost per QALY gained.
Some input parameters are very uncertain, or even unknown, for women. Therefore, a key component of
the research is to evaluate the uncertainty in conclusions by both probabilistic and deterministic sensitivity
analyses. In addition, some possible departures from the design of the AAA screening programme in men
are evaluated.
Although this project has a UK focus, its results have implications for the development of AAA screening
programmes internationally, as is evident, for example, from the recent recommendations on AAA
screening from the US Preventive Services Task Force.5
Scientific objectives
Objective 1
To adapt a previously validated multistate model of AAA screening in men as a more flexible individual
simulation model (see Chapter 2).
The work is based on adapting the previously developed long-term Markov model based on the MASS trial.10
However, as the design of an optimal AAA screening programme for women may require some quite
substantial modifications compared with that adopted for men, it is necessary first to translate the existing
model into the more flexible format of an individual simulation model. This enables relevant potential
modifications (e.g. regarding age at screening, surgical threshold or surveillance intervals) to be more easily
and efficiently assessed.
BACKGROUND AND AIMS
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Objective 2
To obtain information from the published literature, where possible, on input parameters for this model,
relevant to women rather than men (see Chapter 3).
Information on parameters for women, often from outside the UK, is available in published papers. These
include the prevalence of AAAs in women in Sweden14 and operative mortality rates after rupture.23,24 The
most recent systematic review of mortality following elective surgery was published in 2010;25 this needs to
be updated to provide further evidence for endovascular aneurysm repair (EVAR). New systematic reviews
to assess the proportion of women suitable for EVAR, with currently available endografts, and the rates of
non-intervention for elective AAA repair are also necessary.
Objective 3
To seek other information or data sources on input parameters for women that are not available in the
published literature (see Chapters 4–6).
In the case of some parameters, little or no published information relates specifically to women. This
applies to the proportion of elective and emergency AAA operations that are carried out by EVAR rather
than by open repair (a key issue for costs and maybe effects), as well as long-term AAA mortality after
repair. Hence, we search out data sources that might provide relevant estimates, including the UK National
Vascular Registry (NVR),26 the international Vascunet database27 and the English Hospital Episode Statistics
(HES).28 We also obtain additional information on women specifically from particular studies, for example,
about reintervention rates after surgery and resource use for costing purposes, from the endovascular
aneurysm repair trial 1 (EVAR-1)29 and Immediate Management of Patients with Ruptured aneurysm: Open
versus Endovascular Repair (IMPROVE)30 trial. Dropout rates from surveillance were obtained from local
audit data in Leicester (Professor Matthew J Bown, University of Leicester, 2016, personal communication)
and London (Professor Janet T Powell, Imperial College London, 2016, personal communication).
Objective 4
To run the adapted model for women to estimate cost-effectiveness and to assess the impact of parameter
uncertainty on the conclusions using probabilistic and deterministic sensitivity analyses (see Chapter 7).
We first provide cost-effectiveness estimates for women based on the same screening programme design
as used in NAAASP.8 Given new values of the input parameters for women, we run the model to obtain
estimates of AAA-related mortality, all-cause mortality, numbers of elective and emergency operations, life
expectancy and costs. In addition, by using age-related population norms for QoL,31 we also estimate quality-
adjusted life expectancy. The principal results are reported as incremental cost-effectiveness ratios (ICERs) in
terms of Great British pounds (£) per QALY gained or incremental net monetary benefit (INMB). Many of the
input parameters have uncertainty intervals that are used in a probabilistic sensitivity analysis (PSA), thus,
providing an uncertainty interval for the estimated cost-effectiveness. Deterministic sensitivity analyses (DSAs)
are used to explore the impact of different choices of parameter values on the incremental costs, effects
and ICERs.
Objective 5
To assess modifications of the AAA screening programme used for men that may be more appropriate and
cost-effective for women (see Chapter 8).
Some of the design characteristics might be altered to provide a screening programme that is more
appropriate for women, with potentially greater cost-effectiveness. A number of aspects are considered:
(1) increasing the age at which screening is offered, (2) lowering the threshold AAA diameter at which
elective surgery is considered, (3) lowering the aortic diameter that defines an AAA, (4) lengthening the
surveillance intervals for the smallest AAAs and (5) evaluating rescreening of all women at a later age.
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Patient and public involvement group
At the outset of the project, there were no aneurysm-related projects in the INVOLVE database.32
Therefore, we established a female patient and public involvement (PPI) group to provide project-specific
input and help direct the dissemination of the outputs from this research project (see Appendix 1). The PPI
group was used to monitor the progress of the project, assist in interpretation of results from a lay
perspective and help prepare the Plain English summary. The PPI group now forms an ongoing resource
for future work in this area.
Modified objectives
Two objectives set out in the original grant application have not been pursued. One is related to the
evaluation of targeted AAA screening of at-risk groups of women, for example, female smokers or those
with a family history of AAAs. This objective was not pursued for three reasons. First, the PPI group expressed
a strong view against the idea of selective screening of women (see Appendix 1) and very much favoured a
population-based approach. Second, it became apparent that it was already difficult to find information on
key model parameters for women in general. It would be even harder to find evidence relevant to specific
high-risk groups. For example, it might be anticipated that smokers would differ from the general population
in terms of AAA prevalence, rates of attendance at screening, AAA growth and rupture rates, incidental
detection and dropout rates, operative mortalities, costs of surgery and reinterventions, and non-AAA
(competing) mortality; estimates of all these parameters would be necessary to evaluate the cost-effectiveness
of AAA screening for female smokers. Third, AAA mortality in other women (e.g. non-smokers) would be
unaltered, raising issues of both overall effectiveness at the population level and of societal equity.
The second of the original objectives was to estimate the expected value of obtaining more information on
influential parameters, for which estimated values are very imprecise in women. This objective was also not
pursued for two reasons. First, it became clear that there was a more fundamental problem of whether
or not certain parameter estimates obtained were fully relevant for current women in the UK; it was not
just an issue of their imprecision. Second, and as agreed with the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme at an interim progress report, the computational
demands of undertaking such expected value of information analyses within a complex individual
simulation model were too great, and the research should be focused on the more crucial objectives.
Input parameters required
A clinically realistic model for AAA screening is complex (see Chapter 2), and has many input parameters
that require estimation. The parameters include those related to screening, AAA growth and rupture,
and surveillance (Table 1); elective and emergency operations (Table 2); and parameters reflecting costs,
QoL and competing mortality from non-AAA causes (Table 3). These tables indicate the sections in
Chapters 3–6 of this report that describe the way in which these parameters are estimated.
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TABLE 1 Parameters and sources of information for modelling AAA screening in women and sections in the report
where the work is described: screening, AAA growth and rupture, and surveillance
Parameter Assumptions Sources of data Section of report
Screening
Reinvitation proportion Applies to all ages NAAASP8 Chapter 4, Screening
Attendance proportion Varies with age Literature review,
Uppsala14 and
Chichester33
Chapter 4, Screening
Non-visualisation
proportion
Applies to all ages NAAASP8 Chapter 4, Screening
AAA size distribution
at screening
Depends on prevalence NAAASP,8 Uppsala14
and Viborga
Chapter 4, Screening
Prevalence proportion Varies according to age
at screening
Systematic review34 Chapter 3, Current prevalence of
screen-detected abdominal aortic
aneurysm in women and Chapter 4,
Screening
AAA growth and rupture
AAA growth Based on underlying
AAA diameter plus
measurement error
Women in 11 RESCAN
surveillance studies35
Chapter 4, Growth and rupture
rates of abdominal aortic aneurysm
in women
AAA rupture Based on underlying
AAA diameter
Women in six RESCAN
surveillance studies35
Chapter 4, Growth and rupture
rates of abdominal aortic aneurysm
in women
Surveillance
Surveillance intervals Varies with measured
AAA diameter
MASS10 and NAAASP8 Chapter 1, Population-based
screening for abdominal aortic
aneurysm
Dropout rate from
surveillance
Assumed constant NAAASP,8 Leicesterb
and Imperialc
Chapter 4, Surveillance
Incidental detection
rate
Assumed constant New Zealand,36
Manchesterd and
MASS10
Chapter 4, Surveillance
Delay from ≥ 5.5-cm
scan to consultation
Assumed constant NAAASP8 Chapter 4, Surveillance
Consultation scan CT scan not ultrasound
scan
RESCAN35 Chapter 4, Surveillance
Decision at
consultation
Those not undergoing
surgery never receive
surgery
Systematic review37 Chapter 3, Proportion of women
versus men not offered an
intervention, and Chapter 4,
Surveillance
Delay from
consultation scan to
elective surgery
Assumed constant NAAASP8 Chapter 4, Surveillance
CT, computerised tomography.
a Source: Professor Jes Lindholt, University of Southern Denmark, 2016, personal communication.
b Source: Professor Matthew J Bown, University of Leicester, 2016, personal communication.
c Source: Professor Janet T Powell, Imperial College London, 2016, personal communication.
d Source: Professor Ray Ashleigh, University of Manchester, 2016, personal communication.
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TABLE 2 Parameters and sources of information for modelling AAA screening in women and sections in the report
where the work is described: elective and emergency operations
Parameter Assumptions Sources of data Section of report
Elective operations Parameters may vary
with age, AAA diameter
Proportion receiving
EVAR vs. open repair
NVR,26 HES28 and
systematic review37
Chapter 3, Suitability of women
versus men for standard
endovascular repair, and Chapter 5,
Elective operations
EVAR 30-day operative
mortality
Assumed immediate
(not 30 days)
NVR,26 HES28 and
systematic review37
Chapter 3, 30-day operative
mortality in women versus men and
Chapter 5, Elective operations
Open repair 30-day
operative mortality
Assumed immediate
(not 30 days)
NVR,26 HES28 and
systematic review37
Chapter 3, 30-day operative
mortality in women versus men, and
Chapter 5, Elective operations
Reintervention rate
after successful EVAR
Constant rate within
two time periods
EVAR-138 Chapter 5, Elective operations
Reintervention rate
after successful open
repair
Constant rate EVAR-138 Chapter 5, Elective operations
Long-term AAA
mortality rate after
successful EVAR
Constant rate EVAR-138 Chapter 5, Elective operations
Long-term AAA
mortality rate after
successful open repair
Constant rate EVAR-138 Chapter 5, Elective operations
Emergency operations Symptomatic AAAs
excluded from
modelling; parameters
may vary with age
% operated after
rupture
Assumed constant Literature review and
IMPROVE24
Chapter 3, Mortality following
ruptured abdominal aortic aneurysm
in women
Proportion receiving
EVAR vs. open repair
NVR26 and HES28 Chapter 5, Emergency operations for
ruptured abdominal aortic aneurysm
EVAR 30-day operative
mortality
Assumed immediate
(not 30 days)
NVR,26 HES28 and
literature review
Chapter 3, Mortality following
ruptured abdominal aortic aneurysm
in women and Chapter 5, Emergency
operations for ruptured abdominal
aortic aneurysm
Open repair 30-day
operative mortality
Assumed immediate
(not 30 days)
NVR,26 HES28 and
literature review
Chapter 3, Mortality following
ruptured abdominal aortic aneurysm
in women, and Chapter 5,
Emergency operations for ruptured
abdominal aortic aneurysm
Reintervention rate
after successful EVAR
Constant rate IMPROVE30 Chapter 5, Emergency operations for
ruptured abdominal aortic aneurysm
Reintervention rate
after successful open
repair
Constant rate IMPROVE30 Chapter 5, Emergency operations for
ruptured abdominal aortic aneurysm
Long-term AAA
mortality rate after
successful EVAR
Constant rate IMPROVE30 Chapter 5, Emergency operations for
ruptured abdominal aortic aneurysm
Long-term AAA
mortality rate after
successful open repair
Constant rate IMPROVE30 Chapter 5, Emergency operations for
ruptured abdominal aortic aneurysm
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TABLE 3 Parameters and sources of information for modelling AAA screening in women and sections in the report
where the work is described: costs and miscellaneous parameters
Parameter Assumptions Sources of data Sections of report
Costs 2014/15 prices
Invitation, reinvitation NAAASP8 Chapter 6, Unit costs
Screening scan NAAASP8 Chapter 6, Unit costs
Surveillance scan NAAASP8 Chapter 6, Unit costs
Consultation for
elective surgery
Average of 1.6
consultations per
woman
MASS10 and NHS
Reference Costs 2014
to 201539
Chapter 6, Unit costs
Elective EVAR repair Includes all costs for
primary admission
EVAR-1,38 HES28 and
NHS Reference Costs
2014 to 201539
Chapter 6, Unit costs
Elective open repair Includes all costs for
primary admission
EVAR-1,38 HES28 and
NHS Reference Costs
2014 to 201539
Chapter 6, Unit costs
Emergency EVAR
repair
Includes all costs for
primary admission
IMPROVE,24 HES28 and
NHS Reference Costs
2014 to 201539
Chapter 6, Unit costs
Emergency open
repair
Includes all costs for
primary admission
IMPROVE,24 HES28 and
NHS Reference Costs
2014 to 201539
Chapter 6, Unit costs
Surveillance after
operations
Current practice, on
average
Chapter 6, Unit costs
Reintervention after
EVAR
Average across types of
reintervention
EVAR-138 and NHS
Reference Costs 2014
to 201539
Chapter 6, Unit costs
Miscellaneous
Non-AAA mortality
rate
Depends only on age ONS 2012–14 data40 Chapter 6, Quality of life and
competing mortality
QoL utilities Depend only on age Population norms Chapter 6, Quality of life and
competing mortality
QoL harms of
screening
None MASS10 Chapter 6, Quality of life and
competing mortality
QoL harms of surgery None MASS10 Chapter 6, Quality of life and
competing mortality
ONS, Office for National Statistics.
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Chapter 2 A discrete event simulation model for
evaluating the cost-effectiveness of an abdominal
aortic aneurysm screening programme
P revious economic evaluations11,12 of AAA screening for men have been implemented using a multistateMarkov model. The original model was based on data from 4 years of follow-up of the MASS trial10 and
gave an estimated mean cost per QALY gained of £2970 (95% uncertainty interval £2030 to £5430) at
2000–1 prices, over a 30-year time frame. The model was later updated to use data from 10 years of
follow-up in the MASS trial10, data on prevalence and baseline aortic sizes from NAAASP, estimates of growth
and rupture rates from the RESCAN collaboration,12,35 and 2013–14 prices. With these updated parameters,
the mean cost per QALY gained was estimated to be £7370 (95% uncertainty interval £5470 to £9440).
The Markov model, as implemented, calculated the mean numbers of events and mean costs every
3 months over a certain time frame (e.g. 30 years), based on the expected number of persons occupying
each of the model states. This allowed the model to be simple [e.g. it could be easily implemented in
Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA)], but makes it inflexible. First, it is difficult
to change the state structure (i.e. adding or removing states from the model). This problem arose when
the model was adapted to include more small AAA sizes for a recent evaluation of different surveillance
policies.35 Second, events are constrained to occur within each cycle of 3 months, and the amount of time
spent in each state is always a multiple of the cycle length. Third, it is difficult to make modifications to
the screening programme, such as changing the size threshold for diagnosis of an aneurysm or the size
threshold for consideration for surgery.
In this project, a discrete event simulation (DES) was used instead of a Markov model, in which each
individual has their own sequence of events that occur in continuous time. The DES was created using
the freely available statistical programming language R (The R Foundation for Statistical Computing, Vienna,
Austria).41 This chapter describes the development of the DES, its model structure and the main associated
assumptions. Specifically, it addresses objective 1 in Chapter 1, Scientific objectives. A validation exercise
is then presented in which the DES is compared with 4-year results from the MASS trial,10 in which input
parameters relevant to a population of 65-year-old men, similar to those from the MASS trial,10 are used.
This exercise was conducted to verify that the computer program worked properly and that the DES was a
reasonably accurate model. The DES was then run over a 30-year time horizon and the cost-effectiveness
estimates were compared with those previously published.
Model structure
Figure 1 shows the pathways that an individual can take through the DES, starting from the time
when they are invited or not invited to screening and continuing to the time when they die. Events that
can occur during an individual’s lifetime are represented by rectangles and the arrows show the order in
which events can occur. Some events incur costs that are relevant to the assessment of the screening
programme; these are indicated in Figure 1 with circled ‘£’ signs. The DES simulates a number of
individuals and summarises the events that they experience over time and the costs incurred.
For each simulated individual, a set of patient characteristics is first generated. These include their age,
initial aortic diameter and the rate at which their aortic diameter changes over time (see Modelling aortic
growth and abdominal aortic aneurysm rupture). The DES then adopts an event-scheduling approach by
generating a sequence of events for each individual and the times at which they may occur, using a list of
events that are ‘scheduled’ for the future [future events list (FEL)]. The DES has an explicit simulation clock
and chooses the event that has the earliest sampled time, and records it in the individual’s sequence of
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events. It then schedules, reschedules or cancels other events as necessary, updating the FEL. The process
is repeated until death or censoring.
For each individual, scheduled events may or may not actually happen because of competing risks.
For example, if a person’s scheduled time of death from non-AAA causes occurs prior to their scheduled
time of AAA rupture, then the rupture will not occur.
£ £
£
£
££
£
Invite
Require
reinvitation
Fail to attend
screen
Screen
Non-visualisation
Surveillance
scan
In surveillance
Non-invited group Invited group
Not in
surveillance
Contraindicated Consultation
Decide on return
to surveillance
Decide on
elective surgery
Elective
surgery
AAA death
Non-AAA death
Emergency
surgery
Rupture
Immediate
Not immediate
Dropout
Incidental
detection
FIGURE 1 The sequences of events that are possible in the DES. Circled ‘£’ sign: event incurring costs.
Note: although omitted from the figure, post-surgery surveillance and reinterventions can also occur. Adapted
with permission from Sweeting et al.42 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY-NC-ND 4.0 licence.
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As implemented, the DES in fact creates two copies of each person that are identical in terms of their
baseline characteristics and their scheduled times of rupture and non-AAA death. These can be regarded
as twins or a pair of clones. One twin/clone is invited to screening and the other is not. The purpose of this
is to reduce the variation in the final health-economic outputs of the model.43,44
Event types
Table 4 lists the possible events that can occur, when they are first scheduled, whether or not repeat
events can occur and when they are ‘cancelled’ from the FEL.
Screening and monitoring
We refer to an initial ultrasound scan as a ‘screening’ scan and a subsequent check-up scan as a ‘surveillance’
scan. An individual who does not respond to the initial invitation to screening is reinvited, and may either
attend and be screened or fail to attend screening. Invitation, reinvitation and screening all incur costs. In a
small proportion of individuals who attend screening, visualisation of the aorta will be unsuccessful; these
individuals will be discharged from the screening programme. For a person who is successfully screened, there
are three possibilities: (1) if the aortic size, measured using an ultrasound scan, is less than the diagnosis
threshold (currently 3.0 cm), then repeat surveillance is not needed and the individual is discharged; (2) if the
aortic size is greater than or equal to the diagnosis threshold and less than the intervention threshold (currently
5.5 cm), then the individual is entered into surveillance and a surveillance scan is scheduled depending on the
measured AAA size (in NAAASP, this is 1 year for AAAs of diameter 3.0–4.4 cm and 3 months for AAAs of
diameter 4.5–5.4 cm); and (3) if the aortic size is greater than or equal to the intervention threshold (currently
5.5 cm), then a consultation with a vascular surgeon is scheduled. The model is flexible enough to allow any of
the diameter thresholds and/or surveillance times to be modified. For example, a consultation for elective surgery
could be scheduled earlier by changing the intervention diameter threshold from 5.5 to 5.0 cm.
Individuals whose AAA measures less than the diagnosis threshold at any of the surveillance scans (i.e. excluding
the initial screening scan) are kept in the surveillance programme and have another surveillance scan scheduled
as usual. Ultrasound scans are assumed to give imprecise measurements of the underlying aortic diameter
(a latent parameter that changes over time and is defined for each individual by an aortic growth model;
seeModelling aortic growth and abdominal aortic aneurysm rupture).
Dropout and incidental detection
Following the screening scan, if an individual remains in the screening programme, then a future ‘dropout
from surveillance’ time is scheduled to account for a certain proportion of individuals who will drop out of
the screening programme over time. If individuals are not under active follow-up in the screening programme
(e.g. those in the non-invited group and those in the invited group whose screening scan was normal), then
an incidental detection time is scheduled. Individuals become at risk of incidental detection only once their
underlying aortic diameter reaches the diagnosis threshold, and their incidental detection time is, therefore,
scheduled at some time after this occurrence. However, if the diameter is decreasing over time (a rare, but
possible, occurrence when simulating many individuals), then incidental detection is allowed to occur only up
until the time at which the diameter of that individual’s AAA drops below the diagnosis threshold. Incidental
detection and dropout times are both generated from an exponential distribution with a fixed rate.
In the case of individuals who drop out of the screening programme, a further incidental detection time is
scheduled, and, for those entering the screening programme via incidental detection, a further dropout
time is scheduled. Hence, individuals can repeatedly drop out and come back into surveillance, although
this will be a rare phenomenon in practice.
Consultation with a vascular surgeon
If an individual has a consultation with a vascular surgeon then their aortic diameter is remeasured
using a computerised tomography (CT) scan, which may give a different reading to an ultrasound scan
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TABLE 4 List of events and their scheduling times in the DES
Event Initial scheduled time
Can event be
rescheduled (occur
multiple times)? Can event be cancelled?
Invitation to screening Immediately (invited group only) No No
Require reinvitation Immediately for a proportion of
individuals (invited group only)
No No
Attend screening Immediately for a proportion of
individuals (invited group only)
No No
Non-visualisation of the
aorta
Immediately for a proportion of
those who attend screening
(invited group only)
No No
Incidental detection After individual’s aortic diameter
reaches diagnosis threshold
(e.g. 3.0 cm) for those not
currently in surveillance
Yes, following dropout
from the screening
programme
Yes, if rupture or non-AAA
death occur first or the
individual drops below the
diagnosis threshold
Surveillance scan Following screen-detected AAA
below intervention threshold
(e.g. 5.5 cm) or after incidental
detection
Yes, after previous
surveillance scan, after
contraindication or after
incidental detection
Yes, if dropout, rupture or
non-AAA death occur first
Dropout (from
surveillance)
Following screen-detected AAA
or incidental detection
Yes, following incidental
detection
Yes, if consultation, rupture
or non-AAA death occur first
Consultation Following a measured AAA
diameter above the intervention
threshold
Yes, following any repeat
surveillance scan that
measures AAA diameter
above the intervention
threshold
Yes, if dropout, rupture or
non-AAA death occur first
Contraindicated Immediately for a proportion
of those who receive a
consultation
No No
Decide to elective
surgery
Immediately for a proportion
of those who receive a
consultation
No No
Decide on return to
surveillance
Immediately for a proportion
of those who receive a
consultation
Yes, following a repeat
consultation
No
Elective surgery (open
and EVAR separately)
Following decision for elective
surgery
No Yes, if rupture or non-AAA
death occur first
Rupture Any time from start No Yes, if elective surgery or
non-AAA death occur first
Emergency surgery
(open and EVAR
separately)
Immediately for a proportion of
those who rupture
No No
Surveillance following
surgery (elective or
emergency)
Following elective or emergency
operation
Yes, after previous
post-surgery surveillance
scan
Yes, if non-AAA or AAA
death occur first
Reintervention
following surgery
(elective or emergency)
Following elective or emergency
operation
Yes, after a previous
reintervention
Yes, if non-AAA or AAA
death occur first
AAA death Following rupture, emergency
surgery or elective surgery
No Yes, if non-AAA death
occurs first
Non-AAA death Any time from start No Yes, if AAA death occurs
first
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(see Consultation scan: computerised tomography scan versus ultrasound scan). For example, CT may
give a systematically higher reading of the aortic diameter than ultrasound, and may also have a
different measurement error. If the measured size on the CT scan is less than the intervention threshold,
then the individual is returned to surveillance – that is, a new surveillance scan is scheduled. Otherwise,
either an elective operation is scheduled or surgery is deemed to be contraindicated for that individual.
If elective surgery is contraindicated, no surgery is scheduled and the individual remains under a defined
surveillance protocol until their aneurysm ruptures or they die from a non-AAA cause. The DES allows
the non-AAA death rate to change among individuals in whom surgery is contraindicated (e.g. owing to
comorbidities, the death rate in this group is generally much higher than that of the general population).
Emergency and elective surgery
If an individual’s AAA ruptures, then they will either receive emergency surgery or die before they reach the
operating table (in which case their death is recorded as AAA related). Both emergency and elective surgery
carry an initial operative (30-day) mortality risk and a longer-term AAA-related mortality risk to account for
future complications and secondary ruptures. Surgery can be via either EVAR or open repair; the probability
that an individual will undergo EVAR is a parameter of the DES. The DES is flexible enough to allow
specification of operative and longer-term risks separately for EVAR and open repair, emergency and
elective, together with associating different costs to each type of repair. The initial 30-day postoperative
mortality is implemented in the DES as an immediate event.
The model also allows the user to specify whether or not longer-term (> 30 days) postoperative AAA-related
events can occur, such as reinterventions or postoperative surveillance, which incur costs. Such events can be
scheduled at the time of operation or after the occurrence of a postoperative event (to allow for recurrent
events), and the rate and cost of postoperative events can depend on the type of operation (EVAR or open)
and whether the operation was in the elective or emergency setting. These model extensions are not applied
in the validation model described in this chapter, but are considered in the inputs to the DES for women
(see Chapter 5).
Finally, the DES is also flexible enough to allow operative events (i.e. the proportion receiving EVAR, or the
proportion who do not survive 30 days postoperatively) to depend on the age and AAA diameter of the
individual at the time of surgery. These risk factors are incorporated using logistic regression models, with
the user specifying log-odds ratios for covariates associated with each event. As above, these DES model
extensions are considered in Chapter 5 in the model for women.
Death from non-abdominal aortic aneurysm causes
Rates of non-AAA deaths can be input into the DES using age-specific rates (e.g. from population mortality
statistics). The model then calculates the conditional survival curve from age at screening and simulates
for each pair of individuals a time of non-AAA death by sampling from a Uniform(0,1) distribution and
evaluating the inverse function of the survival distribution.
Example sequences of events
Table 5 shows example sequences of events from the DES for four pairs of twins (i.e. individuals with
identical baseline characteristics). Like most individuals, pairs 1 and 2 have rather short sequences of events
and die of non-AAA causes – each twin dies at the same time, so the only difference between them is that
more money was spent on the twin who was invited to screening. Pairs 3 and 4 were chosen because they
have longer sequences of events.
For pair 3, the twin who is invited to screening attends and is found to have a 4.35-cm AAA. He has a
surveillance scan 1 year later and then at 3-month intervals once his aneurysm is observed to be ≥ 4.5 cm.
At 1.75 years, the ultrasound scan finds his aortic size to be 6.08 cm. This high reading is largely due to
measurement error and his true aortic size is only 5.16 cm. Nevertheless, he is referred for a consultation, in
which the more accurate CT scan, 71 days later, measures the aneurysm at 5.04 cm and he is, therefore,
returned to surveillance. This person continues to attend his surveillance scans. About 1 year later his
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TABLE 5 Example sequences of events for four pairs of twins
Time (years) Invited to screening Not invited to screening
Pair 1
0.00 Invited to screening –
0.00 Require a reinvitation –
0.00 Screened (ultrasound measurement of 2.82 cm) –
11.46 Died of non-AAA causes Died of non-AAA causes
Pair 2
0.00 Invited to screening –
0.00 Fail to attend screening –
11.44 Died of non-AAA causes Died of non-AAA causes
Pair 3
0.00 Invited to screening –
0.00 Screened (ultrasound measurement of 4.35 cm) –
1.00 Surveillance scan (ultrasound measurement of 4.64 cm) –
1.25 Surveillance scan (ultrasound measurement of 5.25 cm) –
1.50 Surveillance scan (ultrasound measurement of 5.43 cm) –
1.75 Surveillance scan (ultrasound measurement of 6.08 cm) –
1.95 Consultation (CT measurement of 5.04 cm) –
Returned to surveillance
2.20 Surveillance scan (ultrasound measurement of 4.85 cm) –
2.45 Surveillance scan (ultrasound measurement of 5.18 cm) –
2.70 Surveillance scan (ultrasound measurement of 6.12 cm) –
2.89 Consultation (ultrasound measurement of 5.71 cm) –
Decide on elective surgery
3.05 Elective surgery (open repair) –
5.11 – Ruptured AAA (diameter of 7.13 cm)
Emergency surgery (open repair)
6.24 Died of non-AAA causes Died of non-AAA causes
Pair 4
0.00 Invited to screening –
0.00 Screened (ultrasound measurement of 7.34 cm) –
0.19 Consultation (CT measurement of 6.91 cm) –
Decide on elective surgery
0.36 Elective surgery (open repair)
0.54 – Ruptured AAA
AAA death
1.81 Died of non-AAA causes –
A DISCRETE EVENT SIMULATION MODEL
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aneurysm is again measured to be > 5.5 cm and he has another consultation. This time the large aneurysm is
confirmed by the CT scan and it is decided that he should have elective surgery. The surgery is successful and
he lives for another 3 years.
His twin, who is not invited to screening, experiences a rupture, with a large aneurysm of 7.13 cm, but
receives emergency surgery and survives. In the end, the two twins die at the exact same time due to
non-AAA causes, so there are no gains in life-years in this example. However, the screening programme
has saved overall costs by avoiding a costly emergency operation – the first twin instead has the safer and
cheaper elective surgery.
Pair 4 is another example in which the screening programme works well. The twin who is invited to
screening lives longer as a result of the screening. His aneurysm is detected straight away, he is referred for
a consultation and he has elective surgery, which is successful. The other twin’s AAA ruptures and he dies
without getting to the hospital in time to have emergency surgery.
Modelling aortic growth and abdominal aortic aneurysm rupture
The model for aortic growth
In the DES, the evolution of an individual’s aortic diameter over time must be taken into account as it
affects many aspects of the health economic model, namely (1) when an individual can be diagnosed,
(2) planned surveillance intervals, (3) when an intervention can be considered, (4) the risk of rupture,
(5) the probability of receiving EVAR rather than open repair and (6) the operative mortality risk. Therefore,
the evolution of the aortic diameter over time is modelled using a continuous-time linear mixed model,
which allows the underlying diameter and a measured diameter (using ultrasound or CT) to be determined
at any time point. Let yij be the aortic diameter, as measured using ultrasound, of person i at time tij,
j = 1,. . .,ni; so yi0 is the baseline diameter as measured at screening. The linear mixed model is as follows:
log(yi j) = b0 i + b1 i ti j + ϵi j
=mi j + ϵi j
(b0 i, b1 i)
T∼N2(β,G),
(1)
where
ϵi j ∼ N(0, σ2w ),
β =
β1
β0
 
and (2)
G =
σ20 ρσ0σ1
ρσ0σ1 σ
2
1
 
. (3)
Each person has two random effects: (1) their own intercept (true baseline log-diameter), b0i, and (2) their
own slope (rate of growth), b1i, measured on the log-diameter scale. Correlation between an individual’s
underlying baseline log-diameter and slope is allowed as b0i and b1i have a bivariate normal distribution
with correlation parameter ρ. The parameters σ20 and σ21 determine the between-person variability of the
intercepts and slopes, respectively, while σ2w determines the amount of variability due to measurement error.
The linear mixed model is fitted using data from repeated ultrasound measurements of the aortic diameter
from cohorts of AAA patients such as from the MASS trial10 or RESCAN studies.35 These cohorts are
restricted to the diameter range 3.0–5.5 cm. As a result, model extrapolation is used to infer true baseline
diameters and growth rates for individuals outside this range.
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Baseline diameter distribution and derived random effects
The baseline diameter distribution is a particularly important aspect of the DES, because it determines
how many persons have aneurysms at the time at which screening would be implemented and has a great
effect on how many develop aneurysms in subsequent years. The full specification of the model is that yi0
follows a fixed baseline distribution, which we specify using external data sources (e.g. data on measured
diameters from the first 700,000 men screened in NAAASP), and an individual’s random effects b0i
and b1i are then generated conditional on their observed baseline diameter. Following evaluation of the
performance of the aortic growth model, it was decided to use the following rules to generate an
individual’s random-effects (full details of the reasons for these choices are given in Appendix 2).
If yi0 ≥ 3.0, generate random effects from the linear mixed model posterior distribution
As estimated parameters from the linear mixed model are strictly relevant only to baseline diameters
of ≥ 3.0 cm, for individuals in this range, b0i and b1i are generated from their bivariate normal distribution
conditional on the observed diameter, yi0:
(bijyi0)∼N2(µb, Σb), (4)
where
µb = β +

σ20
ρσ0σ1

log(yi0)− β0
σ20 + σ2w
and (5)
Σb =

σ20 + σ
2
w ρσ0σ1σ
2
w
ρσ0σ1σ
2
w σ
2
0σ
2
1(1−ρ
2) + σ21σ
2
w

. (6)
If yi0 < 3.0, set an individual’s true baseline diameter to their observed diameter
If the observed baseline diameter, yi0, measures < 3.0 cm, then we set b0i = log(yi0). This avoids shrinkage
of the true baseline diameter upwards towards the mean in the AAA cohort used to fit the linear mixed
model [as estimated by exp(β0)].
If 2.0 < yi0 ≤ 3.0, generate an individual’s rate of growth from their posterior distribution
conditional on b0i
If 2.0 ≤ yi0 < 3.0, then b1i is generated from a univariate normal distribution conditional on b0i:
(b1ijb0i)∼N(µb1, σ2b1), (7)
where
µb1 = β1 +
ρσ1
σ0
(b0i − β0) and (8)
σ2b1 = (1− ρ
2)σ21. (9)
If yi0 < 2.0, set rate of growth to zero
This rule means that, if the aortic diameter is < 2.0 cm at baseline, no aneurysm will develop during the
individual’s lifetime. It was felt that, in this range, the model-extrapolated estimates of growth could not
be relied on, and instead it was assumed that in these individuals the aorta would never grow to be
aneurysmal within their lifetime.
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The rules set out here ensure that extrapolated growth rates < 3.0 cm are sensible and approximately
follow empirical data from a group of men with aortic diameters of 2.6–2.9 cm followed over time in the
Gloucestershire study.45 Further technical details are given in Appendix 2.
Prevalence
The user of the DES specifies the baseline diameter distribution as an input as well as, optionally, the
prevalence of AAAs, which is the probability that a baseline diameter is greater or equal to the diagnosis
threshold (e.g. 3.0 cm). If provided, this optional input then reweights the baseline diameter distribution
accordingly (further details of this reweighting procedure are given in Chapter 4).
Calculation of a person’s aortic diameter at any time
The aortic diameter measured at an individual’s initial screening scan is taken to be yi0, because this
ensures the correct prevalence of AAA at screening.
When an individual’s aortic diameter at time t > 0 is needed, one of the following formulas is used.
True diameter: exp(b0i + b1i t). (10)
Measurement using ultrasound: exp(b0i + b1i t + ϵ), where ϵ is drawn from N(0, σ2w ). (11)
Measurement using CT scan: exp(b0i + b1i t) + δ, where δ is drawn from N(µCT , σ
2
CT ). (12)
The measurement error is expressed differently in the formulas for ultrasound and CT scans. This has been
done as a matter of convenience since estimates of σw come from the mixed-effects model that uses
ultrasound measurements and is fitted on the log-diameter scale. Meanwhile, estimates of µCT and σCT will
generally originate from the literature and are assumed to be additive on the diameter scale.
The model for abdominal aortic aneurysm rupture
The model for AAA rupture is the survival component of a joint longitudinal and survival model. According
to this model, the hazard of rupture is:
hi(t) = exp γ + α(b0i + b1i ti j)
 
, (13)
where γ is the log-baseline hazard and α is the log-hazard ratio associated with a 1-unit increase in log-aortic
diameter (the expression in the inner brackets; see The model for aortic growth). In reality, the hazard of
rupture will increase with the aortic diameter, and this is the case if α is positive.
The hazard function corresponds to a Gompertz distribution with shape parameter αb1i and rate parameter
exp(γ + αb0i). Therefore, rupture times are generated from this distribution for each pair of individuals from
the time of screening.
Improving the efficiency of the discrete event simulation and conducting
probabilistic sensitivity analyses
Once a sequence of events has been created for a person, this can be used to calculate health-economic
quantities for them, namely their life-years, the total cost of the events that they experience, and their
discounted life-years, costs and QALYs. Discounting is applied at 3.5% per year for both costs and
life-years, whereas QALYs are calculated based on UK population norms for QoL.31
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A single run of the DES consists of simulating a large number of individuals, calculating their health-economic
quantities and finding the means of these quantities over all the individuals. Differences in mean life-years and
costs between the individuals in the invited and non-invited groups can then be calculated and the ICER and
INMB for a given WTP can be obtained.
Convergence
Differences in life-years and costs between the invited to screening and not invited to screening groups
are generally small, as the prevalence of AAAs is relatively low and, therefore, a screening programme
will benefit only a small proportion of the population. Thus, the model needs to be run on millions of
individuals in order to obtain accurate estimates of incremental life-years. However, if interest is primarily
in incremental costs and life-years (rather than absolute estimates for each group), then this approach is
computationally inefficient. A pair of twins who have an aortic diameter less than the diagnosis threshold
at screening should follow exactly the same life-course, as the twin who is invited to screening will be
found to be normal on screening and will no longer be followed up. The only difference between the
twins is that the twin invited for screening will incur extra screening costs. For this reason, if accurate
estimates are required of incremental life-years, incremental costs, the ICER and INMB, then the DES can
be run by selectively sampling only individuals above the diagnosis threshold. The mean incremental costs
and life-years are then calculated in this subgroup and are weighted by the prevalence (proportion of
individuals in the population who are above the diagnosis threshold at screening). The population below
the diagnosis threshold is never sampled but has zero mean incremental life-years and mean incremental
costs determined by the mean screening costs in the invited to screening group. These are weighted by
(1 – prevalence) and are added to the incremental mean costs in those sampled above the threshold.
An example of the convergence of the ICER using the selective sampling approach versus not using the
approach is shown in Appendix 2.
Probabilistic sensitivity analysis
A PSA is conducted by running the main analysis a large number of times using a different set of
parameter inputs each time to account for uncertainty in the parameters. Each of the main analyses that
are performed in the PSA produces an estimate of the incremental cost and an estimate of the incremental
effectiveness, and these quantities can then be viewed in a scatterplot and a cost-effectiveness
acceptability curve (CEAC) can be generated.
Figure 2 shows how the functions in the DES form a hierarchy in which each function runs the function below
it multiple times. At the top is a function named ‘psa’, which performs a PSA. Next is ‘processIndividuals’,
which conducts the main analysis. Within this function is ‘processOnePair’, which generates a pair of twins
and calculates their health-economic quantities. Embedded into this function is ‘generateEventHistory’, which
generates a single sequence of events for an individual. This is run twice by ‘processOnePair’, once for the
invited twin and once for the non-invited twin.
Distributions for parameters
Model parameters that feature as uncertain parameters in a PSA are one of three types, and are dealt with
using different distributions within the PSA:
1. A probability (e.g. probability of attendance) is generated from a Beta distribution in the PSA.
2. A rate (e.g. rate of incidental detection) is generated from a Gamma distribution in the PSA.
3. Coefficients from a regression model (e.g. a logistic model for a probability, the linear mixed-effects
regression model for aortic growth or the survival analysis regression model for AAA rupture) or
transformations of the coefficients are generated for each regression in combination using a
multivariate normal distribution in the PSA. For example, the regression coefficients in the linear mixed
model for aortic growth are generated in a PSA from a multivariate normal distribution of the
transformed parameter vector (β0,β1,logσ0,logσ1,tanh–1ρ,logσW), while the regression coefficients in the
model for AAA rupture (γ and α) are generated from a bivariate normal distribution in the PSA.
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Validating the discrete event simulation in men
Validating against 4-year data from the Multicentre Aneurysm Screening
Study in men
To validate the DES, a model was developed based on inputs used in the original Markov model developed
for men.11 The values of the parameters used are shown in Table 27, Appendix 2, alongside distributions
psa (probabilistic sensitivity analysis)
•
•
•
Input: global fixed variables
Repeat these steps multiple times
•  generate values of global uncertain variables
•  processIndividuals
Output: mean quantities from all the replications
processIndividuals (the main analysis)
Create and analyse a specified number of invited/non-invited pairs of individuals
•
•
•
Input: global fixed and uncertain variables
Repeat this step multiple times
•  processOnePair
Output: means of the quantities over all the pairs of individuals
processOnePair (create and analyse one pair of individuals)
•
•
•
•
•
Input: global fixed and uncertain variables
Generate values of pair-specific variables (e.g. initial aortic diameter, latent growth rate, rupture and
non-AAA death times)
If the individual is in the screening group then schedule their invitation to screening, otherwise
schedule incidental detection
For each individual in the pair (invited and not invited), repeat these steps
•  generateEventHistory
•  calculate the individual’s health economic quantities
Output: the health economic quantities
generateEventHistory (create an individual’s sequence of events)
•
•
•
Input: global fixed and uncertain variables, pair-specific variables, and intervention group
Repeat these steps until ‘stop’ is reached
•  identify the scheduled event with the earliest time and record this event in the individual’s 
    sequence of events
•  if the event is death or censoring then ‘stop‘
•  perform actions as appropriate for the event (e.g. generate an ultrasound measurement of the
    aortic size)
•  schedule, reschedule and cancel events as appropriate for the event (e.g. if the measurement was
    over the threshold for surgery then cancel dropout and schedule consultation)
Output: this individual’s sequence of events
FIGURE 2 Abdominal aortic aneurysm screening DES: hierarchy of functions.
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placed on the parameters for PSA. The baseline distribution was taken from the first 700,000 screened
men in NAAASP and was then reweighted to give an AAA prevalence of 4.97%, as observed in the MASS
trial.10 A further reweighting was then undertaken to ensure that 70.8% of the individuals’ aneurysms
were small (3.0–4.4 cm), 16.7% were medium (4.5–5.4 cm) and 12.5% were large (≥ 5.5 cm) at screening,
as seen in the MASS trial.10 Non-AAA death rates were taken directly from those observed in the MASS
trial.10 Costs were the same as those used originally:11 invitation (£1.31), reinvitation (£1.28), screening
ultrasound scan (£19.08), surveillance ultrasound scan (£46.04), consultation for elective surgery (£309.88),
elective open repair (£6908.75) and emergency open repair (£11,175.63).
The screening programme evaluated was as specified in the MASS trial10 (1-year monitoring for AAAs of
3.0- to 4.4-cm diameter, 3-month monitoring for AAAs of 4.5- to 5.4-cm diameter and consideration for
elective surgery for AAAs ≥ 5.5-cm diameter). The DES was run for a population of men aged 69 years
(mean age of the MASS trial10), for a mean follow-up of 4 years (with random censoring between 3 and
5 years to mimic censoring in the 4-year MASS trial10 results) and the total number of events were
compared with those observed in the 4-year MASS trial10 data.
Table 6 shows the numbers of key events in the two groups over a 4-year period as estimated by the
DES. The DES was run using 107 pairs of individuals, and then the estimated numbers of events that
occurred was scaled to be relevant to the size of the invited and control (non-invited) groups in the
MASS trial.10 For comparison, the observed numbers in the MASS trial10 are also given, together with the
expected-to-observed (E/O) ratio expressed as a percentage. The E/O ratio is within ± 20% for all events
TABLE 6 Numbers of events observed in the MASS trial10 4-year follow-up and compared with the DES
Event MASS10 observed (n) DESa (n) DES (% of MASS10)
No invitation group
Elective operation 100 98 98
Emergency operation 62 69 111
Rupture 138 157 114
Contraindicated for elective surgery N/A 17 N/A
AAA death 113 122 108
Non-AAA death 3750 3708 99
Invited group
Elective operation
Resulting from screen detection 295 332 113
Resulting from incidental detection 31 27 87
Emergency operation 28 31 109
Rupture 66 70 105
Contraindicated for elective surgery
Resulting from screen detection 41 54 131
Resulting from incidental detection N/A 4 N/A
AAA death 65 65 100
Non-AAA death 3694 3712 100
Loss to recall follow-up 290 281 97
N/A, not available.
a Estimated for a sample size of 33,961 participants in the control group and 33,839 in the invited group, as in the
MASS trial.10
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except for contraindications resulting from screen-detected AAAs. The DES was deemed accurate enough
in estimating the numbers of key events in both arms, and the timing of these events also adequately
followed the occurrence of the events in the trial. Further results from this validation exercise are given
elsewhere, including cumulative numbers of key events over time.46
Validating against 30-year contemporary Markov model in men
The DES was then extended to run for 30 years, with inputs updated to reflect more contemporaneous
estimates for men.12 In particular, national mortality statistics were used for non-AAA death rates, the
baseline diameter distribution from NAAASP was used directly (hence giving an AAA prevalence of 1.34%)
and both EVAR and open repair for elective mortality were considered along with long-term postoperative
mortality. Costs were the same as previously specified:12 invitation (£1.70), reinvitation (£1.70), screening
ultrasound scan (£32.20), surveillance ultrasound scan (£68.00), consultation for elective surgery (£435.25),
elective open repair (£11,532.69), elective EVAR (£13,345.66) and emergency open repair (£19,984.75).
The estimated life-years and costs were compared with the previously published estimates from a Markov
model.12 Table 7 shows that the results, although not identical, provide a similar conclusion regarding the
cost-effectiveness of the AAA screening programme over a 30-year period. The DES estimates a higher
gain in life-years but with similar incremental costs to the 30-year Markov model and as such the
estimated ICER is about £1000 less. Nevertheless, both models suggest that the programme is highly
cost-effective.
TABLE 7 Comparison of 30-year results from the DES compared with those published using a 30-year Markov model
Outcome
30-years
Markov model12 DES
No invitation group
Life-years 12.719 12.556
QALYs 9.921 9.647
Cost (£) 269 364
Invited group
Life-years 12.727 12.567
QALYs 9.928 9.655
Cost (£) 316 414
Difference
Life-years 0.0084 0.01026
QALYs 0.0067 0.00777
Cost (£) 47 50
ICER (£)
Discounted 5758 (95% CI 4285 to 7410) 4876 (95% CI 3727 to 6839)
Discounted, quality adjusted 7370 (95% CI 5467 to 9443) 6440 (95% CI 4920 to 9063)
Life-years, QALYs and costs discounted at 3.5% per year.
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Summary
The DES developed and described in this chapter provides a flexible and comprehensive way to assess the
cost-effectiveness of AAA screening under a number of possible screening scenarios. The DES is applied to
contemporary data for women in Chapter 7, while different screening programme options are evaluated
in Chapter 8. The model allows the assessment of parameter uncertainty through PSAs. The DES has
been validated against 4-year outcomes as observed in the MASS trial10 and was found to perform adequately.
The model also gave comparable results with respect to previously published 30-year cost-effectiveness
results, and further internal validation of the model has been undertaken (e.g. see Appendix 2 regarding
long-term growth and rupture rates).
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Chapter 3 Systematic reviews of the current
prevalence of screen-detected abdominal aortic
aneurysms and management of abdominal aortic
aneurysms in women
The prevalence of AAAs and the efficacy of interventions to prevent ruptures are pivotal to assessing thelikely benefit of AAA screening in women. Therefore, we undertook a series of four systematic reviews
of contemporary (year 2000 or later) AAA prevalence and management in women:
1. the prevalence of screen-detected AAAs
2. the proportion of AAAs suitable for endovascular repair
3. the proportion of patients with AAAs not offered repair
4. the 30-day operative mortality following either endovascular or open repair.
We also undertook a narrative review of the outcome in women following rupture, the fifth piece of work
in this chapter.
Specifically, this chapter addresses objective 2 in Chapter 1, Scientific objectives, providing evidence on the
prevalence of AAAs (see Table 1) and of parameters related to elective surgery (see Table 2), as well as a
literature review of parameters related to emergency surgery for ruptured AAAs (see Table 2). The chapter
is a summary of two published papers,34,37 in which more discussion of the results is provided. Some of the
tables and figures are adapted from these papers in the British Journal of Surgery and Lancet with permission.
The systematic reviews were conducted according to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines47 and registered in the international prospective register of systematic
reviews (PROSPERO) database [www.crd.york.ac.uk/PROSPERO/ (accessed 1 March 2017); registration
numbers CRD42015020444 and CRD42016043227]. For the reviews, MEDLINE and EMBASE databases
were searched, using a combination of controlled vocabulary [medical subject heading (MeSH) or Emtree®]
terms and free-text terms in ProQuest Dialog™. Clinicaltrials.gov (http://clinicaltrials.gov), Current
Controlled Trials [www.controlled-trials.com/ (accessed 1 March 2017)] and the National Research Register
(UK) were also searched for details of ongoing or unpublished studies, complemented by hand-searching
the abstracts of the 2015 and 2016 annual meetings of the Society for Vascular Surgery (North America)
and the European Society for Vascular Surgery. The quality of studies was assessed using the relevant
Newcastle–Ottawa scores.48 Searches were restricted to the major European languages. The MeSH
headings, search dates for each review and the inclusion and exclusion criteria are shown in Table 8, and
the PRISMA search strategies and flow charts are given in Appendix 3 (Boxes 1–4 and Figures 19–22).
Random-effects meta-analyses of proportions across studies were undertaken on a logit scale and
transformed back to the probability scale for presentation.
Current prevalence of screen-detected abdominal aortic aneurysms
in women
The literature search identified seven studies,14,49–54 all based on ultrasound screening. Of these, only
three14,49,50 were based on screening using population registers: two51,52 were screening studies of people
in the USA offered free screening by advertisement and two53,54 were screening studies of those paying a
fee to the Lifeline screening programme, also recruited by advertisement. For the Norwegian study,49 data
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TABLE 8 Inclusion and exclusion criteria for the systematic reviews
Inclusion criteria Exclusion criteria
Prevalence reviewa
Screening date year 2000 onwards; final search date 13 January 2016 Review articles
Women ≥ 60 years of age Editorials
All ethnic groups Letters
Population described clearly Case reports
Screening of ≥ 1000 women Studies of people with known
cardiovascular disease
Ultrasound or CT for aortic diameter measurement
EVAR suitability reviewb
Published 1 January 2005 to 2 September 2016 Review articles
Sex-specific data Editorials
Population of all or nearly all of the patients considered for AAA repair Letters
Morphological criteria for suitability clearly defined with measurements
or device IFU
Case reports
≥ 20 women Studies including only patients with EVAR
CT with 1-mm slices and 3D reconstruction
Non-intervention reviewc
Published 1 January 2005 to 2 September 2016 Review articles
Sex-specific data Editorials
Population of all or nearly all of the patients considered for AAA repair Letters
Team decision whether or not repair offered Case reports
≥ 20 women Studies including only patients with EVAR
30-day operative mortality reviewd
Published 1 January 2009e to 26 August 2016 Review articles
Study period after year 2000 Editorials
Sex-specific 30-day mortality data Letters
≥ 50 women Case reports
Studies that only provide hazard ratios
Studies that only report in-hospital mortality
3D, three-dimensional; IFU, instructions for use.
a Aortic aneurysm, abdominal; women/sex/women’s health; genetic predisposition to disease, prevalence/incidence;
mass screening; population. Search to 13 January 2016.
b Endovascular procedures/stents/vascular surgical procedures/blood vessel prosthesis/blood vessel prosthesis implantation/
vascular grafting; aortic aneurysm, abdominal; female/women/women’s health; sex factors/sex distribution/sex ratio/sex
characteristics; iliac artery/calcification.
c Endovascular procedures/stents/vascular surgical procedures/blood vessel prosthesis/blood vessel prosthesis implantation/
vascular grafting; aortic aneurysm, abdominal; female/women/women’s health; sex factors/sex distribution/sex ratio/sex
characteristics; elective surgical procedures; comorbidity; risk factors/risk assessment; refusal to treat/patient selection;
palliative care.
d Aortic aneurysm, abdominal; blood vessel prosthesis/blood vessel prosthesis implantation/vascular grafting; aortic
aneurysm, abdominal – surgery; aortic aneurysm, abdominal – mortality/aortic aneurysm, abdominal – complications/
hospital mortality/minimally invasive surgical procedures – mortality/vascular surgical procedures – mortality/vascular
surgical procedures – adverse effects; sex factors/sex distribution/sex ratio/sex characteristics; treatment outcome.
e Therefore, were not included in the 2010 review.25
Note
For duplicated data, the most recent or most comprehensive paper was included.
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for women with an aortic diameter of ≥ 3.0 cm were obtained from the corresponding author. Women
with a known AAA were excluded from screening in all studies. Only one study14 reported the exact
method of ultrasound diameter measurement (anterior–posterior or transverse, based on inner to inner
wall, outer to outer wall or leading edge to leading edge). Variation in the method of measurement could
produce considerable heterogeneity, as there is up to a 6 mm difference between inner to inner and outer
to outer wall diameters.
Correspondence with authors provided further details of several studies,51–53 and one author52 provided an
eighth unpublished study, a follow-on to their earlier study. Data were extracted, wherever possible, by
age band and smoking status. The main US Lifeline screening study did not report on smoking status;
however, smoking status was available for a subgroup of women, with sponsored screening, and this was
included only for assessment of the effect of smoking on prevalence.13 One excluded study55 reported on
physician-initiated screening (with both ultrasound and CT) in a socioeconomically deprived population in
the USA and did not define the specific criteria for screening; however, it provided additional useful
information about the effects of smoking on prevalence.
An estimate of the prevalence was made from each study (number of women with an AAA divided by the
number of women who were screened successfully). Three studies49,53,54 included women < 60 years of age
in their screening. As the present review excludes younger women, only those aged ≥ 60 years from these
studies were included.
The characteristics of the included studies are summarised in Table 9. Two studies53,54 of very large cohorts
were identified (about 1.4 and 0.9 million women, respectively, aged ≥ 60 years), mainly self-referred for
self-purchased Lifeline screening, from the USA and the UK and Ireland. Smaller studies offering free
screening based on population registers were from Sweden,14 Norway49 and Italy,50 but only two14,49 of
these were of very high quality, and, in total, this type of study contributed only 11,003 women. With the
three further studies offering, by advertisement, sponsored free screening in the USA, this gave an overall
total of 1,537,633 women screened in eight separate studies, with a pooled prevalence of AAAs of 0.74%
[95% confidence interval (CI) 0.53% to 1.03%] in women aged ≥ 60 years, but with considerable
heterogeneity (see Figure 23, Appendix 3).
The overall prevalence of AAAs increased rapidly with age: 0.43% at 61–70 years, 1.15% at 71–80 years
and 1.68% in those aged ≥ 81 years (Figure 3). However, there was considerable heterogeneity even for
these pooled estimates (I2 = 74–94%), and in every age band the prevalence was lowest in the self-referred
cohorts and highest in the Norwegian population register-based cohort. However, when relative risks were
assessed, there was more consistency between studies (I2 = 0–49%) than seen with the absolute risks.
Compared with the 60- to 69-year age group, the prevalence was 2.7 (95% CI 1.8 to 4.2) times higher in
the 70- to 79-year age group and 4.3 (95% CI 4.0 to 4.7) times higher among women aged ≥ 80 years.
Only four studies reported on prevalence by smoking status (see Table 9), although the recording of
smoking status was not uniform. Hupp (Dr Jon A Hupp, Anne Arundel Medical Center, Annapolis, MD,
USA, 2016, unpublished) recorded those who remembered having smoked > 100 cigarettes in their
lifetime, which is the definition used by the US Preventive Services Task Force.5 The overall prevalence was
lower for never smokers (0.28%) than for ever smokers (1.34%) (see Figure 24, Appendix 3). Three studies
reported the prevalence in current smokers 2.08%,14 4.63%49 and 2.82%.51 The study by Jahangir et al.55
provides support for this effect as the association between AAAs and former smoking had a hazard ratio
of 3.4, rising to 9.2 in current smokers.
Summary
This review provided an overall AAA prevalence of 0.74% for women aged ≥ 60 years, with the prevalence
increasing sharply with age and current smoking. The overall prevalences of 0.43% for the 61- to 70-year
age group and of 1.15% for the 71- to 80-year age group are used in the modelling (see Chapters 7 and 8)
as the prevalences for women aged 65 and 75 years, respectively.
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TABLE 9 Prevalence review: characteristics of included studies, ordered by date of screening
Study Selection for screening Screening dates Country
No. of women
screened
(% attendance)
Age range
(years)
Never
smoked, n
(current
smokers) (%) N–O score*
No. of AAAs
(% prevalence)
Forsdahl et al.49 Population based, free 2001 Norway 1956 (85†) 61 to ≥ 80 35 (25) 9 30 (1.53)
Ogata et al.51 Self-referred, free 2001–4 USA 1298 (n.a.) 60–89 n.a. (9.2) 5 19 (1.46)
Hupp et al.52 Self-referred, free 2000–6 USA 4982 (n.a.) 60–89 n.a. 7 47 (0.94)
Savji et al.54‡ Mainly self-referred, self-purchased 2003–8 USA 1,428,316 (n.a.) 61–100 n.a. 6 6229 (0.44)
Hupp (unpublished) Self-referred, free 2006–8 USA 3060 (n.a.) 66–105 22 (n.a.) 7 28 (0.92)
Svensjö et al.14 Population based, free 2007–9 Sweden 5140 (74) 70 56 (10) 9 19 (0.37)
Palombo et al.50 Population based, free 2007–9 Italy 3907 (48) ≥ 65 n.a. 7 43 (1.10)
Bulbulia et al.53 Self-referred, self-purchased 2008–12 UK, Ireland 88 974 (n.a.) 60 to ≥ 80 n.a. 6 278 (0.31)
n.a., not available.
*Newcastle–Ottawa score (N–O), used to assess study quality; higher scores represent the better quality studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
†Similar numbers of men and women screened; overall uptake 85%.
‡Does not report aneurysm size and smoking; used for prevalence only owing to the very large population of women and supplemented by data from Derubertis and colleagues,13 who also
used the same Lifeline screening, but provided data on a subgroup of 10,012 women, mean age 69 years, with at least one cardiovascular risk factor, screened between 2004 and 2006.
§Physician-initiated screening study reporting only minimum prevalence; not included in data synthesis, but outline details are provided for comparison with a group of lower socioeconomic
status.
Reproduced from Ulug et al.34 with permission. © 2016 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. This is an open access article under the terms of
the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial
and no modifications or adaptations are made.
CU
RREN
T
PREVA
LEN
CE
O
F
SCREEN
-D
ETECTED
A
A
A
A
N
D
M
A
N
A
G
EM
EN
T
O
F
A
A
A
IN
W
O
M
EN
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
26
Suitability of women versus men for standard endovascular repair
After searching and evaluation, only five papers based on five studies56–60 were eligible for inclusion in the
meta-analysis. One study also included suitability for endovascular sealing technology but used a selected
population.61 All the studies focused on standard endovascular repair and did not consider the use of
fenestrated grafts. The characteristics of the included studies are summarised in Table 29, Appendix 3.
Only one58 of these studies included > 100 women; most were small, and the quality of these studies was
not good. The criteria of morphological suitability for EVAR were different in each study: three studies56,58,59
included all patients with an aneurysm (including those not offered intervention), one study60 did not
specify which patients were being considered for EVAR and one study57 considered only patients who had
undergone elective repair. The largest study58 has published two further updates62,63 but neither provided
sufficient information to merit inclusion in the review. The threshold AAA diameter for inclusion ranged
from 4 cm to 5 cm. In total, there was information for 1507 men, but only 400 women, with the
proportion considered suitable for EVAR ranging from 25% to 47%. The overall estimate of suitability for
EVAR in women was 34.0% (95% CI 25.4% to 43.8%) compared with 53.6% (95% CI 46.4 to 60.6%)
in men, both overall estimates having significant heterogeneity (Figure 4a).
Estimate (95% CI) % Weight
0 0.5 1 1.5 2
Prevalence (%)
 70
Forsdahl (2009)
Ogata (2006)
Hupp (2007)
Savji (2013)
Hupp (unpublished)
Svensjö (2013)
Subtotal (I-squared  = 90.67%)
1.13 (0.66, 1.94)
1.05 (0.52, 2.08)
0.25 (0.12, 0.52)
0.23 (0.22, 0.24)
0.19 (0.05, 0.76)
0.37 (0.24, 0.58)
0.43 (0.23, 0.80)
17.86
16.49
16.06
20.58
10.36
18.65
71 – 80
Forsdahl (2009)
Ogata (2006)
Hupp (2007)
Savji (2013)
Hupp (unpublished)
Subtotal (I-squared = 94.38%)
2.02 (1.24, 3.27)
1.88 (0.94, 3.71)
1.83 (1.29, 2.58)
0.60 (0.58, 0.62)
0.50 (0.27, 0.93)
1.15 (0.59, 2.24)
19.92
18.01
21.01
22.29
18.77
81 +
Forsdahl (2009)
Ogata (2006)
Hupp (2007)
Savji (2013)
Hupp (unpublished)
Subtotal (I-squared = 73.98%)
7.14 (1.00, 37.03)
2.78 (0.90, 8.26)
1.97 (1.03, 3.73)
1.01 (0.96, 1.06)
1.69 (1.06, 2.66)
1.68 (1.02, 2.74)
5.17
12.30
21.60
34.35
26.58
FIGURE 3 Prevalence of AAAs in women aged ≥ 60 years, by 10-year age groups. References for studies are in
Table 9. Reproduced from Ulug et al.34 with permission. © 2016 The Authors. BJS published by John Wiley & Sons Ltd
on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is
properly cited, the use is non-commercial and no modifications or adaptations are made.
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20 30 40 50
Percentage EVAR suitable (%)
60 70
Estimate (95% CI)
Author
(country)
(a)
Year
EVAR suitable
(proportion) % Weight
26.83 (15.52, 42.25)
46.88 (30.59, 63.86)
25.10 (20.12, 30.83)
42.86 (27.74 , 59.43)
36.59 (23.41, 52.14)
33.96 (25.36, 4376)
17.33
17.25
28.85
17.85
18.72
100.00
54.00 (47.06, 60.79)
57.14 (48.82, 65.08)
46.06 (42.65, 49.50)
47.44 (39.73, 55.27)
64.32 (57.43, 70.67)
53.60 (46.42, 60.64)
19.92
18.38
23.16
18.94
19.60
100.00
11/41
15/32
63/251
15/35
15/41
108/200
80/140
374/812
74/156
128/199
Women
Kristmundsson
Hultgren
Sweet
Park
Moise
Overall Women (I-squared = 62.72%)
Men
Kristmundsson
Hultgren
Sweet
Park
Moise
Overall Men (I-squared = 84.13%)
2014
2013
2011
2011
2006
2014
2013
2011
2011
2006
FIGURE 4a Proportion of patients morphologically suitable for EVAR in women and men separately. References for studies are in Table 29, Appendix 3. Reproduced from
Ulug et al.37 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under CC BY-NC-ND licence.
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0 10 20 30
Non-intervention rate (%)
40 50
Estimate (95% CI)Author
(b)
Period
Non-intervention
(proportion) % Weight
36.92 (26.13, 49.21)
25.42 (15.95, 37.99)
37.18 (27.22, 48.37)
35.56 (23.06, 50.39)
27.60
20.39
33.21
18.80
21.34 (17.55, 25.69)
23.84 (20.36, 27.71)
22.83 (18.08, 28.40)
7.77 (4.81, 12.30)
26.86
27.74
25.63
19.77
24/65
15/59
29/78
16/45
83/389
123/516
58/254
16/206
Whittaker
Scott
Gorst
Karthikesalingam
Whittaker
Scott
Gorst
Karthikesalingam
Jan 2013 - Dec 2015
Jan 2006  - Apr 2012
Jul 2007 - May 2011
Jan 2008 - Dec 2009
Jan 2013 - Dec 2015
Jan 2006  - Apr 2012
Jul 2007 - May 2011
Jan 2008 - Dec 2009
Women
Overall Women (I-squared = 0.00%) 34.23 (28.54, 40.41) 100.00
Men
Overall Men (I-squared = 86.64%) 18.63 (13.44, 25.24) 100.00
FIGURE 4b Non-intervention rates in women and men separately. References for studies are in Table 30, Appendix 3. Reproduced from Ulug et al.37 © 2017 The Authors.
Published by Elsevier Ltd. This is an open access article under CC BY-NC-ND licence.
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Some studies considered relaxing the morphological criteria for EVAR, which increased the proportion
of women suitable for EVAR. For instance, in the largest study,58 reducing the eligible neck length to
> 7.5 mm (from > 15 mm) increased the proportion of women suitable for EVAR from 63 out of 251
(25%) to 113 out of 251 (45%). The 2014 Swedish study56 also considered relaxation of the minimum
iliac diameter from 7.5 mm (Cook Zenith Flex®) or 8 mm (Gore Excluder or Medtronic Endurant) to 6 mm,
which would have increased the proportion of women eligible for EVAR from 27% to 39%. The type
of endograft considered also affects the proportion of women suitable for EVAR. For instance, in one
excluded study61 that considered both conventional endografts and endovascular sealing, just 41% (32/78)
of women were suitable for the Gore Excluder graft but 78% (61/78) would have been eligible for the
Nellix endovascular sealing technology.61 In the largest study,58 evidence was provided showing how
suitability for EVAR declined with increasing aneurysm diameter, with almost no women being suitable for
EVAR if their AAA diameter exceeded 6.5 cm. However, the other four studies56,57,59,60 provided few
demographic or clinical details, so it was not possible to investigate how the suitability for EVAR in women
might depend on age or other characteristics.
Summary
Overall, only 34% of women are suitable for standard endovascular repair (compared with 54% for men).
Even with devices newer than those considered in this systematic review, the proportion of women
suitable for endovascular repair according to the manufacturer’s instructions for use is likely to reach
only 40%.
Proportion of women versus men not offered an intervention
Searching and evaluation yielded four publications, all from the UK: two papers20,64 and two abstracts
(both with additional information from the authors).65,66 All four studies were retrospective, with a total
of just 1365 men and 247 women; the studies were only of fair quality (see Table 30, Appendix 3). The
overall results showed greater heterogeneity for men and suggested that one-third (34.2%, 95% CI
28.5% to 40.4%) of potentially eligible women were not offered or were refused AAA repair, this
proportion being about double the non-intervention rate in men, 18.6% (95% CI 13.4% to 25.2%)
(see Figure 4b). The difference in non-intervention rates between men and women was highest for the
earliest study at a specialist tertiary referral centre.20
Surgical registries and national databases do not record or report the numbers of patients with an AAA
who either are morphologically suitable for EVAR or are denied elective repair. In the case of the latter,
the only data we identified came from four single-centre series in the UK, where the decisions about
repair are made at a multidisciplinary team meeting: presumably the women not offered repair had
extensive comorbidities and had a high risk of early postoperative death. Only one of these series has
provided detailed follow-up data for those initially assigned to a non-intervention policy.64 The authors
found that after 3 years only about one-third of these patients remained alive and that 37% had died
of rupture.
Summary
Overall, 34% of women with clinically relevant an AAA (usually ≥ 5.5 cm in diameter) were not offered
an elective repair of their intact aneurysm, after consideration at a multidisciplinary team meeting.
The non-intervention proportion in women is twice as high as in men.
Thirty-day operative mortality in women versus men
After searching and evaluation, seven papers18,67–72 based on seven studies met the inclusion criteria. Among
these, one study72 reported on perioperative mortality in a combined cohort from 1992 to 2012, but the
30-day operative mortality data for the late era (2003–2012) were obtained from the corresponding author.
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Similarly, the corresponding author of a study investigating the outcomes of primary infrarenal AAA repairs
in the Swedish Vascular Registry (Swedvasc) between 1994 and 2010 provided data on 30-day mortality for
the time period 2006–10.69 All studies included consecutive patients undergoing EVAR and/or open repair
for infrarenal AAAs between 1 January 2000 and 31 December 2013. One further study73 was identified
and the few patients with repairs before 2000 were excluded. Therefore, eight studies18,67–73 were included
in the meta-analysis. All eight studies provided data for intact infrarenal aneurysms only; there were two
studies72,73 that excluded symptomatic AAAs. One very large study74 of an English administrative database
(2002–13) was excluded because much of the 30-day mortality was not aneurysm related. A rather similar
study,75 but for endovascular repair only, based on the same database for the years 2006–15, was not
identified in searches carried out by 26 August 2016.
The characteristics of the included studies are summarised in Table 31, Appendix 3. There were two
population-based studies, one with 765 from Sweden69 and one including 5421 women from the USA.71
Other, mostly smaller, studies, based on either single centre or voluntary registries, were all from the
USA;18,67,68,70,72 in total, this type of study contributed 2438 women. Individual patient data meta-analysis
of four prospective randomised controlled trials (RCTs) [EVAR-1,38 Dutch Randomised Endovascular
Aneurysm Management (DREAM),76 US Open Versus Endovascular Repair (OVER)77 and French Anevrysme
de l'aorte abdominale: Chirurgie versus Endoprothese (ACE)78 trials] contributed data for 148 women.
This gave a total of 8772 women operated on in eight separate studies, with an overall 30-day mortality of
2.23% after EVAR (95% CI 1.86% to 2.68%) with no heterogeneity (Figure 5a), and of 5.37% after open
repair (95% CI 4.18% to 6.88%) with some heterogeneity (Figure 5b). These data contrast with the results
for a much larger cohort of 33,803 men operated on in these same studies with an overall 30-day mortality of
1.29% (95% CI 0.96% to 1.72%) after EVAR and 2.82% (95% CI 1.88% to 4.22%) after open repair; both
overall estimates were subject to considerable heterogeneity (see Figure 5a and b). The Medicare study71
provided more than half the numbers of both men and women. When this study was removed from the
meta-analysis, the 30-day mortality for women changed little: overall mortality 2.55% (95% CI 1.83% to
3.55%) and 4.72% (95% CI 3.83% to 5.82%) for EVAR and open repair, respectively.
Data on confounding factors such as age, AAA diameter, number of symptomatic AAAs included and
comorbidities were sparse, so that the influence of such variables could not be evaluated.
A comprehensive systematic review and meta-analysis25 of sex differences in mortality after either EVAR or
open repair of AAAs was published in 2010. This review included the English-language literature data from
1995 to July 2009 and, for operative mortality, used either 30-day or in-hospital mortality (the latter is
usually lower than 30-day mortality). The review concluded that operative mortality was higher in women
than men: overall odds ratio 2.51 (95% CI 1.72 to 3.69) for EVAR and 1.50 (95% CI 1.33 to 1.69) for
open repair. The results, particularly for open repair, were dominated by a 20-year review (1980–2000)
from the USA with 81,384 women.79 All but two of the 21 papers that offered data for EVAR included
< 60 women. We focused on 30-day mortality only in more recent material, published since January 2009;
this time the included studies had more data for EVAR and the lowest number of women included in any
study was 121. Again, we observed that mortality for both EVAR and open repair was higher in women
than in men, but that mortality rates for EVAR were lower than for open repair. Although the overall
mortality rates have decreased since the earlier systematic review, the odds ratio for women versus men
has changed little. The mortality rate following open repair in women would appear to be unacceptably high.
Summary
Overall, the 30-day operative mortality for intact AAAs in women is almost twice as high as in men.
For EVAR, the pooled operative mortality in women was 2.2% and 5.4% for open repair.
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Estimate (95% CI)Author Repair date Year % Weight
3.13 (1.31, 7.29)
1.65 (0.41, 6.37)
1.23 (0.51, 2.91)
3.04 (1.64, 5.56)
3.20 (1.78, 5.68)
1.30 (0.18, 8.64)
2.11 (1.69, 2.62)
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2003-11
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2002-09
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2016
2012
4.47
1.81
4.55
8.94
9.82
0.91
69.50
0.57 (0.22, 1.52)
1.78 (0.99, 3.19)
0.90 (0.55, 1.49)
2.34 (1.71, 3.18)
0.96 (0.55, 1.69)
1.14 (0.69, 1.89)
1.30 (1.14, 1.49)
Nevidomskyte
Chung
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Mehta
Powell
Schermerhorn
2010-13
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2003-11
2006-10
2002-09
2000-09
2008
2016
2015
2013
2013
2012
2016
2012
6.48
12.00
13.88
18.61
12.57
13.87
22.60
(a)
Women
Overall Women (I-squared = 0.00%) 2.23 (1.86, 2.68) 100.00
Men
Overall Men (I-squared = 0.00%) 1.29 (0.96, 1.72) 100.00
FIGURE 5a The 30-day mortality after EVAR for intact AAAs, in women and men separately. References for studies are in Table 31, Appendix 3. Reproduced from Ulug et al.37
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under CC BY-NC-ND licence.
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8.93 (3.77, 19.72)
3.64 (2.21, 5.95)
3.90 (2.44, 6.18)
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7.04 (2.96, 15.83)
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17/436
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6.58
26.11
2.63 (0.99, 6.80)
1.70 (1.09, 2.65)
1.35 (0.90, 2.03)
2.88 (2.25, 3.69)
4.66 (3.22, 6.71)
2.84 (2.04, 3.93)
5.20 (4.56, 5.92)
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Mehta
Powell
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23/1698
61/2117
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2002-09
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2010-13
2003-11
2006-10
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2002-09
2000-09
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Women
Overall Women (I-squared = 55.58%)
Men
5.37 (4.18, 6.88) 100.00
2.82 (1.88, 4.22) 100.00Overall Men (I-squared = 91.38%)
FIGURE 5b The 30-day mortality after open repair for intact AAAs, in women and men separately. References for studies are in Table 31, Appendix 3. Reproduced from
Ulug et al.37 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under CC BY-NC-ND licence.
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Mortality following ruptured abdominal aortic aneurysms in women
The mortality of women following AAA rupture depends on how many reach hospital alive, how many are
turned down for, or refuse, AAA repair, and mortality following emergency repair, either endovascular
(EVAR) or open repair. There is no recent evidence concerning the proportion of women who reach hospital
alive versus those who do not. Moreover, given the sometimes unreliable reporting of causes of death,
the number of women dying from a ruptured AAA outside hospital may be an underestimate. There is a
suspicion that women may not fare as well as men following rupture of their AAA.17,80 This narrative review
also considers the late mortality (after 3–5 years) of women after successful emergency AAA repair.
Non-intervention rates for emergency repair of ruptured abdominal aortic aneurysms
in women
Earlier work by Anjum and Powell81 reported that up to 75% of women with a ruptured AAA did not
receive an emergency repair, but the source data from English Hospital Episode Statistics (HES) did not
permit full differentiation between patients who did and did not reach hospital alive. Later work used
stratified matching by age and sex to compare non-corrective in-hospital treatment rates in the USA and
England for the years 2005–2010.82 The English data showed that non-corrective treatment was selected
for about 40% women aged < 75 years, rising to over 80% for women aged ≥ 85 years; in the USA,
the comparable rates were about 20% and 60%, respectively. In England, the rate of non-corrective
treatment for men was far lower, about 15% for those aged < 75 years and about 40% for those aged
≥ 85 years. Data from northern Norway83 show that, for the period 2010–14, 42% of women underwent
non-corrective treatment in hospital, compared with 17% of men.
These data can be supplemented by further data from the IMPROVE trial centres, where approximately
25% patients assessed by the vascular team were not considered to be candidates for emergency repair.
The relative proportions of women and men considered not to be candidates for (or refusing) emergency
repair were very different: 161 out of 255 (63%) and 107 out of 548 (20%) respectively. Those not
considered for repair were older than those who underwent repair.
Operative mortality after emergency repair for rupture in women
There are few sources of information for cohorts including more than 100 women. A summary of the
main sources (published and unpublished since 2000, often with < 100 patients) is given in Table 10. The
rates in all sources are likely to depend on the proportion of patients turned down for repair, information
that is rarely provided (see Non-intervention rates for emergency repair of ruptured abdominal aortic
aneurysm in women). Lower mortality is likely to be reported when the proportion of patients receiving an
intervention is lower (selection of the best surgical candidates).
These data all suggest that 30-day operative mortality is higher after open repair than EVAR. This also was
identified in an earlier large cohort Medicare study17 (1995–2006), in which 30-day mortality in women
after EVAR was 41% versus 53% after open repair. Similarly Vascunet (international registry collaboration)
shows lower in-hospital mortality in women after EVAR versus open repair, 36% and 44%, respectively
(Professor Maarit Venermo, University of Helsinki, 2016, personal communication).
Late mortality after emergency repair of ruptured abdominal aortic aneurysms in women
There is a paucity of information regarding survival beyond 30 days for women who have undergone
repair of a ruptured AAA. Several publications in the endovascular era since 2000 have assessed mid-term
survival between 1 and 5 years following the repair of a ruptured AAA. Although the results are not
separated by sex, in the multivariate analyses the odds or hazard ratios reported for women range from
1.1 to 1.4, indicating a higher mortality overall in women. Further details, with a breakdown of results by
sex, were requested for two of these cohorts with a strong population base, the Amsterdam region,
the Netherlands87 and New England, USA (VSGNE),88 but were not available. This leaves the only data
to 1 year and beyond, as shown in Table 10, with a total of only 245 women. Table 10 also shows
unpublished 2- and 3-year survival data from HES and the data for the IMPROVE trial.30
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The only published longer-term follow-up comes from the earlier large Medicare data set from 1995 to
2006 with 48,865 participants (23.5% women). Among women, the 5-year survival following EVAR was
32% (95% CI 25% to 39%), compared with 19% (95% CI 18% to 21%) following open repair.
Summary
The turn-down rate or non-corrective treatment rate of women with ruptured AAAs is not usually reported
but is likely to be at least 40% and rises with age. Recent data indicate that, overall, the 30-day mortality in
women is about 40% but probably is lower after EVAR compared with open repair. Although longer-term
data for women are scant, overall about half the patients who undergo repair are alive at 3 years. The
differential mortality between EVAR and open repair observed at 30 days appears to be preserved at 1 year
and data from HES suggest that this difference is maintained at 2 years, with possibly some attenuation by
3 years.
TABLE 10 Mortality in women undergoing repair of a ruptured AAA
Trial or study
(recruitment
period)
Number
of women
30-day mortality 1-year mortality
2-year
mortality
3-year
mortality
EVAR Open EVAR Open EVAR Open EVAR Open
AJAX,84 2004–11,a
the Netherlands
17 2/8 3/9 3/8 3/9 N/A N/A
ECAR,85 2008–13,a
France
10 0/5 0/5 1/3 2/4 N/A N/A
IMPROVE,24
2009–13,a mainly
the UK
133b 26/70 36/63 28/70 38/63 N/A 35/69 44/63
VSGNE18 2003–11,
USA
84 6/22 30/62 10/22 36/62 N/A N/A
Norway,83 2007–12 21 – 12/21a – 13/21 N/A N/A
Total 245 34/105
(32%)
81/160
(51%)
42/103
(41%)
92/159
(58%)
N/A N/A
HES 2010–14
for those aged
> 65 years, England
995 49/215
(22.8%)
300/780
(38.5%)
33.7% 47.0% 37.4% 50.7% 45.4% 54.1%
N/A, not available.
a Combined in an individual patient data meta-analysis, and shown by type of repair started.86
b Mortality outcome for one woman censored before 3 years.
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Chapter 4 Screening, abdominal aortic aneurysm
growth and rupture, and surveillance parameters
for women
This chapter describes the sources of data and modelling approaches used to obtain importantparameters relevant to screening, AAA growth, rupture and surveillance for women invited to an AAA
screening programme. At the end of each section, the base-case estimate that is used for the economic
modelling in Chapter 7 is presented, together with other estimates used in sensitivity analyses. This chapter
addresses part of objective 3 in Chapter 1, Scientific objectives, and the parameters listed in Table 1.
A summary of all these parameter estimates is provided in Table 32, Appendix 4.
Screening
Reinvitation
No information on the proportion of women who would be reinvited to AAA screening following
non-attendance could be found. Therefore, the reinvitation rate is based on data in men from NAAASP.
Table 33, Appendix 4, shows the numbers invited and attending screening in the 2013/14 and 2014/15
cohorts in NAAASP. The total attendance rate was 242,674/300,667 (80.7%) in 2013/14 and 236,936/
293,709 (80.7%) in 2014/15. The proportion reinvited, which affects the overall costs of the screening
programme, is calculated as the number who did not attend the first appointment minus the number
who declined screening, all divided by the total number offered an appointment. The proportion who are
reinvited stays at a constant 23.9% across the 2 years. This is higher than the 13.6% reinvited in the
MASS trial,10 which was used as the basis for the health economic evaluation in men. Uncertainty in
this figure for the PSA is very low if the number of reinvitations and total number are used directly as
parameters of a Beta distribution (see Table 32, Appendix 4).
In the base-case analysis, a reinvitation rate of 23.9% is used based on NAAASP data for men from
2013/14 and 2014/15.
Attendance rate
The attendance rate is an important consideration and will influence the cost-effectiveness of any AAA
screening programme. Evidence regarding the potential attendance rate for screening programmes
involving both men and women is summarised here.
Participation of women in colorectal cancer screening
Screening for colorectal cancer is based on testing for faecal occult blood, with test kits posted to
individuals’ homes and the completed test kits returned to the screening centre by post. The results of the
first 2.6 million invitations to colorectal screening (October 2006 to January 2009) have been analysed in
some detail.89 Overall, the uptake (returned kits) was 51% in men and 56% in women. In women, the
uptake rate was the same in those aged 60–64 years as in those aged 65–69 years (although uptake in
men increased from 49% to 53% over these age bands). The overall uptake was 54%, which compares
favourably with similar screening programmes in Australia90 and the Netherlands91 (uptake rates of 46%90
and 49%,91 respectively).
However, because the uptake is relatively low, with scope for improvements, the barriers to participation
have been analysed in some detail.89,92 In common with many other screening programmes, including
NAAASP, socioeconomic status is of great importance, with deprived areas reporting lower uptake rates;
non-white ethnic groups also appear to have a lower screening uptake, although the difference may be
lower in women than in men. Furthermore, among women, there appears to be dislike of the actual
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screening test, contributing towards much lower participation in colorectal screening than in breast
screening.92 The lower uptake rates in men, and change with age, have been attributed to the difficulty of
completing the test kit while out at work.
In summary, for UK colorectal cancer screening, uptake is higher in women than in men, but there is no
change in uptake in the age range 60–69 years.
Population screening for abdominal aortic aneurysms in women
There is limited experience, but the main results come from the Chichester screening RCT33 in the early
1990s. This showed that the uptake of AAA ultrasound screening was lower in women than in men and
declined with age, particularly in those aged > 75 years. Table 11 shows the attendance rate at screening
by age and sex from the 7887 men and women in the group invited to screening.
Although this is a relatively small, now dated, sample (4682 women), the results from a more recent study
(2007–9) of 6925 women from two Swedish counties showed only a slight increase in uptake: 74% of
70-year-old women accepted the invitation to screening.14 This contrasts with an acceptance rate for
65-year-old Swedish men of 85% for national AAA screening, 2006–10.93 Furthermore, the MASS trial94
showed that the uptake in men aged 65–69 years was similar to the uptake at 70–74 years (81% and
79%, respectively). The uptake rate in NAAASP is very similar at around 80% (see Reinvitation).
In summary, uptake rates in AAA screening may be lower (by up to 10%) in women than in men.
Increasing the age of screening attenuates the participation in screening.
Summary
Data in Table 11 from the Chichester study33 are used in the modelling: for 65-year-old women in the base-case
analysis (see Chapter 7) and for other age groups when assessing different screening strategies (see Chapter 8).
A Beta(218,82) distribution is used to account for parameter uncertainty in the base-case PSA.
TABLE 11 Acceptance of invitation to screening in the Chichester area, by age and sex
Age (years) Total screened (n) Total invited (n) Accepted (%)
65
Men 169 210 80.5
Women 218 300 72.7
66–70
Men 922 1208 76.3
Women 1123 1635 68.7
71–75
Men 676 919 73.6
Women 905 1364 66.3
76–80
Men 575 868 66.2
Women 806 1383 58.3
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Non-visualisation
There is no information on the proportion of women whose aortic diameter would be non-visualised at a
screening session, and so this information has also been obtained from NAAASP (see Table 34, Appendix 4).
Based on NAAASP data for men from 2013/14 and 2014/15 combined, the non-visualisation proportion (after
attempts on two separate occasions) is very low, at 0.35%, considerably lower than the 1.21% reported in the
MASS trial.10
A non-visualisation rate of 0.35%, based on NAAASP data for men, is used in the base-case analysis.
Aortic diameter distribution
A crucial consideration when screening a population of women is the distribution of aortic diameters and,
related to this, the prevalence of AAAs detected at screening (i.e. the proportion of diameters detected
above the diagnosis threshold, e.g. diameter of ≥ 3.0 cm). We obtained data on the full aortic diameter
distribution in women from two sources: (1) 5140 women from Uppsala and Dalarna, Sweden, aged
70 years who were screened using leading edge to leading edge diameter measurements between 2007
and 2009,14 and (2) 570 women from Viborg, Denmark, aged 67 years who were screened using
outer-to-outer wall diameter measurements in 2015 (Professor Jes Lindholt, personal communication).
A third source of information comes from the first 700,000 men screened in NAAASP, using inner to inner
wall diameter measurements. Although not directly relevant, this large source of information may still be
useful if it is suitably reweighted (see Prevalence of abdominal aortic aneurysms) so that it has the same
prevalence of AAAs as seen in women. Table 12a compares each data source in terms of the proportion of
screened individuals by 0.5-cm categories of aortic diameter. These results show that the prevalence of AAAs
≥ 3.0 cm is higher in the population of men in NAAASP than in the population of women screened in
Sweden and Denmark, as is the prevalence of aortic diameters ≥ 2.0 cm (18.3% in NAAASP vs. 8.4% and
14.0% in Sweden and Denmark, respectively). This latter size range is important as it is aortic diameters of
this size that are allowed to grow and potentially rupture within the DES model (see Chapter 2, Modelling
aortic growth and abdominal aortic aneurysm rupture). The mean aortic diameters are 1.79 cm and 1.66 cm
in NAAASP men and Swedish women, respectively. The mean diameter could not be accurately calculated in
the Danish women as aortic diameter was available only in 0.5 cm categories. In the Swedish study, the
standard deviation (SD) of the distribution is 0.26 cm, resulting in an aortic diameter of 2.5 cm being 3.2 SDs
above the mean (or 51% higher) and one of 3.0 cm being 5.2 SDs above the mean (or 81% higher). In
comparison, in men (NAAASP), 2.5 cm is 2.0 SDs above the mean (40% higher) and 3.0 cm is 3.4 SDs above
TABLE 12a Original (unweighted) aortic diameter distributions for two screening studies for women in Sweden
and Denmark and comparison with the UK NAAASP in men
Aortic diameter (cm)
Uppsala and Dalarna,
Sweden (N= 5140 women),
n (%)
Viborg, Denmark
(N= 570 women), n (%)
NAAASP (N= 700,000 men),
n (%)
< 1.0 1 (0.02) 0 (0.0) 37 (0.01)
1.0–1.4 909 (17.7) 131 (23.0) 49,147 (7.0)
1.5–1.9 3796 (73.9) 359 (63.0) 522,513 (74.6)
2.0–2.4 385 (7.5) 77 (13.5) 108,988 (15.6)
2.5–2.9 30 (0.6) 3 (0.5) 9927 (1.4)
3.0–4.4 (small AAA) 16 (0.31) 0 (0.00) 7605 (1.09)
4.5–5.4 (medium AAA) 3 (0.06) 0 (0.00) 1028 (0.15)
≥ 5.5 (large AAA) 0 (0.00) 0 (0.00) 755 (0.11)
Prevalence (≥ 3.0) 0.37% 0.00% 1.34%
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the mean (68% higher). Outer–outer diameter measurements are expected to be larger than leading
edge–leading edge or inner–inner measurements, which makes it even more surprising that the prevalence
of AAAs was 0% in the Viborg study.
Prevalence of abdominal aortic aneurysms
The estimates obtained from the systematic review of AAA prevalence in women (see Chapter 3, Current
prevalence of screen-detected abdominal aortic aneurysms in women) are used to inform the proportion
of the aortic diameter distribution, that is, ≥ 3.0 cm. The pooled prevalence estimate from this systematic
review was found to be 0.74% (95% CI 0.53% to 1.03%) overall and 0.43% (95% CI 0.23% to 0.80%) in
60- to 69-year-old women. This is higher than the estimate found in either the Swedish or Danish studies,
but lower than that seen in NAAASP. To use this information from the systematic review, each of the aortic
distributions described is reweighted. This has the effect of shifting the distribution in order for the desired
prevalence to be achieved. A linear reweighting approach is taken using the following algorithm.
Let pold be the prevalence of AAAs calculated in the aortic diameter distribution being considered and
pnew be the prevalence that we wish to recalibrate the distribution to (e.g. 0.43% for 60- to 69-year-old
women). Each aortic diameter size x (accurate to 1 mm) has an associated probability weight w(x)
indicating the proportion of individuals in the distribution who were screened with that diameter.
The weights sum up to 1. It follows that:
pold =∑x ≥ 3:0w(x). (14)
Given the desired prevalence, pnew, calculate new weights, w*(x), as follows:
w*(x) = f (x)w(x), (15)
where f(x) = a + bx is a linear function of x. The conditions that must be satisfied are:
∑x ≥ 3:0 f (x)w(x) = pnew (16)
and
∑xf (x)w(x) = 1: (17)
TABLE 12b Reweighted aortic diameter distributions for two screening studies for women in Sweden and Denmark
and comparison with the UK NAAASP in men (both reweighted distributions have an AAA prevalence of 0.43%)
Aortic diameter (cm) Uppsala and Dalarna, Sweden (reweighted) (%) NAAASP (reweighted) (%)
< 1.0 0.02 0.01
1.0–1.4 17.24 8.05
1.5–1.9 73.93 76.49
2.0–2.4 7.75 14.01
2.5–2.9 0.63 1.01
3.0–4.4 (small AAA) 0.356 0.426
4.4–5.4 (medium AAA) 0.074 0.004
≥ 5.5 (large AAA) 0.000 0.001
Prevalence (≥ 3.0) 0.43% 0.43%
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A pair of simultaneous equations can, therefore, be obtained to give the solutions:
b =
pold −pnew
pold∑xx w(x)−∑x ≥ 3:0x w(x)
(18)
and
a = 1− b ∑xx w(x). (19)
After reweighting, some of the new weights may be negative. If this occurs, these are set to zero and then
a further reweighting step is performed to ensure the weights above the diagnosis threshold (e.g. 3.0 cm)
sum to the desired prevalence. Applying this algorithm to the aortic diameter distributions shown in Table 12a,
using the estimated prevalence of 0.43% found from the systematic review for 60- to 69-year-old women
(see Chapter 3, Current prevalence of screen-detected abdominal aortic aneurysms in women), gives the
distributions shown in Table 12b. Note that this approach could not be used with the Viborg data as there
were no cases of AAAs reported in this screening study (and, hence, the slope parameter b is infinite). It can
be seen that the reweighted Swedish and NAAASP distributions are different, with a higher proportion of
≥ 2.0-cm aortic diameters in NAAASP. Furthermore, no AAAs of diameters of ≥ 5.5 cm were found in the
Swedish study. This would have an important impact in the modelling, giving rise to no AAAs that are
immediately referred for elective surgery.
Summary
The reweighted NAAASP distribution is used in the base-case analysis. The distribution is reweighted to
have 0.43% prevalence, as found in the 60- to 69-year age group in the systematic review. In a one-way
sensitivity analysis, the reweighted NAAASP distribution is replaced with the reweighted Swedish aortic
diameter distribution. Two other DSAs are conducted to assess the robustness of results to a doubling or a
halving of the prevalence. Within the PSA, uncertainty in the estimated prevalence of 0.43% is incorporated
to assess how this affects uncertainty in the health economic outputs. To do this, in repeated PSA iterations,
the prevalence is drawn from a normal distribution on the logit scale since this was the scale used to
perform the meta-analysis (see Table 32, Appendix 4). For each draw from this distribution, a reweighted
NAAASP distribution is calculated. When assessing ages other than 65-year-old women, the prevalence is
changed accordingly to the age-specific estimates from the systematic review.
Growth and rupture rates of abdominal aortic aneurysms in women
Data from observational surveillance studies of AAAs in the diameter range 3.0–5.4 cm in the RESCAN
collaborative project16 were used to estimate growth and rupture rates in women. Eleven studies from
RESCAN35 recruited women (see Table 35, Appendix 4, for a descriptive summary of these studies).
Growth modelling
A mixed-effects model was used to model the longitudinal AAA diameter trajectories for each woman in
each of the 11 studies. A model was fitted separately within each study assuming a linear relationship
between log-AAA diameter and time since entry into the study (see Chapter 2, Modelling aortic growth
and abdominal aortic aneurysm rupture, for the rationale to using this model). The model allowed a
separate intercept and slope parameter for each individual through the use of random effects. For
individual i with measurement j at time tij years after study entry, the AAA diameter yij (cm) is modelled as:
log(yi j) = b0i + b1i ti j + ϵi j
=mi j + ϵi j
(b0i, b1i)
T∼ N2(β,G),
(20)
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where
ϵi j ∼ N

0, σ2w

, (21)
β =

β0
β1

(22)
and
G =

σ20 ρσ0σ1
ρσ0σ1 σ
2
1

. (23)
β0 and β1 represent the mean intercept and slope of the AAA diameter trajectories on the log-scale,
respectively, while b0i and b1i allow for individual variation about the intercept and slope (random effects).
The random effects for each patient are correlated and come from a bivariate normal distribution.
Parameter estimates obtained from this model for each study are shown in Table 36, Appendix 4, and a
forest plot for the average factor increase in AAA diameter per year (exp β1) is shown in Figure 6. In a
second stage, study-specific estimates are pooled via multivariate random-effects meta-analysis (overall
estimates shown in Table 36, Appendix 4). On average, AAA diameter increases by 5% per year, but with
considerable heterogeneity between both studies and people. The average and distribution of AAA growth
rates in women and men are in fact similar.35
As described in Chapter 2, Modelling aortic growth and abdominal aortic aneurysm rupture, the approach
taken in the DES is first to sample baseline diameters from our chosen distribution (see Aortic diameter
distribution) and then generate random effects for each individual conditional on their baseline diameter,
using the parameter estimates obtained from the overall linear mixed-effects model.
Table 37, Appendix 4, shows the estimated proportion of individuals predicted to cross the intervention
threshold (5.5 cm) within 5 and 10 years, in the absence of any deaths. For comparison, the empirical rates
estimated in the 11 RESCAN35 studies for women in the absence of any competing risks (e.g. deaths) are
also shown. The data from the 11 RESCAN35 studies are naively pooled to estimate the empirical rates.
The predicted rates lie within the 95% CIs for the observed rates in all size/threshold categories.
I 2 = 87%
Overall (multivariate meta-analysis)
UKSAT
Sweden
Stirling
Spain
PROPRANOLOL
PIVOTAL
Tromsø, Norway
Manchester
Leeds
Edinburgh
Chichester
exp(β1) (95% CI)
1.05 (1.05 to 1.06)
1.06 (1.06 to 1.07)
1.06 (1.04 to 1.07)
1.06 (1.05 to 1.06)
1.06 (1.04 to 1.08)
1.05 (1.03 to 1.06)
1.03 (1.02 to 1.04)
1.05 (1.04 to 1.06)
1.05 (1.04 to 1.06)
1.06 (1.05 to 1.07)
1.08 (1.07 to 1.08)
1.04 (1.02 to 1.05)
1.00 1.05 1.10
FIGURE 6 Mean proportionate increase in AAA diameter per year, from RESCAN35 studies.
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Summary
In the base-case analysis, growth rate parameters are taken from the overall parameters estimated by
two-stage meta-analysis, as given in Table 36, Appendix 4. The PSA uses the variance–covariance matrix of
these parameters to propagate uncertainty through to health economic outputs (see footnote to Table 32,
Appendix 4).
Rupture rates
Rupture data were available in only 6 out of the 11 RESCAN studies35 that provided growth data
(Edinburgh and Leeds did not record rupture information and the Propranolol, PIVOTAL and Swedish
studies did not have rupture events in both men and women; see Table 35, Appendix 4). Characteristics of
these six studies are shown in Table 38, Appendix 4.
A joint growth and rupture model was fitted to the data separately within each study before pooling
estimates using multivariate random-effects meta-analysis. As ruptures were rare, we used data from
both men and women and allowed for sex differences in the baseline AAA diameter and rate of rupture
by including sex as a covariate in both the longitudinal (growth) and survival (rupture) submodels. As
described in Growth modelling, a linear relationship between log (diameter) and time was assumed to
model the growth of an aneurysm. The hazard of rupture was related to an individual’s current predicted
(log) AAA diameter, mi(t), and their sex as follows:
loghi(t) = γ0 + γ1 mi(t) + γ2 sexi. (24)
mi(t) = β0 + β1t + β2sexi + b0i + b1i t. (25)
Pooled estimates obtained from the rupture submodel are shown in Table 39, Appendix 4, together with
an estimate of between-study heterogeneity as given by the I2 statistic. The association between the risk
of rupture and AAA diameter is depicted in Figure 7 for women, predicted from each study-specific model
and from the pooled estimates. For comparison purposes, the empirical observed rates of rupture by
0.5 cm categories are also shown. The pooled model trajectory gives a reasonable fit to the overall data.
Study-specific estimates can be seen to vary considerably. The pooled rate of rupture reaches 1 per 100
person-years at a predicted diameter of 4.2 cm.
Summary
In the base-case analysis, estimates for parameters relating to the risk of rupture are obtained from the
pooled multivariate meta-analysis. Parameter uncertainty in the PSA is accounted for using the estimated
variance–covariance matrix. Estimates are shown in Tables 32 and 39, Appendix 4.
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FIGURE 7 Comparison of observed rates of rupture (with 95% CIs) and those predicted from study-specific models
and a pooled model, from RESCAN studies.35
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Surveillance
The clinical effectiveness and cost-effectiveness of a screening programme will be reliant on the operation
of a surveillance programme for detected AAAs, and will be affected by (1) the rate of dropout from
the screening programme, (2) the rate of incidental detection for individuals found to have an AAA not
through the screening programme and (3) the efficiency of the programme in ensuring consultations and
surgical operations are performed in a timely manner. Sources of data for each of these three parameters
are addressed in this section.
Dropout
Data on the rate at which women drop out from regular surveillance were kindly made available from two
AAA surveillance programmes that have recruited both men and women with incidentally detected AAAs:
(1) the Leicester AAA surveillance programme (81 women and 353 men between September 2004 and
September 2015; Professor Matthew J Bown, personal communication) and (2) the Imperial College AAA
surveillance programme (28 women and 97 men recruited in 2010; Professor Janet T Powell, personal
communication). Dropout information from Leicester was available from January 2014 onwards and,
hence, only individuals still in the surveillance programme from 2014 onwards were considered (n = 389).
Dropout was defined as any of the following reasons for leaving surveillance: (1) discharged, (2) patient
cancelled, (3) moved location, (4) referral for other surgery and (5) other. For the Imperial College AAA
surveillance programme, information on dropouts was collected from 2010 to 2015 and included the
following reasons: (1) did not attend and (2) moved away. Only year of scan was recorded and, hence,
follow-up time was an integer defining year of last scan minus year of first scan. In this study, 30 individuals
had only one scan recorded and were excluded from the analysis. Table 13 shows the rate of dropout for
women and men from the two screening programmes along with the estimated hazard ratio between men
and women from a Cox regression model. There was no evidence from either of the screening programmes
of a differential dropout rate between women and men.
A further source of data on dropout rates in men is NAAASP. NAAASP includes 13,271 men who were
under surveillance (11,136 screen detected, 2135 self-referrals) up to 4 April 2016. Follow-up was defined
as the date of first scan to the date of last scan or status update date, whichever came later. Of these
TABLE 13 Sources of data for dropout rates in women and men
Item
Leicester
surveillance
programme
Imperial College
surveillance
programme NAAASP
Number in surveillance
Women 72 23 –
Men 317 72 10,734
Dropout from surveillance (n)
Women 7 7 –
Men 28 8 1072
Rate of dropout per person-year
Women 7/74= 0.0945 7/80= 0.0875 –
Men 28/338 = 0.0827 8/209= 0.0383 1072/19,650 = 0.0546
Hazard ratio (men vs. women) 0.887 (95% CI
0.385 to 2.045);
p= 0.78
0.516 (95% CI
0.186 to 1.427);
p= 0.20
–
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individuals, 2537 in whom only one scan was recorded were excluded from these analyses. Dropout was
defined as any of the following reasons for leaving the programme: (1) appointment missed, (2) declined,
(3) non-visualised, (4) out of cohort, (5) surveillance ceased or (6) temporarily ineligible. These additional
data are also summarised in Table 13. The dropout rate was estimated to be 5.5 per 100 person-years.
A sensitivity analysis including the 2537 individuals with only one scan (giving them a very small follow-up
time) gave a very similar estimated rate (5.6 per 100 person-years). There was also little evidence of a
difference in dropout rates between self-referred and screen-detected individuals (p = 0.081).
Summary
From these analyses, there is little evidence of a difference in dropout rates between men and women.
Therefore, owing to the large sample size of NAAASP and the fact that any screening programme for
women is likely to be incorporated within NAAASP’s screening processes, the dropout rate estimated in
NAAASP (5.46 per 100 person-years) is used in the base-case analysis. This is lower than the dropout
rate seen in the MASS trial10 (8.20 per 100 person-years), which was originally used to model the
cost-effectiveness in men, although an updated model for men used a dropout rate of 5.57 per
100 person-years,12 which closely reflects the figure seen in NAAASP. A Gamma(1072,19650) distribution is
used in PSA to account for uncertainty in the dropout rate. In DSAs, the dropout rate is doubled and halved
to investigate the effect on key health economic quantities.
Incidental detection
Data from electronic hospital records of women aged ≥ 65 years undergoing CT scanning were obtained
from the University Hospital of South Manchester in 2014; 2494 women underwent an abdominal CT
during this period and 65 AAAs were identified. Of these, 53 were newly identified AAAs, but only
seven were referred on to vascular surgeons to be followed up with surveillance or elective surgery.
The population (women aged ≥ 65 years) of the referral catchment area for the university hospital is
approximately 24,500. Assuming that 181 (0.74%) of these women have an aneurysm (see Chapter 3,
Current prevalence of screen-detected abdominal aortic aneurysms in women), this would indicate an
incidental detection rate to a surveillance programme of approximately 7/181 = 3.9 per 100 person-years
for women aged ≥ 65 years with an AAA. This is similar to the rate of 4.6 per 100 person-years used in
the most recent health economic model for men.12
Further data come from a study conducted in Canterbury, New Zealand,36 in which 167 new incidental
AAAs were detected in men and women from CT scans over a period of 4.25 years. About one-quarter of
all detected AAAs (incidental and known) were in women. Assuming this proportion also applies to the
incidental AAAs and that 97% of AAAs were in individuals aged ≥ 65 years, there would be approximately
40 AAAs detected in women aged ≥ 65 years. From census data, the 2006 population of women aged
≥ 65 years for the catchment area (Canterbury, West Coast and Timaru regions of South Island, New
Zealand) was approximately 43,500. Assuming that 321 (0.74%) of these women had an aneurysm
(see Chapter 3, Current prevalence of screen-detected abdominal aortic aneurysm in women), this would
indicate an incidental detection rate of approximately 40/(321 × 4.25) = 2.93 per 100 person-years for
women aged ≥ 65 years with an AAA. This is also quite similar to the rate of 4.6 per 100 person-years
used in the most recent health economic model for men.12
Summary
An incidental detection rate of 2.93 per 100 person-years, as estimated from the New Zealand study,36
is used in the base-case analysis. A Gamma(40,1364.25) distribution is used in the PSA to account for
uncertainty in the incidental detection rate. In DSAs, the incidental detection rate is doubled and halved to
investigate the effect on key health economic quantities.
Delay from ≥ 5.5-cm scan to consultation
Data from NAAASP for the years 2013/14 and 2014/15 indicate that 981 men in total were referred
to vascular services, of whom 947 (97%) received a consultation. The mean time from referral scan to
consultation was 10.6 days, much lower than the mean delay of 71 days observed in the MASS trial.10
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A time delay from referral screen to consultation of 10.6 days based on NAAASP is used in the modelling.
Consultation scan: computerised tomography scan versus ultrasound scan
At consultation, an AAA is confirmed (or otherwise) using a CT scan. The measurement of the AAA
diameter made with this CT scan may be systematically higher than that seen on an ultrasound scan.
Evidence for this comes from the RESCAN collaboration35 in which four studies measured diameters using
both ultrasound and CT scans. CT measurements were, on average, significantly larger than ultrasound
measurements {Leeds 3.91 mm [standard error (SE) 0.33 mm], PIVOTAL 1.75 mm (SE 0.21 mm), Galdakao
1.77 mm (SE 0.10 mm), Stirling 2.46 mm (SE 0.27 mm)}. A pooled estimate from these studies suggests an
average increase of 2.44 mm.
There is also evidence that the measurement error for a CT scan may be different from that based on an
ultrasound scan. A paper by Singh et al.95 suggests that a CT measurement of AAA diameters has
interobserver ‘variability’ of 5.2 mm (defined as 1.96 multiplied by the SD of interobserver differences).
This equates to a CT measurement error SD of 1.9 mm. This is lower than the estimated ultrasound
measurement error SD from the RESCAN35 model for a large AAA, approximately 55exp(–2.96) = 2.9 mm
for a 5.5-cm aneurysm (see Table 36, Appendix 4).
In the modelling, the mean observed diameter from a CT scan is assumed to be 2.44 mm higher than that
obtained from an ultrasound scan, with a measurement error SE of 1.9 mm.
Decision at consultation: proportion returned to surveillance
The DES programmed for men (see Chapter 2) used the observed CT scan diameter at consultation to
decide whether or not the individual should be returned to surveillance, with those with AAAs of
measured diameter < 5.5 cm returned to surveillance. Based on the CT measurements, 13.7% of
consultations resulted in an individual being returned to surveillance. This is a much higher rate than the
36 out of 947 men (3.8%) who were ‘inappropriate referrals’ (AAA diameter of < 5.5 cm, other or not
stated) in NAAASP data. Nevertheless, in our modelling, the proportion of women who are returned
to surveillance after a consultation is derived from the proportion of CT measurements that are < 5.5 cm.
Decision at consultation: non-intervention rate in women not returned to surveillance
Women may refuse surgical intervention, or may be turned down because of contraindications.
Information on the non-intervention rate in women not returned to surveillance (i.e. the proportion
turned down for elective surgery or refusing an operation) comes from four hospitals in the UK (see
Chapter 3, Proportion of women versus men not offered an intervention). The overall non-intervention
rate is 34% (95% CI 29% to 40%), with no between-study heterogeneity (I2 = 0%).
The proportion of individuals elective surgery in whom surgery is deemed to be contraindicated is based
on the pooled estimate from four UK hospitals of 0.3423. The PSA is based on a normal(–0.653, 0.1352)
distribution for the logit pooled probability.
Decision at consultation: proportion who will receive elective surgery
The proportion of women who receive elective surgery is defined in the model based on the remaining
population who are not turned down, refuse surgery or are returned to surveillance.
Delay from consultation to elective surgery
Among 827 individuals in whom surgery took place in NAAASP, the mean time from referral to surgery
was 81.4 days. Assuming that the mean time from consultation to referral was 10.6 days, this would imply
a mean time from consultation to surgery of 70.8 days, slightly higher than the mean delay of 59 days
observed in the MASS trial.10 In our modelling, a time delay from consultation to surgery of 70.8 days is
used for everyone for whom surgery is planned, based on NAAASP data.
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Chapter 5 Surgery-related parameters for women
C rucial parameters in any AAA screening model are those that relate to surgical AAA repair. Theseinclude operative mortality rates for both EVAR and open repairs, for both elective and emergency
operations. For example, high postoperative mortality rates following elective AAA repair would reduce any
benefits of a screening programme. Also important are the rates of reinterventions and the long-term
AAA-related mortality rates after these operations. Of particular relevance to the assessment of the clinical
effectiveness of AAA screening in women is the evidence that both postoperative morbidity and mortality
are higher in women than in men.74 This may negatively affect the clinical effectiveness of AAA screening
in women.
This chapter provides estimates of the parameters for women listed in Table 2, addressing part of objective 3
in Chapter 1, Scientific objectives.
Sources of data
Data on operations and patient outcomes were available for the UK from the NVR,26 for England and
Wales from HES,28 and internationally from the voluntary Vascunet register.27 Postoperative data on
reinterventions can, in principle, be extracted from HES by linking records, as can long-term mortality from
HES–Office for National Statistics (ONS) linkage. We also used published data and other particular data
sets to provide information on these parameters; these are described later in this chapter.
National Vascular Registry
The submission of data to the NVR by vascular units is voluntary, but it is generally thought to be about
90% complete.26 Data are entered into the NVR by surgeons at the time of surgery and/or at the time of
discharge from hospital. The registry covers all types of vascular surgery, including elective and emergency
AAA repairs. Under a data sharing agreement with the Healthcare Quality Improvement Partnership,
individual-level data were obtained for all AAA repairs reported to the NVR from 1 January 2010 to
31 December 2014. The initial year was set at 2010 to focus on recent practice and because this is when
EVAR became reliably recorded in the NVR. NVR provides data on AAA size and in-hospital mortality
(rather than 30-day mortality). For men, incidentally detected and screen-detected AAAs are sometimes
(but not always) distinguished; for women, it is assumed that all AAAs have been incidentally detected as
no systematic screening was in place in the UK during the period covered by the data extract.
Hospital Episode Statistics
Summary tabular data were made available from HES28 for the same time period as the NVR data extract
(1 January 2010 to 31 December 2014). To comply with confidentiality requirements, cells in the tables
with values of 5 or below were either merged with neighbouring categories or supressed. Identifying
operations as AAA repairs is more difficult in HES than the NVR, as one admission may generate multiple
hospital episodes each recorded separately in HES. Data on both 30-day and in-hospital mortality can be
extracted from HES.
Vascunet
Vascunet is an international register of vascular surgical procedures, and includes data principally from
mainland Europe but also some from the UK and Australasia.27 Submission of data to this register is
performed much less routinely than for the NVR, and Vascunet should be regarded as far from complete.
Nevertheless, it provides an interesting comparator as it includes data from outside the UK. Summarised
tabular data from Vascunet were obtained for the years 2010–13.
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Use of National Vascular Registry data as a source of parameter estimates in women
As the NVR provides the most detailed data, it is the principal source of evidence we use for surgical
parameters for women. This section describes the principles employed.
The NVR allows modelling of individual data with respect to sex (men vs. women), age and AAA diameter.
Most of the information is in the form of proportions (p), for example, the proportion of patients receiving
EVAR, or the proportion of patients undergoing EVAR who die in hospital. We use logistic regression
models, including all possible sex interactions, to provide estimates for women in two ways, as described
here. The SEs from these regressions are used to represent parameter uncertainty in the PSA via correlated
normal distributions. The data in the NVR on whether the AAA was detected by screening or incidentally
are available only for men (as there was no screening for women during this time period) and, even for
men, this information is only about 35% complete. As we are primarily concerned with estimates for
women, we do not include this variable in the logistic regression models.
First, we consider just the overall proportion for women derived from the simple logistic regression:
logit (p) = aF + aM × sex, (26)
where sex is coded as ‘0’ for women and ‘1’ for men. The parameter aF is the log-odds for women and aM
is the log-odds ratio comparing men with women. We use expit(aF) = exp(aF)/[1 + exp(aF)] as the estimated
probability for women.
In a second analysis, we use the more detailed logistic regression:
logit (p) = aF + aM × sex + b1F × (age – 80) + b1M × sex × (age – 80) + b2F × (AAA diameter – 6:0)
+ b2M × sex × (AAA diameter – 6:0).
(27)
Here, b1F is the change in the log-odds per year of age and b1M is the difference in this log-odds between men
and women. Similarly, b2F is the change in log-odds per cm increase in AAA diameter and b2M is the difference
in this log-odds between men and women. Subtracting the values of age (80 years) and AAA diameter
(6.0 cm) reduces the correlations between parameter estimates; the intercept aF now refers to a woman
aged 80 years with an AAA diameter of 6.0 cm. For example, we use Equation 27 to estimate the relevant
proportion for a woman aged 71.2 years with an AAA of diameter 6.2 cm, as expit (aF – 8.8 × b1F+ 0.2 × b2F).
In this second analysis, we include all the terms in the logistic regression (Equation 27), whether or not
they are statistically significant. We use linear terms for age and AAA diameter. We do not model trends
according to calendar time, as the purpose here is to use relevant recent evidence; any extrapolation to
the future would likely be very unreliable. One slight disadvantage of the second model is that the few
patients with missing values of age or AAA diameter in the NVR have to be omitted.
Elective operations
We separate AAA operations into those that were planned (i.e. electively for large AAAs) and those that
were performed either urgently (e.g. for symptomatic AAAs) or as an emergency (i.e. for AAA rupture).
This section focuses on elective operations.
Proportion receiving endovascular aneurysm repair for elective abdominal aortic
aneurysm surgery
Open AAA repair and EVAR have different immediate mortality rates and different subsequent rates of
reinterventions and AAA-related mortality,96 so the proportion of women receiving each type of operation
needs to be estimated.
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Data for women from the NVR and HES are shown in Table 14a. The NVR reports fewer operations than
HES for the same period (around 80% of the HES total), reflecting under-reporting in the NVR. The overall
proportion of EVAR operations is 58.6% in the NVR and very similar to the HES at 60.6%. These overall rates
conceal strong trends: the use of EVAR increases with age and decreases with AAA diameter (Figure 8).
For comparison, the overall use of EVAR in men in the NVR was 63.5% and there were similar trends
according to age and aneurysm diameter as in women.97 Data from Vascunet give the overall proportion
of women receiving EVAR as 56.1%, similar to the figures from the NVR and HES (see Table 14a).
We use the data from the NVR as described in Use of NVR data as a source of parameter estimates in
women to provide estimates of the proportion of women receiving EVAR in the model (see Table 40,
Appendix 5). In the base-case analysis, the overall proportion is simply that observed in the NVR (i.e. 58.6%).
Proportion who are morphologically suitable to receive endovascular aneurysm repair
for elective abdominal aortic aneurysm surgery
In a sensitivity analysis, we instead use the proportion of women whose AAA was considered
morphologically suitable for elective EVAR. This may be different from the proportion of women who
receive EVAR in practice (i.e. in the NVR or HES). An estimate of this is provided by the systematic review
of the literature described in Chapter 3, Suitability of women versus men for standard endovascular repair.
TABLE 14a Elective operations: number of women receiving open AAA repair or EVAR for elective operations
Source Open repair (n) EVAR (n) % EVAR
NVR 922 1306 58.6
HES 1066 1642 60.6
Vascunet 2137 2726 56.1
TABLE 14c Elective operations: operative mortality rate in women receiving elective open AAA repair
Source Open repairs (n) Deaths (n) % deaths
NVR in-hospital 922 64 6.9
HES in-hospital 1066 64 6.0
HES 30-day 1066 75 7.0
Vascunet 30-day 2137 142 6.6
TABLE 14b Elective operations: operative mortality rate in women receiving elective EVAR
Source EVAR repairs (n) Deaths (n) % deaths
NVR in-hospital 1306 23 1.8
HES in-hospital 1642 27 1.6
HES 30-day 1642 37 2.3
Vascunet 30-day 2726 54 2.0
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Across the five studies included, the pooled estimate of suitability for EVAR according to the manufacturers’
instructions for use (IFU) was 34% (95% CI 25% to 44%). This is substantially less than the NVR estimate
of 59% for the proportion of women receiving EVAR. Assuming that only those within IFU receive EVAR,
the proportion of 34% could be used in place of 59%, although the consequent effects on postoperative
mortality for both EVAR and open repair are unknown. More recent data, which could not be included in the
systematic review (see Chapter 3, Suitability of women versus men for standard endovascular repair) but assess
the use of newer endografts, suggest that 40% of women are eligible for EVAR within the IFU.
Elective endovascular aneurysm repair operative mortality
Overall in-hospital or 30-day postoperative mortality rates from the NVR and HES in women undergoing
elective EVAR are shown in Table 14b. There were too few deaths to show any convincing trends
according to age or AAA diameter in women. The overall figures for in-hospital mortality from the NVR
and HES are very similar, 1.8% and 1.6%, respectively. From the HES data, 30-day mortality is somewhat
greater than in-hospital mortality (2.3% vs. 1.6%).
For comparison, the overall in-hospital mortality in the NVR for men was 0.7%, lower than in women, with
evidence of increasing mortality with age.97 Data from Vascunet give an overall value of 2.0% for 30-day
mortality in women, slightly lower than the figure of 2.3% from HES (see Table 14b). In the systematic
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FIGURE 8 Proportion of women receiving elective EVAR in the NVR (with 95% CIs). (a) By age, and a superimposed
logistic regression fit (for women with an AAA of diameter 6.2 cm, the mean in the NVR data); and (b) by AAA
diameter, and a superimposed logistic regression fit (for women aged 76.8 years, the mean in the NVR data).
SURGERY-RELATED PARAMETERS FOR WOMEN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
literature review (see Chapter 3, Thirty-day operative mortality in women versus men), the overall estimate
of 30-day mortality for women after elective EVAR was 2.2% (95% CI 1.9% to 2.7%), similar to the figure
from HES.
For the modelling, we adjust the NVR in-hospital mortality to reflect the (greater) 30-day mortality.
Thus, we use the NVR data to estimate the log-odds of in-hospital mortality (see Table 40, Appendix 5)
according to Equation 26 or 27 in Use of National Vascular Registry data as a source of parameter
estimates in women, but then add the log-odds ratio corresponding to the 30-day mortality compared
with the in-hospital mortality in HES (namely log-odds of 2.3% vs. 1.6% = 0.370) before transforming
back to the probability scale. Working on the log-odds scale ensures that probabilities cannot exceed 1.
For the base-case analysis, this gives an overall 30-day mortality estimate of 2.4%. In the PSA, we ignore
the fact that the difference between 30-day and in-hospital mortality from HES is estimated with error.
Elective open abdominal aortic aneurysm repair operative mortality
Overall, postoperative mortality rates for women following elective open AAA repair are shown in
Table 14c. In-hospital mortality rates are much higher than those after elective EVAR: 6.9% and 6.0% in
the NVR and HES, respectively. In HES, as for elective EVAR, the 30-day mortality rate is slightly higher than
the in-hospital mortality rate, 7.0% vs. 6.0%. The in-hospital mortality rate in the NVR increased with age,
but not convincingly with AAA diameter (Figure 9).
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FIGURE 9 In-hospital mortality rate in women receiving elective open AAA repair in the NVR (with 95% CIs).
(a) By age, and a superimposed logistic regression fit (for women with an AAA of diameter 6.2 cm, the mean in
the NVR data); and (b) by AAA diameter, and a superimposed logistic regression fit (for women with AAA at age
76.8 years, the mean in the NVR data).
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Compared with women, the overall in-hospital mortality was lower in men: 4.0% and 3.8% in the NVR
and HES, respectively.97 The Vascunet data show an overall 30-day mortality rate of 6.6% for women,
again quite similar to HES (see Table 14c). In the systematic literature review (see Chapter 3, Thirty-day
operative mortality in women versus men), the overall estimate of 30-day mortality for women after
elective open repair was 5.4% (95% CI 4.2% to 6.9%), somewhat lower than the figure from HES.
To estimate the 30-day mortality rate for women (see Table 40, Appendix 5), we follow the procedures in
Use of National Vascular Registry data as a source of parameter estimates in women along with a similar
conversion from in-hospital to 30-day mortality (as described at the end of Elective endovascular aneurysm
repair operative mortality). For the base-case analysis, this gives an overall 30-day mortality estimate of 8.1%.
Reintervention rate after successful elective surgery
A ‘successful operation’ is taken to mean that the patient is alive 30 days after the operation. The NVR
does not provide information on reintervention rates after the initial hospitalisation for AAA repair. In
principle, such reinterventions can be extracted from HES data, but the correct linking of subsequent
hospitalisations for individuals that are related to the initial AAA repair (as opposed to other related
or unrelated conditions) is fraught with difficulty. Moreover, the length of follow-up available in the
2010–14 HES data is limited to a maximum of 5 years. Thus, we base our estimates on the long-term
follow-up (up to 15 years) of the EVAR-1 trial38 of 1252 patients with a large AAA (diameter of ≥ 5.5 cm)
randomised to either open AAA repair or EVAR.
There are some drawbacks of the EVAR-1 trial38 data for our purpose. The first is that about 90% of the
patients in the trial were men. The second is that the trial patients were restricted to those deemed both
fit for open repair and anatomically suitable for EVAR, whereas the groups receiving open repair or EVAR
in practice include additional patients. Furthermore, rather than analysing the trial by randomised group
from the date of randomisation, we present the data by operation received from the date of operation,
omitting patients who did not receive an operation; this makes only a slight difference for the EVAR-1
trial38 since 93% of patients received their randomly allocated surgical intervention, and the median delay
between randomisation and surgery was only 40 days. Patients in whom EVAR was converted to open
AAA repair in the initial admission are classified as open repairs. We include all reinterventions, excluding
the first 30 days following the operation, whether they are first or subsequent ones, and express them as
a rate per 100 person-years. We also note that there was strict adherence to the IFU in the EVAR-1 trial,38
and for both EVAR and open repairs reintervention rates rise where morphology is outside the IFU.
Reinterventions are taken to include the following AAA-related conditions: added stent, staple or ligation,
type I–III endoleaks, embolisation of endoleak, sclerosis, conversion to open repair, aneurysmal extension
above or below original graft, thrombosis of graft limb, graft infection, incisional hernia, false femoral
aneurysm, fem-fem graft, FEVAR, axillo bi-fem, distal limb procedure/revascularisation, reoperation of open
repair, replacement stent graft and amputation. Reinterventions for laparotomy-related complications were
not initially included in the EVAR-1 trial.38
Based on these definitions, the analysis is based on 1172 patients (1065 men and 107 women) who
survived 30 days after their operation, rather than the 1252 originally randomised in EVAR-1.38 The number
of reinterventions occurring in these patients was 262, over a period of up to 15 years, constituting 9321
person-years of observation. The rate of these reinterventions over time is depicted in Figure 25, Appendix 5.
The rate of reinterventions is much higher after EVAR than after open AAA repair. The rates can be adequately
represented by exponential distributions (constant hazard over time) within periods of 31–120 days and
> 120 days after the operation; Weibull distributions did not provide a better fit to the data.
There was substantial evidence that the rates of reintervention differed between women and men, and
that this sex effect differed for EVAR and open AAA repair (see Figure 26, Appendix 5); the p-value for
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including the main effect of sex and its interaction with operation type was 0.006. Reintervention rates
were higher in women than in men after EVAR, but lower in women than in men after open AAA repair.
Thus, we use the reintervention rates for women alone as parameters in our modelling (see Table 15).
For example, the rate of reinterventions for days 31–120 after successful EVAR is estimated as 3 per
15 woman-years or 20.3 per 100 woman-years. For the PSA, we use a Gamma(3,15) distribution to reflect
the number of reinterventions and woman-years in the EVAR-1 trial data.38 There were no reinterventions
after 30 days after open AAA repair in 388 woman-years of observation (Table 15); we combine these two
periods after 30 days, and apply a zero rate in the base-case analysis. In a sensitivity analysis, we use data
from the DREAM76 and OVER77 trials in men to estimate an alternative reintervention rate.
Long-term abdominal aortic aneurysm-related mortality rate after successful
elective repair
For similar reasons as for reinterventions, we use the long-term EVAR-1 trial data38 in preference to HES–ONS
data. The latter has limited follow-up available and it is doubtful that AAA-related mortality can be reliably
defined based on death certification. For example, many of the deaths occurring within 30 days of an AAA
operation are not categorised as AAA related in the HES–ONS data set. We also note that data to 14 years
for all-cause mortality from the DREAM trial76 are similar to those from the EVAR-1 trial.38
Following the same principles as for reinterventions, the rates of AAA-related deaths in the EVAR-1 trial38
after successful AAA repair are shown in Figure 27, Appendix 5; AAA-related deaths include all those within
30 days of any AAA surgery. For AAA-related deaths occurring > 30 days after operation, an exponential
model fit to the data was reasonable. There was strong evidence of an increased hazard for females (hazard
ratio 2.72, 95% CI 1.35 to 5.46; p = 0.005). Therefore, we use AAA-related mortality rates for women
alone in our modelling (see Table 15). For example, the AAA-related mortality after successful EVAR is
estimated as 8 per 444.7 woman-years, or 1.8 per 100 woman-years. For the PSA, we use a Gamma
(8,444.7) distribution to reflect the number of deaths and woman-years in the EVAR-1 trial data.38
TABLE 15 Rates of reinterventions and AAA-related mortality per 100 person-years after successful elective AAA
repair: data from the EVAR-1 trial38
Item
Men Women
Number/
person-years
Rate per
100 person-years (SE)
Number/
person-years
Rate per
100 person-years (SE)
Reinterventions after EVAR
31–120 days 20/135 14.8 (3.3) 3/15 20.3 (11.7)
> 120 days 153/4221 3.6 (0.3) 27/421 6.4 (1.2)
Reinterventions after open repair
31–120 days 5/125 4.0 (1.8) 0/11 0.0
> 120 days 53/4017 1.3 (0.2) 0/377
AAA-related mortality
> 30 days after EVAR 34/4436.3 0.766 (0.131) 8/444.7 1.799 (0.636)
> 30 days after open repair 3/4291.1 0.070 (0.040) 2/400.8 0.499 (0.353)
DOI: 10.3310/hta22430 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 43
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
Emergency operations for ruptured abdominal aortic aneurysms
A similar set of parameters as described for elective operations are required for emergency operations.
We define emergency surgery as that done for an acute rupture, whereas urgent surgery is undertaken
for a symptomatic AAA. In the NVR data, this distinction is recorded. In the HES data, these cannot be
directly separated, but have been approximated by classifying those operations done on the same day as
admissions as emergencies. We disregard the consideration of symptomatic AAAs in our modelling:
operations are either emergency or elective. For emergency operations, we do not include AAA diameter
in the logistic regression models. This is because the post-rupture assessment of AAA diameter (as
recorded in the NVR) is not a reliable assessment of the pre-rupture AAA diameter (as used in the
individual simulation modelling).
Proportion operated on after an abdominal aortic aneurysm rupture
Many patients with an AAA rupture die before getting to hospital or the operating theatre, are turned
down or refuse AAA repair. So, the proportion of patients with an AAA rupture receiving an operation is
an important parameter that crucially influences the survival rate after an AAA rupture. However, estimates
of this parameter for women are not easy to obtain.
We have taken data from the literature and from recruitment to the randomised trials of EVAR versus
open repair for ruptured AAAs (such as the IMPROVE trial30) to provide relevant estimates (see Chapter 3,
Mortality following ruptured abdominal aortic aneurysm in women). The conclusion is the overall proportion
of women with a ruptured AAA who receive an emergency repair is low, at around 25%. We use this figure
in our modelling, but allow considerable uncertainty (95% uncertainty interval 15–35%) in the PSA.
Proportion receiving endovascular aneurysm repair for an abdominal aortic
aneurysm rupture
The numbers of women in the NVR and HES receiving open repair or EVAR for ruptured AAAs are shown
in Table 16a. The proportion of operations identified in HES that are also reported in the NVR is lower than
for elective operations (around 70%). This may underlie the more substantial difference in the reported
proportions receiving EVAR: 16.8% in the NVR compared with 22.4% in HES. There is an increasing rate
of EVAR use with age (Figure 10a).
TABLE 16a Emergency operations: number of women receiving open AAA repair or EVAR for emergency operations
Source Open repair (n) EVAR (n) % EVAR
NVR 653 132 16.8
HES 845 244 22.4
Vascunet (urgent + emergency) 1069 328 23.5
TABLE 16b Emergency operations: operative mortality rate in women receiving emergency EVAR for AAA ruptures
Source EVAR repairs (n) Deaths (n) % deaths
NVR in-hospital 132 33 25.0
HES in-hospital 244 31 12.7
HES 30-day 244 48 19.7
Vascunet in-hospital (urgent + emergency) 254 53 20.9
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FIGURE 10 Emergency surgery data in the NVR. (a) Proportion of women receiving EVAR for an AAA rupture by
age in the NVR, and a superimposed logistic regression fit; and (b) in-hospital mortality rate in women receiving
open repair for an AAA rupture by age in the NVR, and a superimposed logistic regression fit.
TABLE 16c Emergency operations: operative mortality rate in women receiving emergency open repair for
AAA ruptures
Source Open repairs (n) Deaths (n) % deaths
NVR in-hospital 653 260 39.8
HES in-hospital 845 284 33.6
HES 30-day 845 319 37.8
Vascunet in-hospital (urgent + emergency) 927 318 34.3
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For comparison, the overall proportion of men receiving EVAR for emergency operations in the NVR was
19.4%;97 an increasing trend with age was again evident. Data from Vascunet give the overall proportion
of women receiving EVAR as 23.5% (see Table 16a), but do not distinguish urgent and emergency cases.
In our analysis, we use the data from the NVR, first, because of the potential coding problems with HES
and, second, because individual-level data were available for incorporating the influence of age. We use
the same methods as before, described in Use of National Vascular Registry data as a source of parameter
estimates in women, but ignore any effect of AAA diameter. Parameter estimates from the logistic
regressions are given in Table 41, Appendix 5; in the base-case analysis, the overall proportion for women
is simply that observed in the NVR (i.e. 16.8%).
Emergency endovascular aneurysm repair operative mortality
The in-hospital and 30-day mortality rates from the NVR and HES are shown in Table 16b. The overall
in-hospital mortality rate from the NVR is 25.0%, substantially greater than the 12.7% reported in HES.
This may reflect mortality events being missed in HES when patients are transferred to another hospital
(e.g. for rehabilitation or long-term nursing care) and subsequently dying. The transfer of care results in the
end of a HES episode. There were increasing mortality rates with increasing age. As for elective operations,
the 30-day mortality rate determined by HES–ONS linked data is greater than the in-hospital mortality
rate (19.7% vs. 12.7%). Vascunet provided very incomplete data for 30-day mortality after urgent and
emergency operations (which are combined in Vascunet), in contrast to the data for 30-day mortality after
elective operations shown earlier. So we report the Vascunet in-hospital mortality data, which are more
complete, giving a figure of 20.9% after EVAR (see Table 16b). The literature review (see Chapter 3,
Mortality following ruptured abdominal aortic aneurysms in women) suggested a 30-day mortality rate of
32%. Some of the differences may relate to how EVAR converted to open repair (which has very high
mortality) and is categorised in the different studies and to the differential use of anaesthesia types in
different countries.
For comparison, the in-hospital mortality rate for men in the NVR is 20.7%,97 slightly lower than the
25.0% for women.
In our modelling for women, again we use the NVR data for in-hospital mortality and make an adjustment
to reflect 30-day mortality based on HES (as in Elective endovascular aneurysm repair operative mortality).
For the base-case analysis, this yields an overall 30-day mortality rate of 35.9%. Parameter estimates from
the logistic regressions are given in Table 41, Appendix 5.
Emergency open abdominal aortic aneurysm repair operative mortality
The corresponding mortality rates for women after open AAA repair are shown in Table 16c. The overall
in-hospital mortality rate is 39.8% in the NVR, compared with 33.6% in HES. An increasing mortality rate
with age was again evident (see Figure 10b). Again, in HES–ONS, the 30-day mortality was greater than
the in-hospital mortality (37.8% vs. 33.6%, respectively). Vascunet data give the in-hospital mortality rate
as 34.3%, which is similar to HES, but does not distinguish emergency and urgent cases. The literature
review (see Chapter 3, Thirty-day operative mortality in women versus men) suggested a 30-day mortality
rate of 51%.
For comparison, the in-hospital mortality rate for men in the NVR is 36.9%,97 slightly lower than the
39.8% for women.
We use the same methods as before to provide estimates from the logistic regressions in Table 41,
Appendix 5. For the base-case analysis, this yields an overall 30-day mortality rate of 44.2%.
Reintervention rates after successful emergency surgery
Again, a ‘successful operation’ is taken to mean that the patient is alive 30 days after the operation.
Obtaining information on reintervention rates after emergency AAA operations, especially for women,
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is difficult. For similar reasons as for elective operations, we based estimates on the IMPROVE trial,30
the largest and longest trial of EVAR versus open repair for ruptured AAAs. The trial randomised patients
with a ruptured AAA either to a policy of EVAR if possible, compared with open repair. We have access
to the provisional unpublished 3-year follow-up data from the IMPROVE trial,30 and are able to report
reinterventions by operation received, for the group of patients with confirmed ruptured AAAs. The time
between randomisation and operation (if received) in IMPROVE30 is very short (median 0.7 hours), so we
use time since randomisation as the time scale.
The IMPROVE trial data30 were limited by the fact that only about 20% of the patients were women, and
that the available follow-up extends only to 3 years. In the trial, about 50% of the ruptured AAA patients
had died within 3 years. Because of the available follow-up, we consider the period after 30 days after the
operation as one period, include all reinterventions, whether they are first or subsequent ones, and express
this as a rate per 100 person-years. The reinterventions included are as listed in Reintervention rate in
successful elective surgery.
The reinterventions data from the IMPROVE trial30 are summarised in the upper two rows of Table 17.
Because there are possible differences in rates between men and women, we use the data for women
alone despite the small numbers. Thus, the rate of reinterventions after 30 days after EVAR is estimated as
15.8 per 100 woman-years and correspondingly after open repair as 2.3 per 100 woman-years.
Long-term abdominal aortic aneurysm-related mortality rate after successful
emergency surgery
For similar reasons as before (see Long-term abdominal aortic aneurysm-related mortality rate after
successful elective repair), we use the IMPROVE trial30 data to estimate the long-term AAA-related mortality
rates after emergency surgery in women (lower two rows of Table 17). For the period after 30 days after
emergency EVAR, the rate is estimated as 0; correspondingly, after emergency open repair, the rate is
estimated as 1.2 per 100 woman-years.
Comparability of National Vascular Registry and Hospital Episode
Statistics data
Both the NVR and HES are large data sets that can provide information about patients with an aortic
aneurysm. Each suffers from some drawbacks. The NVR is voluntary and may be incomplete and, although
the submission rates are high, selective censoring may have an impact on estimates of less frequent events
and mortality. It is also a procedure-based registry, which does not contain information about longer-term
follow-up or include patients with aneurysms who do not undergo procedures. However, it does include rich
clinical data regarding risk factors, and anatomical and procedural information that is not included in HES.
TABLE 17 Rates of reinterventions and AAA-related mortality per 100 person-years after successful emergency
AAA repair: data from the IMPROVE trial30
Item
Men Women
Number/
person-years
Rate per
100 person-years
(SE)
Number/
person-years
Rate per
100 person-years
(SE)
Reinterventions > 30 days after EVAR 29/267 10.9 (2.0) 9/57 15.8 (5.3)
Reinterventions > 30 days after open repair 25/410 6.1 (1.2) 2/85 2.3 (1.7)
AAA-related mortality > 30 days after EVAR 4/406 0.985 (0.493) 0/87 0.0
AAA-related mortality > 30 days after open
repair
9/626 1.437 (0.479) 2/124 1.163 (1.140)
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Hospital Episode Statistics is primarily an administrative data set in which patients with an aneurysm can
be identified based on procedural and diagnostic codes. Although there are concerns about accuracy, in
recent years both data quality and coverage have improved and HES data have been found to be useful in
studying mortality rates. The exact information will differ between the data sources as, apart from missing
data and true coding errors, there are differences in definition of cases owing to the need to interpret
multiple diagnostic and procedural codes in HES for categorising procedures. However, HES does provide
information about longer-term readmission rates and repeat procedures and can be linked to ONS data to
provide long-term mortality estimates.
It is notable that, for elective procedures, operative mortality rates were very similar in both the NVR and
HES (see Table 14). The main discrepancy between the NVR and HES data related to emergency procedures
(see Table 16). This is likely to be due to the aforementioned limitations of both data sets. NVR mortality
rates were consistently higher than those in HES, but especially so for emergency EVAR. One factor may be
the method by which these data are recorded. NVR data entry is completed by the surgeon performing the
procedure whereas HES is based on hospital coding data. In the NVR data set, patients undergoing urgent
repair of a non-ruptured AAA is specifically captured. These patients were excluded from our analysis of
NVR data. Such patients are not coded specifically in HES and, therefore, may be inadvertently coded as a
ruptured AAA because they underwent an unplanned operation and were admitted as an emergency. In the
analysis of the HES data used here, patients with coding records inconsistent with a ruptured AAA were
excluded, but it remains possible that some ‘urgent’ patients with a non-ruptured AAA remained in the HES
dataset. These patients have better outcomes than true ruptured AAAs and may account for the lower
mortality seen in HES.
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Chapter 6 Costs and miscellaneous parameters
for women
The original AAA Markov model11 assessing the cost-effectiveness of a one-off invitation to screening formen aged 65 years used cost estimates from the MASS trial98 presented in 2000/1 prices. These costs
were subsequently uprated to 2010/11 prices, incorporating changes in surgical repair resource use and
unit costs. Contemporary screening costs were acquired from NAAASP, and cost estimates were updated
to reflect the increased use of EVAR.35
In this previous study35 a bottom-up costing was not feasible, but more recent randomised trial surgical
resource use data were available. Data from the EVAR-1 trial99 were used to estimate the costs of elective
open repair and EVAR. Contemporary registry data from the National Vascular Registry (NVR)26 were
utilised to update significant components of resource use [operation length, hospital length of stay (LOS)],
and general NHS inflation was accounted for. The MASS trial98 was used to estimate the cost of
emergency repairs, with emergency procedures assumed to be limited to open repair on the basis of
appropriate National Institute for Health and Care Excellence (NICE) guidance.100 Similar to open repair,
major components of resource use were updated using registry data from the NVR.
For the current modelling, new estimates of costs were necessary for three reasons: to reflect (1) changes
in unit costs since 2010/11, (2) possible trends in procedure resource use and (3) potential differences
in resource use between men and women. This chapter provides estimates of these costs and a few
remaining parameters (see Table 3), representing the final aspect of objective 3 in Chapter 1,
Scientific objectives.
Unit costs
All costs are considered from a NHS perspective, rather than from a societal or personal perspective, and
are presented in 2014/15 prices.
Screening costs
Screening costs were taken from NAAASP (Professor Jonothan Earnshaw, Gloucestershire Hospitals NHS
Foundation Trust, 2012, personal communication) and updated to reflect general health service inflation to
2014/15 prices.101 The cost of screening women was assumed to be the same as in the programme for
men (Table 18).
Pre-surgical consultation costs
In previous modelling, the cost of a pre-surgical consultation was based on data from the MASS trial98 and
subsequently uprated for general NHS inflation.35 This estimate was from data collected from a subsample
of the full trial population. On average, 1.6 consultations were conducted before elective surgery. Unit
costs came from the finance departments of centres involved in the trial. In the current modelling, the
number of consultations was assumed to be the same as observed in the MASS trial,98 but the unit cost
TABLE 18 Screening costs
Resource use item Cost 2010/11 (£) Updated cost 2014/15 (£)
Invitation to screen 1.70 1.80
First scan 32.20 34.11
Surveillance scan 68.00 72.03
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was updated using contemporary estimates from the Department of Health and Social Care’s NHS
Reference Costs 2014 to 2015.39 The unit cost comprised a weighted mean of face-to-face consultant-led
outpatient visits for vascular surgery, cardiothoracic surgery and cardiac surgery specialties. The new
estimate of the cost of pre-surgical consultations was £328.64, rather than £435.25 as used before.35
Costs of elective and emergency abdominal aortic aneurysm repair
A similar approach was adopted to estimate contemporary costs for women undergoing surgical AAA
repair, given the infeasibility of conducting detailed microcosting. Cost estimates were taken from UK-based
randomised trials (EVAR-138 and IMPROVE24) focusing on women-specific data. These were updated using
registries to provide robust data on the general AAA repair population and reflect potential trends in
hospital LOS. LOS data were available from HES28 and the NVR26,97 between 2010 and 2014. Hospital stay
constitutes the largest component of resource use, with significant differences between men and women,
and includes that incurred by renal dialysis in the primary admission. Unlike previous modelling, which had
limited emergency surgery to only open repair, an estimate of the cost of emergency EVAR was required,
given evidence of its increased use in this setting from both the NVR and HES.
For elective repair costs, the EVAR-1 trial38 was again utilised. EVAR-1 recruited patients between 1999 and
2004 in 38 UK centres.38 Women-specific elective AAA repair costs were obtained from the EVAR-1 trial38
investigators in 2014/15 prices and updated using LOS data from HES. These costs related to the primary
admission. HES LOS data were preferred to the NVR as HES is a more complete database of AAA repairs,
and additional analysis using more accurate coding was possible.
The components of total cost comprising mean vascular ward and critical care stay were removed and
replaced with women-specific mean LOS data from HES, multiplied by unit costs obtained from NHS
Reference Costs 2014 to 2015.39 Elective AAA repair LOS observed in HES was significantly lower than
in the EVAR-1 trial38 for EVAR repair, particularly the general vascular ward stay; however, open repair
hospital LOS was similar. Updated costs are shown in Tables 19a and b.
TABLE 19a Mean LOS and costs of elective EVAR in women
Elective EVAR
EVAR-138 LOS
(n= 60) (days)
EVAR-138 cost
(n= 60) (£)
HES LOS
(n= 1491) (days)
Updated cost
2014/15 prices (£)
Vascular ward 13.1 4463 5.8 1984
Critical care 2.7 3084 1.0 1142
Othera N/A 10,758 N/A 10,758
Total cost 18,306 13,884
TABLE 19b Mean LOS and costs of elective open repair in women
Elective open repair
EVAR-138 LOS
(n= 54) (days)
EVAR-138 cost
(n= 54) (£)
HES LOS
(n= 1009) (days)
Updated cost
2014/15 prices (£)
Vascular ward 10.07 3444 10.0 3420
Critical care 4.17 4764 3.7 4227
Othera N/A 5413 N/A 5413
Total cost 13,621 13,060
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Emergency AAA repair cost data for women were obtained from the IMPROVE trial30 investigators in 2011/12
prices for the primary admission. The trial recruited patients between 2009 and 2013 in 29 UK centres and
one Canadian centre. Data provided were restricted to those patients with a confirmed AAA rupture and
according to treatment received rather than randomised group. In the trial, an ‘EVAR where possible’ strategy
was adopted and analysed by intention to treat, so that patients in that group did not always receive EVAR.
Components of total cost comprising general vascular ward and critical care stay were removed and the
remaining costs were inflated for general NHS inflation to 2014/15 prices using published indices.101
Women-specific HES data were used to update LOS and were multiplied by unit costs from NHS Reference
Costs 2014 to 2015.39 Critical care LOS observed in HES was lower for both EVAR and open repair,
although mean stay on vascular ward was higher. Updated costs are shown in Table 19c and d.
For comparison, HES data on AAA repair for men were utilised to update costs from the EVAR-138 and
IMPROVE24 trials using the same approach. Elective AAA repair, both EVAR and open repair, was estimated
to be less costly for men than for women (EVAR £12,993, open repair £11,712), largely due to a lower
observed LOS. For emergency repair, costs for men were higher than for women (EVAR £18,045, open
repair £17,995) because of longer critical care stays. This could be related to the higher mortality rate
among women undergoing AAA repair, reducing LOS, although the pattern of general ward stay between
men and women was dissimilar.
Surveillance costs
Post-surgery surveillance resource use was based on expert opinion [one vascular surgeon (MJB) and one
vascular biologist (JTP) on the study team] of additional imaging performed in UK clinical practice. All unit
costs were obtained from NHS Reference Costs 2014 to 2015.39 For open repair, it was assumed that
patients received one 6-week follow-up consultation. The cost of this consultation was assumed to be the
same unit cost as pre-surgical consultation (£196.79). For EVAR, patients were assumed to have annual
surveillance for their lifetime, consisting of one consultation (£196.79) and one ultrasound scan.
TABLE 19c Mean LOS and costs of emergency EVAR in women
Emergency EVAR
IMPROVE30 LOS
(n= 29) (days)
IMPROVE30 cost
(n= 29) (£)
HES LOS
(n= 380) (days)
Updated cost
2014/15 prices (£)
Vascular ward 8.1 2308 10.2 3488
Critical care 3.1 3627 2.2 2513
Otherb N/A 10,152 N/A 10,152
Total cost 16,088 16,154
TABLE 19d Mean LOS and costs of emergency open repair in women
Emergency open repair
IMPROVE30 LOS
(n= 69) (days)
IMPROVE30 cost
(n= 69)
HES LOS
(n= 1044) (days)
Updated cost
2014/15 prices (£)
Vascular ward 6.2 1961 21.0 7182
Critical care 6.3 7617 3.7 4227
Otherb N/A 6204 N/A 6204
Total cost 15,783 17,613
N/A, not applicable.
a Graft, blood products, radiology, theatre time.
b Time in emergency room, devices and consumables, time in theatre, readmission and secondary hospital.
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A weighted mean of unit costs of an ultrasound scan with duration of ≥ 20 minutes (RD42Z-RD43Z) was
obtained (£61.37).
Reintervention costs
Reintervention costs were incorporated into the model explicitly using data from the EVAR-1 trial.38
The cost, reflecting mean resource use, of a reintervention during the 10-year follow-up of the EVAR-1
trial38 was estimated for women only for EVAR and open repair. The costs were £7546 and £8986,
respectively. These costs were assumed to be the same for reinterventions occurring after elective and
emergency repairs.
Sensitivity analyses for costs
Because of the nature of the costing exercise, which produced surgical cost estimates with components
combined from different sources (both randomised trial data and observational data), a formal estimate
of the associated stochastic precision could not be computed. Therefore, imprecision in unit costs was
included in the PSA conducted by representing a 95% uncertainty interval from 20% lower to 25% higher
costs as a symmetrical normal distribution for log-costs. The impact of changes in costs was also explored
in DSAs by varying the costs of screening, surveillance and surgical operation by –20% or + 25%
(see Costs).
Quality of life and competing mortality
Quality of life in the population
There is limited evidence that an AAA-screened population has a lower health-related QoL than the
general population.10 For the purpose of calculating QALYs, the life-years accrued of all women, screened
and unscreened, in the model were adjusted using UK population EuroQol-5 Dimensions (EQ-5D) utility
survey data, specific to women.102 The QoL weights used were as follows: 0.81 for ages 55–64 years, 0.78
for ages 65–74 years and 0.71 for ages of ≥ 75 years.
Quality of life after surgery
An additional consideration relates to the QoL of those who undergo surgery. Trials of elective AAA repair
indicate that there is a reduction in QoL following repair, but that this is transient.103 In the EVAR-1 trial,99
mean EQ-5D utility (range 0–1) score in the EVAR arm was 0.74, 0.73, 0.71 and 0.74 at baseline and
1-month, 3-month and 12-month follow-up, respectively. Using a visual analogue scale [(VAS); scale
0–100] the corresponding figures were 70.82, 70.20, 69.69 and 71.29, respectively. In the open repair
arm, mean EQ-5D utility score was 0.74, 0.67, 0.73 and 0.75 at baseline and 1-month, 3-month and
12-month follow-up, respectively (corresponding figures for the VAS were 70.78, 64.09, 71.36 and 72.53,
respectively). Given the focus on a whole-screened population, these small differences in QoL are not likely
to have a material bearing on results, and it is more important to reflect age-related differences in QoL.
Given the nature of emergency repair and the patient’s condition at randomisation and baseline,
comparative utility scores are harder to acquire. However, at the 12-month compared with the 3-month
follow-up in the IMPROVE trial,30 mean EQ-5D utility score was 0.01 higher for EVAR and 0.04 higher for
open repair. Again, it was considered that these differences were not material in terms of long-term
modelling for a whole population.
Non-abdominal aortic aneurysm mortality
Mortality not related to an AAA is a competing risk, in that AAA screening will be less effective when such
competing mortality is higher. Age-specific non-AAA mortality rates for women were estimated using two
data sets: (1) overall life tables and (2) rates of death by age and cause. Life tables for 2012–14 were
available from the ONS for the UK population.40 Overall annual mortality risks were adjusted by subtracting
the AAA-specific death rates for women among the UK population, using ONS cause-of-death data.104
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Previous modelling exercises of AAA screening based on the MASS trial98 have noted that the non-AAA
mortality after being turned down for elective surgery was higher than that in the general population.11,12
This is because comorbidities are a major reason for surgery being contraindicated. In previous modelling
for men, the corresponding non-AAA mortality rate was taken directly from data in the MASS trial.98
However, such comorbidities occur at the same rate in both the invited and non-invited groups, although
in the latter they may be largely unobserved. Hence, including an increased non-AAA mortality rate after
being turned down for elective surgery, which occurs mainly in the group invited to screening, unfairly
biases the results against screening. With this understanding, the current modelling for women does not
include a similar increase in the rate of non-AAA mortality. This provides fair estimates of incremental
costs, life-years and QALYs (i.e. the differences between the invited and non-invited groups). However,
it will very slightly overestimate absolute life-years and QALYs, and maybe absolute costs as well, because
the women following contraindication to elective surgery are on average being assumed to survive for
longer than they may do in reality.
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Chapter 7 Cost-effectiveness analyses for women
based on current NHS Abdominal Aortic Aneurysm
Screening Programme policy
Using the women-specific parameter estimates generated in Chapters 3–6, this chapter addressesobjective 4 in Chapter 1, Scientific objectives. It presents the cost-effectiveness of a screening
programme for women, based on an identical protocol that is currently implemented by NAAASP for men.
Specifically, estimates are presented for the cost-effectiveness of a one-off invitation to screening for an
AAA for women aged 65 years, in which women whose aortic diameter measures ≥ 3.0 cm at the first
screening are entered into the surveillance programme, with annual ultrasound scans for AAAs that
measure 3.0–4.4 cm and 3-monthly scans for AAAs that measure 4.5–5.4 cm. Women are considered for
elective surgery once their AAA diameter reaches ≥ 5.5 cm. A PSA is conducted, along with a range of
DSAs, to investigate the impact of changing parameter values on the cost-effectiveness results.
Base-case analysis
The base-case analysis uses the best available evidence for the input parameters, based on systematic reviews,
registry data, cohort studies, other hospital data and contemporary costs, as described in Chapters 3–6. These
parameters are listed in full in Table 20. The prevalence for women aged 65 years is assumed to be 0.43%,
with average growth and rupture rates of 1.5 mm per year and 0.2 per 100 woman-years for a 3.0-cm AAA,
respectively, increasing to 2.5 mm per year and 2.7 per 100 woman-years for a 5.0-cm AAA, respectively.
The DES model, based on a 30-year time horizon, is run on 10 million pairs of individuals to obtain reliable
estimates of the health economic quantities and counts key events occurring within the non-invited and
invited to screening groups. Parameter uncertainty is accounted for through a PSA in which the DES model is
run 1000 times on 500,000 pairs of individuals, using a different set of input parameters in each run. Input
parameters are drawn from suitable distributions, as detailed in Table 20.
Numbers of key events
Table 21 shows the numbers of women in the non-invited and invited to screening groups that experience
key events from the base-case run of the DES model over 30 years. About three-quarters of all elective
operations in the invited to screening group occur through incidental detection, indicating that many AAAs
are not initially detected at age 65 years, owing to non-attendance or an aneurysm that has yet to develop.
Elective operations following screen detection of an AAA occur predominantly in the 68- to 78-year age
group (Figure 11). In total, 86% of the population die by the age of 95 years in the non-invited group and
0.83% die of AAA-related causes. Screening prevents approximately 2500 AAA deaths in this population of
10 million women, with the percentage who die of AAA-related causes in the invited to screening group
being reduced to 0.80%. The relative risk reduction is 3.0%; 4100 women need to be invited to screening
to save one death from an AAA.
The difference in numbers of emergency operations and AAA deaths between the invited and non-invited
groups accrues gradually over the 30-year period after initial screening (see Figure 11). No effect is evident
within the first 5 years as only a small proportion of women are initially over the diameter threshold for
elective intervention. This is in contrast to the MASS trial10 of screening in men, in which the benefit of
screening was apparent at an earlier stage. In the non-invited group, 0.92% of women have a ruptured
AAA over the course of 30 years, compared with 0.88% of the invited group (see Table 21).
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TABLE 20 Input parameters to base-case model, and distributions and estimates used in the probabilistic and
deterministic sensitivity analyses
Parameter
Source
(base case) Base case PSA DSA
Screening
Reinvitation
proportion
NAAASP8 142,127/
594,376 ≈ 0.239
None None
Attendance
proportion
Chichester33 218/300 ≈ 0.727 Beta(218,82) None
Non-visualisation
proportion
NAAASP8 1652/470,531 ≈ 0.0035 None None
AAA size
distribution at
screening
NAAASP8 NAAASP distribution,
reweighted to give
0.0043 prevalence
NAAASP distribution
based on uncertain
prevalence
Uppsala distribution,
reweighted to give
0.0043 prevalence
Prevalence
proportion
Systematic
review34
0.0042756 Based on normal
(–5.45054, 0.323212)
distribution for logit(p)
(a) 0.0021378
(b) 0.0085512
AAA growth and rupture
AAA growth RESCAN35 Mixed linear model for
log-AAA diameter (see
Chapter 4)
Using
variance–covariance
matrix for the six
parameters (see
Chapter 4)
None
AAA rupture RESCAN35 Joint model for
log-rupture rates and
log-underlying AAA
diameter (see
Chapter 4)
Using
variance–covariance
matrix for the two
parameters (see
Chapter 4)
None
Surveillance
Dropout from
surveillance
NAAASP8 1072/19,650 ≈ 0.0546
per year
Gamma(1072,19650) (a) 0.0273 per year
(b) 0.1092 per year
Incidental
detection rate
New Zealand36 40/1364.25 ≈ 0.0293
per year
Gamma(40,1364.25) (a) 0.0147 per year
(b) 0.0586 per year
Delay from
≥ 5.5-cm scan to
consultation
NAAASP8 10.6 days None None
Consultation scan RESCAN,35
Singh et al.95
CT is on average
0.244 cm greater
than ultrasound;
measurement error SD
of 0.19 cm for CT
None None
Decision at
consultation:
proportion
returned to
surveillance
N/A Modelled directly from
AAA measurements by
CT
N/A None
Decision at
consultation:
non-intervention
proportion
Meta-analysis
from four
hospitals37
0.34226 of those not
returned to surveillance
Based on normal
(–0.65324, 0.135022)
distribution for logit(p)
None
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TABLE 20 Input parameters to base-case model, and distributions and estimates used in the probabilistic and
deterministic sensitivity analyses (continued )
Parameter
Source
(base case) Base case PSA DSA
Decision at
consultation:
proportion elective
surgery
N/A 1 – 0.34226 = 0.65774
of those not returned to
surveillance
Obtained by subtraction None
Delay from
consultation scan
to elective surgery
NAAASP8 70.8 days None None
Elective operations
Proportion
receiving EVAR vs.
open repair
NVR26 0.586 Based on normal(0.348,
0.0432) for logit(p)
(a) Dependence of
logit(p) on (age-80) and
(AAA diameter-6.0)
(b) 0.3396 based on
systematic review of
EVAR suitability
EVAR 30-day
operative mortality
NVR,26 HES28 Expit[logit(23/1306)
+ F1] ≈ 0.024
F1= log{[37/(1642–37)]/
[27/(1642–27)]}
Based on normal
(–4.022, 0.2102) + F1 for
logit(p)
(a) Dependence of
logit(p) on (age-80) and
(AAA diameter-6.0)
(b) 0.0223 based on
systematic review
Open repair
30-day operative
mortality
NVR,26 HES28 Expit[logit(64/922)
+ F2] ≈ 0.081
F2= log{[75/(1066–75)]/
[64/(1066–64)]}
Based on normal
(–2.596, 0.1302) + F2 for
logit(p)
(a) Dependence of
logit(p) on (age-80) and
(AAA diameter-6.0)
(b) 0.0537 based on
systematic review
(c) 0.05
Reintervention
rate after
successful EVAR
EVAR-1 RCT38 20.3 and 6.4 per
100 woman-years
during 31–120 and
> 120 days, respectively
Based on Gamma(3,15)
and Gamma(27,421),
respectively
None
Reintervention
rate after
successful open
repair
EVAR-1 RCT38 0.0 None DSA based on DREAM76/
OVER77 RCT rates in
men, as these trials
include incisional
hernias. Overall rate
across the two trials
combined, 4.4 and 2.9
per 100 woman-years
during 31–120 and
> 120 days, respectively
Long-term AAA
mortality rate after
successful EVAR
EVAR-1 RCT38 1.799 per 100 woman-
years
Based on Gamma
(8,444.7)
None
Long-term AAA
mortality rate after
successful open
repair
EVAR-1 RCT38 0.499 per 100 woman-
years
Based on Gamma
(2,400.8)
None
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TABLE 20 Input parameters to base-case model, and distributions and estimates used in the probabilistic and
deterministic sensitivity analyses (continued )
Parameter
Source
(base case) Base case PSA DSA
Emergency operations
% operated after
rupture
Literature review
and the IMPROVE
RCT24
0.25 Based on normal(0.25,
0.052), with truncation
to within [0,1]
None
Proportion
receiving EVAR vs.
open repair
NVR26 0.168 Based on normal
(–1.599, 0.0952) for
logit(p)
Dependence of logit(p)
on (age-80)
EVAR 30-day
operative mortality
NVR26 and HES28 Expit[logit(33/132)
+ F3] ≈ 0.359
F3 = log{[48/(244–48)]/
[31/(244–31)]}
Based on normal
(–1.099, 0.2102) + F3 for
logit(p)
(a) Dependence of
logit(p) on (age-80)
(b) 0.32 based on
systematic review
Open repair
30-day operative
mortality
NVR26 and HES28 Expit[logit(260/653)
+ F4] ≈ 0.442
F4 = log{[319/(845–319)]/
[284/(845–284)]}
Based on normal
(–0.413, 0.0802) + F4 for
logit(p)
(a) Dependence of
logit(p) on (age-80)
(b) 0.51 based on
systematic review
Reintervention
rate after
successful EVAR
IMPROVE RCT24 15.8 per 100 woman-
years
Based on Gamma(9,57) None
Reintervention
rate after
successful open
repair
IMPROVE RCT24 2.3 per 100 woman-
years
Based on Gamma(2,85) None
Long-term AAA
mortality rate after
successful EVAR
IMPROVE RCT24 0.0 None 0.985 per 100 woman-
years based on men
Long-term AAA
mortality rate after
successful open
repair
IMPROVE RCT24 1.613 per 100 woman-
years
Based on Gamma(2,124) 1.437 per 100 woman-
years based on men
Costs
Invitation,
reinvitation
NAAASP8 £1.80 In all cases: based on
normal[log(base-case
estimate), 0.1142] for
log-costs
In all cases:
(a) base-case
estimate × 0.80
(b) base-case
estimate ×1.25
Screening scan NAAASP8 £34.11
Surveillance scan NAAASP8 £72.03
Consultation for
elective surgery
MASS10 and NHS
Reference Costs
2014 to 201539
£328.64
Elective EVAR
repair
EVAR-1,38
HES28 and NHS
Reference Costs
2014 to 201539
£13,844
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Health economic outputs
Estimates of mean life-years, QALYs and costs per woman invited to screening for the base-case are given
in Table 22. The group not invited to screening has an average life expectancy from age 65 years of
20.5429 years, which increases by 0.00285 years for the group invited to screening. The gain of 0.00285
life-years equals 1.04 days of life; this average figure reflects the very many who have no change in life
expectancy through screening, the few who gain (some substantially) because rupture of the AAA is
prevented and the very few who lose by dying in elective surgery.
TABLE 20 Input parameters to base-case model, and distributions and estimates used in the probabilistic and
deterministic sensitivity analyses (continued )
Parameter
Source
(base case) Base case PSA DSA
Elective open
repair
EVAR-1,38
HES28 and NHS
Reference Costs
2014 to 201539
£13,060
Emergency EVAR
repair
IMPROVE,24
HES28 and NHS
Reference Costs
2014 to 201539
£16,154
Emergency open
repair
IMPROVE,24
HES28 and NHS
Reference Costs
2014 to 201539
£17,613
Surveillance after
operations
Expert opinion
and NHS
Reference Costs
2014 to 201539
£258.16 annually after
EVAR, £196.79 at
6 weeks after open
repair
Reintervention
after EVAR
EVAR-138 £7546
Reintervention
after open repair
EVAR-138 £8986
Miscellaneous
Non-AAA
mortality rate
ONS40 ONS 2012–14 data by
single year of age, ages
65–94 years
None None
Overall QoL/
utilities
EQ-5D102 0.81 for age 55–64
years, 0.78 for age
65–74 years and 0.71
for age ≥ 75 years
None None
QoL harms of
screening
MASS10 No effect None None
QoL harms of
surgery
EVAR-138 and
IMPROVE24
No effect None None
Discounting rates N/A (a) Undiscounted
(b) 3.5% per year for
costs, 3.5% per year for
life-years
None None
N/A, not applicable.
Adapted with permission from Sweeting et al.42 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY-NC-ND 4.0 licence.
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For health economic analyses, life-years and costs are both discounted at 3.5% per annum. The increase in
QALYs associated with screening is 0.00110 years per woman invited to screening. Mean discounted costs
associated with screening and AAA-related events increase by £33.99 from £49.56 to £83.55. Overall, this
gives an ICER of £22,000 per life-year gained and £31,000 per QALY gained for the base-case screening
strategy versus no screening. Therefore, the INMB [calculated as (net discounted QALYs ×WTP) – net
discounted costs] is negative for both £20,000 and £30,000 per QALY thresholds (see Table 22). This
suggests that a screening programme for women based on the current NAAASP implementation is unlikely
to be cost-effective.
TABLE 21 Numbers of women with key events among 10 million women in the base-case analysis
Event
Number of events
Not invited to screening Invited to screening
Emergency open surgery 18,957 18,108
Emergency EVAR surgery 3915 3728
Elective open surgery
Incidentally detected 9039 8221
Screen detected 0 2718
Total 9039 10,939
Elective EVAR surgery
Incidentally detected 12,743 11,551
Screen detected 0 4010
Total 12,743 15,561
AAA ruptures 91,759 87,855
AAA deaths 82,932 80,476
Non-AAA deaths 8,552,257 8,554,234
Reinterventions
After elective open 0 0
After elective EVAR 4367 5776
After emergency open 1582 1480
After emergency EVAR 1522 1447
Total 7471 8703
Surveillance measurements
Entered surveillance 94,371 115,699
After open surgery 18,688 19,951
After EVAR surgery 13,606 16,087
After contraindication 10,638 13,133
Total 137,303 164,870
Contraindications
Incidentally detected 11,469 10,581
Screen detected 0 3402
Total 11,469 13,983
Dropout from surveillance 23,563 35,101
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FIGURE 11 Cumulative elective operations, emergency operations and AAA deaths in the base-case analysis ages
65–95 years among 10 million women. (a) Elective operations; (b) emergency operations; and (c) AAA deaths.
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TABLE 22 Health economic results for base-case analyses and DSAs relating to aortic size distribution, prevalence, dropout and incidental detection rates
Sensitivity analysis change
Base-case
Baseline aorta distribution and prevalence
Dropout and incidental
detection rates
Uppsala distribution
(0.43% prevalence)
Halve prevalence
(0.21%)
Double prevalence
(0.86%)
Halve both
ratesa
Double
both ratesb
No screening Screeningc Difference Difference Difference Difference Difference Difference
Life-years
Undiscounted 20.5429 20.5458 0.00285 0.00504 0.00123 0.00840 0.00399 0.00154
Discounted 13.9338 13.9353 0.00153 0.00286 0.00065 0.00472 0.00212 0.00084
Discounted, QA 10.4474 10.4485 0.00110 0.00207 0.00047 0.00342 0.00152 0.00061
Costs (£)
Undiscounted 88.40 124.57 36.170 39.569 31.238 49.330 40.381 31.761
Discounted 49.56 83.55 33.990 37.179 30.187 44.770 36.905 30.803
ICER (per life-year or QALY) (£)
Undiscounted 12,685 7849 25,405 5871 10,115 20,647
Discounted 22,180 12,987 46,346 9477 17,393 36,543
Discounted, QA 30,955 17,931 64,841 13,107 24,302 50,888
INMB, discounted, QA (£)
Lambda of £20,000 –12.03 4.29 –20.88 23.55 –6.53 –18.70
Lambda of £30,000 –1.05 25.02 –16.22 57.71 8.65 –12.64
QA, quality adjusted.
a Halving dropout rate from 5.5 to 2.7 per 100 person-years and incidental detection rate from 2.9 to 1.5 per 100 person-years.
b Doubling dropout rate from 5.5 to 10.9 per 100 person-years and incidental detection rate from 2.9 to 5.9 per 100 person-years.
c Calculated by adding the values in the ‘Difference’ column to the values in the ‘No screening’ column.
Note
Life-years and costs discounted at 3.5% per annum.
Lambda: threshold WTP per QALY gained.
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Uncertainty from the PSA in the estimated incremental QALYs and incremental costs is shown in Figure 12a.
The scatterplot lies in the north-east quadrant, where invitation to screening is both more effective and more
expensive. However, the majority of the points lie above the threshold of £20,000 per QALY gained and
about half lie above a £30,000 threshold (shown in Figure 12a by the diagonal lines that pass through the
origin). There is considerable uncertainty in the incremental discounted QALYs. In particular, the prevalence
of AAAs is highly correlated with the estimated incremental QALYs and, as this quantity is not precisely
known, it is a key driver behind the large amount of uncertainty. We express uncertainty on the INMB scale:
an INMB of –£12.03 (95% uncertainty interval –£27.88 to £22.12) per woman invited is estimated if a QALY
is valued at £20,000, and an INMB of –£1.05 (–£23.76 to £54.79) per woman invited if a QALY is valued at
– 0.002 0.000 0.002 0.004
Discounted incremental QALYs
In
cr
em
en
ta
l d
is
co
u
n
te
d
 c
o
st
s 
(£
00
0)
0.006
– 20
0
20
40
60
(a)
0
0.0
0.2
0.4
0.6
0.8
1.0
(b)
10 20 30
WTP (£000)
Pr
o
b
ab
ili
ty
 A
A
A
 s
cr
ee
n
in
g
 is
 c
o
st
-e
ff
ec
ti
ve
40 50
FIGURE 12 Cost-effectiveness from the PSA of the base-case model. (a) Results on the cost-effectiveness plane; the
green and blue lines indicate WTP thresholds of £20,000 and £30,000 per QALY, respectively; and (b) CEAC.
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£30,000. A CEAC (Figure 12b) indicates that the screening programme, as implemented, is unlikely to be
considered cost-effective: there is a < 20% probability that the programme would be cost-effective at a
threshold of £20,000 per QALY.
Deterministic sensitivity analyses
A total of 15 one-way DSAs are undertaken to investigate the robustness of the cost-effectiveness
estimates to changes in parameter inputs. The sensitivity analyses investigated are detailed here,
and Table 23 (and see Table 22) shows the results for incremental life-years, QALYs and costs, and
cost-effectiveness estimates.
Baseline aortic diameter distribution and prevalence
We first consider how changes in the aortic diameter distribution and prevalence affect the cost-effectiveness
of the screening programme. Although the base-case model is derived from the aortic size distribution
from 700,000 men in NAAASP, a sensitivity analysis is based on the Uppsala study14 aortic size distribution,
undertaken in 5140 women (see Chapter 4, Screening). After reweighting both distributions to give the
desired prevalence (0.43% ≥ 3.0 cm), the Uppsala study14 had a much higher proportion of medium and
large AAAs (0.074% vs. 0.005% in the reweighted NAAASP distribution; see Table 12b). In addition,
we investigate the effect of halving the prevalence, from 0.43% to 0.21%, and doubling the prevalence,
from 0.43% to 0.86%, from the base-case model.
A notable change in the ICER is seen when changing the baseline aortic diameter distribution from the
(weighted) NAAASP distribution to the (weighted) Uppsala distribution (see Table 22). There is a small
increase in costs, due to an increase in elective operations, but the mean difference in life-years almost
doubles owing to timely elective operations taking place and the subsequent reduction in ruptures.
The effect is a screening programme that is more cost-effective, with the ICER reduced to £18,000 per
QALY gained and an INMB gain of £4.29 per woman invited if a QALY is valued at £20,000. This effect
becomes even clearer if the prevalence of AAAs is doubled to 0.86%, with the ICER decreasing to £13,000
per QALY gained, and an INMB gain of £23.55 per woman invited if a QALY is valued at £20,000. As
expected, the ICER increases substantially if the prevalence is halved, to £65,000 per QALY gained.
Dropout and incidental detection rates
We next consider the effect of a change in the dropout and incidental detections rates. First, the dropout
and the incidental detection rates are halved, from 5.5 to 2.7 per 100 person-years and from 2.9 to
1.5 per 100 person-years, respectively. Following this, the dropout and the incidental detection rates are
doubled, from 5.5 to 10.9 per 100 person-years and from 2.9 to 5.9 per 100 person-years, respectively.
Halving the dropout rate ensures that a larger number of individuals stay in the surveillance programme,
giving a greater chance of preventing a rupture via an elective operation should their AAA grow large
enough. This increases the cost of the programme, but a greater number of life-years are gained owing
to the increase in AAA treatment. In addition, life-years are lost in the non-invited group owing to the halving
of the incidental detection rate. This results in a more cost-effective programme than in the base-case, with
an ICER of £24,000 per QALY gained (see Table 22). Conversely, an increase in the dropout and incidental
detection rates results in a greater ICER of £51,000 per QALY gained, attributable to a greater relative
reduction in the incremental life-years than in the reduction in the incremental costs.
Parameters affecting elective operations
We now consider the effects age and AAA size have on an individual’s suitability for elective EVAR surgery and
their operative mortality rates, and whether or not changes in these parameters affect the cost-effectiveness of
the screening programme. First, the percentage receiving elective EVAR and the elective operative mortality
rates for EVAR and open repair are allowed to depend on age and AAA diameter (see Chapter 5). Next, the
percentage receiving elective EVAR and the elective operative mortality rates are based on the systematic
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TABLE 23 Health economic results for DSAs relating to elective and emergency surgery, reintervention rates and costs
Sensitivity analysis
change
Elective surgery parametersa
Emergency surgery
parametersa
Parameters
affecting
postoperative
complications Costs
Difference
Dependent
on age and
AAA
diameter
Based on
systematic
literature
reviews
Open
repair
operative
mortality
of 5%b
Dependent on
age
Based on
systematic
literature
reviews
Increasing the
reintervention
rate after elective
open repair and
increasing AAA
mortality rate after
emergency repairc
20% lower
costs of
screening,
surveillance
and
consultation
25% higher
costs of
screening,
surveillance
and
consultation
20% lower costs
of elective
surgery, and
25% higher costs
of emergency
surgery
25% higher
costs of elective
surgery, and
20% lower costs
of emergency
surgery
Life-years
Undiscounted 0.00296 0.00304 0.00293 0.00284 0.00291 0.00286 0.00285 0.00285 0.00285 0.00285
Discounted 0.00159 0.00163 0.00158 0.00152 0.00156 0.00154 0.00153 0.00153 0.00153 0.00153
Discounted, QA 0.00114 0.00117 0.00113 0.00109 0.00112 0.00110 0.00110 0.00110 0.00110 0.00110
Costs (£)
Undiscounted 35.923 35.097 36.173 36.165 36.153 36.807 30.106 43.751 34.532 38.031
Discounted 33.824 33.329 33.991 33.989 33.982 34.373 28.095 41.359 32.758 35.405
ICER per life-year or QALY) (£)
Undiscounted 12,153 11,534 12,331 12,744 12,416 12,864 10,558 15,344 12,111 13,338
Discounted 21,257 20,409 21,506 22,306 21,716 22,353 18,333 26,988 21,376 23,103
Discounted, QA 29,656 28,481 29,998 31,135 30,308 31,196 25,586 37,666 29,833 32,244
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TABLE 23 Health economic results for DSAs relating to elective and emergency surgery, reintervention rates and costs (continued )
Sensitivity analysis
change
Elective surgery parametersa
Emergency surgery
parametersa
Parameters
affecting
postoperative
complications Costs
Difference
Dependent
on age and
AAA
diameter
Based on
systematic
literature
reviews
Open
repair
operative
mortality
of 5%b
Dependent on
age
Based on
systematic
literature
reviews
Increasing the
reintervention
rate after elective
open repair and
increasing AAA
mortality rate after
emergency repairc
20% lower
costs of
screening,
surveillance
and
consultation
25% higher
costs of
screening,
surveillance
and
consultation
20% lower costs
of elective
surgery, and
25% higher costs
of emergency
surgery
25% higher
costs of elective
surgery, and
20% lower costs
of emergency
surgery
INMB, discounted, QA (£)
Lambda of £20,000 –11.01 –9.92 –11.33 –12.16 –11.56 –12.34 –6.13 –19.40 –10.80 –13.44
Lambda of £30,000 0.39 1.78 0.00 –1.24 –0.35 –1.32 4.85 –8.42 0.18 –2.46
QA, quality adjusted.
a Parameters include the percentage receiving EVAR vs. open repair, and EVAR and open repair operative mortality.
b Decreased from 8.1% estimated from the NVR and HES to 5%.
c Reintervention rate after successful elective open repair increased from 0 per 100 woman-years as observed in EVAR-1 trial38 to 4.4 and 2.9 per 100 woman-years during 31–120 and
> 120 days, respectively, as observed in DREAM76/OVER77 trials. Long-term AAA-related mortality rate after successful emergency EVAR and open repair increased from 0 and 1.613 per
100 woman-years, respectively, to 0.985 and 1.437 per 100 person-years based on rates in men in the IMPROVE trial.30
Note
Life-years and costs discounted at 3.5% per annum.
Lambda: threshold WTP per QALY gained.
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reviews (see Chapter 3). Finally, the elective open AAA repair operative mortality, estimated from the NVR26
and HES,28 is decreased from 8.1% to 5%; this might be regarded as a potentially attainable target after a
performance improvement programme.
These changes all have a similar, but small, effect on the cost-effectiveness estimates, with ICERs in the
range £28,000–30,000 (see Table 23). Although the incremental costs are similar or slightly lower than in
the base case, the incremental QALYs are slightly higher. A reduction in the elective open repair operative
mortality to 5% has little effect on the cost-effectiveness estimates when compared with the base case,
which suggests that cost-effectiveness is largely unaffected by even quite substantial changes in elective
open AAA repair mortality.
Parameters affecting emergency operations
As earlier, we first allow the percentage receiving emergency EVAR, and emergency operative mortality
rates for EVAR and open repair, to depend on age. Second, the percentage receiving emergency EVAR,
and emergency operative mortality rates are based on the literature reviews (see Chapter 3, Mortality
following ruptured abdominal aortic aneurysms in women).
Allowing emergency operations to depend on age has limited overall effect on the cost-effectiveness, with
an ICER of £31,000 per QALY gained. The effect of the systematic review point estimates also has little
effect on the cost-effectiveness estimates, resulting in an ICER of £30,000 per QALY gained (see Table 23).
Reintervention rates following successful abdominal aortic aneurysm repair
Uncertainties in the reintervention rates estimated as zero in the base-case analysis were not included in
the PSA. We consider complications following both elective and emergency operations, by increasing the
reintervention rate after successful elective open repair from 0.0 to 4.4 (31–120 days) and 2.9 (> 120 days)
per 100 person-years (based on men in the DREAM76 and OVER77 trials), and increasing the long-term
AAA mortality rate after successful emergency EVAR repair from 0.0 to 0.985 per 100 person-years
(based on men in the IMPROVE trial30). This has almost no effect on the cost-effectiveness of the screening
programme for women (see Table 23). This highlights the fact that overall cost-effectiveness is relatively
insensitive to changes in rates of events that affect only a small proportion of the population (e.g. those with
an AAA who have undergone and survived an elective or emergency operation). Therefore, although there
were no long-term data for women about reinterventions after successful emergency surgery, it is reassuring
that this parameter is unlikely to have any substantial effect on overall cost-effectiveness estimates.
Costs
Finally, we consider the effect of costs, by means of combinations of alterations to the unit costs in
different stages of the screening programme. First, we lower the costs of screening, surveillance and
consultation by 20%. This is followed by the increase in screening, surveillance and consultation costs
of 25%, a symmetrical increase on a log-scale. Next, we consider opposing decreases and increases in
costs of elective and emergency surgeries: a 20% lower cost of elective surgery and 25% higher cost of
emergency surgery, then a 25% increase in the cost of elective surgery and 20% decrease in the cost
of emergency surgery.
The decrease and increase in costs associated with screening and surveillance result in an expected
increase and decrease in the incremental costs with no change in the incremental life-years. This has
the effect of decreasing and increasing the ICER by approximately 20% to £26,000 and £38,000 per
QALY gained, respectively (see Table 23). A smaller effect on the ICER was seen when the elective and
emergency surgery costs were varied. Decreasing elective surgery costs and increasing emergency surgery
costs makes the screening programme more cost-effective, but only slightly, with the ICER decreasing to
£30,000 per QALY gained. Similarly, increasing elective surgery costs and decreasing emergency surgery
costs increases the ICER to only £32,000 per QALY gained.
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Conclusions
Based on our best estimates, an AAA screening programme for women, as currently implemented by
NAAASP, is unlikely to be considered cost-effective for the NHS, with an estimated ICER of £31,000 per
QALY gained compared with the NICE valuation of a QALY (£20,000–30,000). However, this conclusion is
sensitive to the prevalence of AAAs in 65-year-old women and the distribution of aortic sizes among AAAs
in women. We have shown that, if the prevalence is as high as 0.86%, then the ICER would be lowered to
£13,000 per QALY gained and screening could be considered cost-effective. This prevalence is below that
estimated from two out of the six studies included in our systematic review for women aged < 70 years
(see Figure 3). Similarly, if more women who are detected with an AAA at screening have a medium or
large AAA (as indicated in the Uppsala distribution of aorta sizes), then the programme could also be
considered cost-effective. This highlights the urgent need to obtain robust evidence about both the
prevalence and aortic diameter distribution in the UK population of women at ages that could be
considered for screening.
Other key parameters that could change conclusions regarding cost-effectiveness are the rate at which
women drop out from a screening programme and the rate at which AAAs are incidentally detected.
The latter parameter in particular is very difficult to estimate, and good-quality data on this are lacking.
Halving the incidental detection and dropout rates would decrease the ICER to £24,000 per QALY gained.
Finally, we have shown in this chapter that varying the rates and costs associated with elective and
emergency operations does not change the cost-effectiveness results very much since they affect a
relatively small proportion of the population. This provides some confidence that the results are robust to
moderate deviations in estimates for these parameters.
NHS ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAMME POLICY
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Chapter 8 Screening options for women
A more cost-effective screening programme for women may depart from the options used for men in anumber of ways. Given their lower AAA prevalence and longer life expectancy, inviting women to
screening at a higher age may be more cost-effective than doing so at age 65 years. In addition, given
the higher AAA rupture risk in women than men, the threshold for considering elective surgery might be
lowered from 5.5 cm. The ‘prevalence’ may also be increased by considering an aortic diameter < 3.0 cm
as defining an AAA in women, and including this group in the surveillance programme. Surveillance
intervals might be lengthened for this group and, indeed, others with the smallest AAAs, in order to
reduce costs. Finally, women might be offered rescreening after some years, even if they were screened
as normal initially.
In this chapter, each of these options is first investigated separately. Then the options are combined to
find the most cost-effective joint option. Therefore, this chapter addresses objective 5 in Chapter 1,
Scientific objectives.
Single screening options
The options considered include changing the age at screening or the AAA diameter for considering
elective surgery. These changes affect the age and AAA diameter at which women receive elective
operations, and the age when AAAs rupture. Thus, it is important that all these analyses include the
effects of age and AAA diameter on the parameters for elective operations and the effect of age on
those for emergency surgery. Thus, we start with a ‘reference case’ for this chapter, which combines the
two relevant sensitivity analyses in Chapter 7, Parameters affecting elective operations and Chapter 7,
Parameters affecting emergency operations, so that these age and AAA diameter effects are included.
Reference case
This includes the effects of age and AAA diameter on parameters for elective operations, and the effect
of age on parameters for emergency operations, but does not make any other changes. Neither of these
sensitivity analyses in Chapter 7 changed the cost-effectiveness estimates very much compared with the
base case. Therefore, their combination is also similar to the base case (Table 24 Reference case columns),
with an ICER of £30,000 per QALY gained. The numbers of key events are provided for this reference case
in Table 25 (Reference case columns), which are, again, similar to the base case (see Table 21).
Age at screening
We consider raising the screening age from 65 years to 70 or 75 years. The AAA prevalence at age 65 years
was 0.43% (95% CI 0.23% to 0.80%), based on the systematic review for women aged < 70 years (see
Chapter 3, Current prevalence of screen-detected abdominal aortic aneurysms in women), and increased
to 1.15% (95% CI 0.59% to 2.24%) for women aged 75 years, based on the 70- to 79-year age group in
the systematic review. Interpolating linearly on a logit scale between these two estimates gives an AAA
prevalence of 0.70% (95% CI 0.37% to 1.34%) at age 70 years. The attendance rate at screening was
72.7% at age 65 years, and this is estimated to decrease to 67.6% at age 70 years and to 62.3% at age
75 years (see Chapter 4, Screening). Both of these factors are taken into account when adjusting the
screening age.
As shown in Table 24, offering screening at age 70 or 75 years increased the gain in QALYs per woman
invited to screening by factors of about 1.4 and 2.2, respectively, compared with the reference case. The
costs per woman invited decreased in both groups compared with the reference case, with the incremental
cost being larger, especially for age 75 years screening. The estimated ICERs were £24,000 per QALY
gained for age 70 years screening and £18,000 for age 75 years screening. The more favourable ICER for
age 75 years screening gives rise to a positive INMB at a threshold of £20,000 per QALY.
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TABLE 24 Health economic results for screening options for women, each considered separately
Option, surveillance
interval changes
Reference case Screening age (years) Intervention threshold Diagnosis threshold Surveillance intervals
Age and AAA diameter effects on
operation parameters included 70 75
5.0 cm,
3 months for
4.0–4.9 cm
4.5 cm,
3 months for
3.5–4.4 cm
2.5 cm,
1 year for
2.5–2.9 cm
2.5 cm,
5 years for
2.5–2.9 cm
2 years
for
3.0–3.9 cm
Rescreen
< 3.0 cm
every
5 years
No
screening Screeninga Difference Difference Difference Difference Difference Difference Difference Difference Difference
Life-years
Undiscounted 20.5451 20.5480 0.00291 0.00366 0.00520 0.00337 0.00374 0.00403 0.00405 0.00285 0.00591
Discounted 13.9351 13.9367 0.00156 0.00216 0.00346 0.00181 0.00200 0.00211 0.00212 0.00153 0.00296
Discounted, QA 10.4484 10.4495 0.00112 0.00154 0.00246 0.00130 0.00143 0.00151 0.00152 0.00110 0.00211
Costs (£)
Undiscounted 90.33 126.23 35.899 39.759 47.719 38.201 41.255 45.215 41.818 34.686 154.928
Discounted 50.55 84.36 33.806 36.849 44.084 35.892 38.925 40.378 37.636 32.802 114.687
ICER (per life-year or QALY) (£)
Undiscounted 12,335 10871 9180 11,333 11,022 11,231 10,317 12,151 26,233
Discounted 21,620 17,034 12,741 19,802 19,443 19,174 17,732 21,386 38,737
Discounted, QA 30,170 23,966 17,946 27,628 27,151 26,817 24,798 29,844 54,294
INMB, discounted, QA (£)
Lambda of £20,000 –11.40 –6.10 5.05 –9.91 –10.25 –10.26 –7.28 –10.82 –72.44
Lambda of £30,000 –0.19 9.28 29.61 3.08 4.08 4.79 7.90 0.17 –51.32
QA, quality adjusted.
a Calculated by adding the values in the ‘Difference’ column to the values in the ‘No screening’ column.
Note
Lambda: threshold WTP per QALY gained.
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The improved cost-effectiveness at higher ages illustrates the importance of AAA prevalence. This offsets
the disadvantages incurred through a lower life expectancy (16.4 years at age 70 years and 12.6 years at
age 75 years, compared with 20.5 years at age 65 years) resulting from the increased mortality rates from
non-AAA causes, as well as the increased mortality from elective operations at higher ages (see Chapter 5).
However, two points should be noted. First, the non-intervention rate for elective operations used in the
model is not age dependent, as there was insufficient evidence to quantify this in the systematic review
(see Proportion of women versus men not offered an intervention). This is not clinically realistic, and it is
TABLE 25 Numbers of women with key events among 10 million women in the reference case and combined
option 1
Event
Reference case (see Reference case)
Combined option 1 (see Detailed
results for option 1)
Not invited to
screening (n)
Invited to
screening (n)
Not invited to
screening (n)
Invited to
screening (n)
Emergency open surgery 18,824 18,126 14,911 13,037
Emergency EVAR surgery 4533 4260 3780 3325
Elective open surgery
Incidentally detected 6097 5267 5487 3802
Screen detected 0 2960 0 5966
Total 6097 8227 5487 9768
Elective EVAR surgery
Incidentally detected 15,555 14,351 18,262 14,652
Screen detected 0 3597 0 12,337
Total 15,555 17,948 18,262 26,989
AAA ruptures 92,346 88,389 74,653 65,545
AAA deaths 83,877 81,311 68,864 63,205
Non-AAA deaths 8,550,791 8,552,846 8,497,888 8,502,202
Reinterventions
After elective open 0 0 0 0
After elective EVAR 5054 6192 5428 9134
After emergency open 1606 1466 1086 908
After emergency EVAR 1612 1549 1249 1023
Total 8272 9207 7763 11,065
Surveillance measurements
Entered surveillance 95,290 115,463 138,346 207,259
After open surgery 15,446 16,984 12,391 15,239
After EVAR surgery 16,090 18,168 17,530 25,460
After contraindication 10,905 13,056 11,681 18,522
Total 137,731 163,671 179,948 226,480
Contraindications
Incidentally detected 11,725 10,565 12,606 9889
Screen detected 0 3410 0 9671
Total 11,725 13,975 12,606 19,560
Dropout from surveillance 24,050 35,226 38,340 84,809
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appreciated that non-intervention rates probably increase markedly with age, especially for women in
whom EVAR is not suitable (as open repair operations in elderly women have the greatest risk). This
implies that the results for screening, at age 75 years in particular, may be overly optimistic. Second, by
screening at a higher age, AAA deaths at younger ages are not prevented. From the unscreened group
in the base-case analysis (see Figure 11c), one can see that about 5% of all AAA deaths occur between
the ages of 65 and 70 years, and about 15% between the ages of 65 and 75 years. These earlier
deaths are also associated with the greatest number of life-years lost. Although this does not affect the
cost-effectiveness of screening at higher ages, it reduces the benefit of screening at the population level.
Abdominal aortic aneurysm diameter for considering surgery
We consider reducing the threshold of the AAA diameter for considering elective surgery to 5.0 or 4.5 cm.
The surveillance intervals were also altered in these scenarios, so that a 3-month interval applied for the
1.0 cm range below the threshold (i.e. 4.0–4.9 cm when the threshold is 5.0 cm, and 3.5–4.4 cm when
the threshold is 4.5 cm). This is in keeping with the use of 3-month intervals for 4.5- to 5.4-cm AAAs in
both the base case and reference case in which the threshold is 5.5 cm.
Using lower thresholds increased the incremental life-years and QALYs compared with the reference
case (see Table 24). Both options slightly increased the incremental costs because of a greater number of
elective operations, especially in the invited group. The consequence is that for a 5.0-cm threshold the
ICER was £28,000 per QALY gained, while, for a 4.5-cm threshold, the ICER was £27,000, both slightly
lower than the reference case.
Aortic diameter defining an abdominal aortic aneurysm
We consider reducing the aortic diameter for defining an AAA in women to 2.5 cm. In both the Swedish
and Danish data, (see Chapter 4, Screening), 2.5 cm is roughly 1.5 times the average aortic diameter in
women (which is sometimes suggested as an appropriate definition of an AAA105) and roughly 3 SDs above
the mean. Based on an AAA prevalence of 0.43% for an aortic diameter of ≥ 3.0 cm at age 65 years,
the AAA prevalence becomes 1.44% for an aortic diameter of ≥ 2.5 cm. For the 2.5- to 2.9-cm group,
which are now entered into the surveillance programme, we consider two choices of surveillance intervals:
(1) 1 year (as in the 3.0–4.4 cm group) or (2) 5 years (as has been suggested for men with subaneurysmal
aortic diameters106).
Both options similarly increased the life-years and QALYs gained (see Table 24), but only by about
one-third compared with the reference case. However, they also increased the incremental costs, through
more surveillance scans in the invited group, especially in the first option, which employed 1-year surveillance
intervals, and more elective operations. As a result, the cost-effectiveness estimates were more favourable
than in the reference case, with ICERs of £27,000 and £25,000 in the two cases, respectively. However,
the programme would still not be considered cost-effective at a threshold of £20,000 per QALY.
Surveillance intervals and rescreening
Finally, we consider changing the surveillance intervals. First, we increase the surveillance intervals for
the smallest AAAs (3.0–3.9 cm) to 2 years, an option that improved cost-effectiveness slightly for men.35
Second, we consider a programme in which all women are rescreened every 5 years from age 65 years
upwards. In essence, this includes everyone with an aortic diameter of < 3.0 cm into a monitoring
programme with a surveillance interval of 5 years.
In this first option, unsurprisingly, the number of life-years and QALYs gained is very slightly lower, but the
incremental cost is also slightly lower than the reference case through fewer surveillance scans (see Table 24,
penultimate column). This yields an ICER of £30,000 per QALY gained, hardly changed compared with the
reference case. The second option has dramatic effects on both the life-years and QALYs gained, which are
approximately doubled compared with the reference case, and the incremental cost, which is increased more
than three-fold (see Table 24). The result is not favourable in terms of cost-effectiveness, with an estimated
ICER of £54,000 per QALY gained.
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Combined screening options
We take the more favourable options considered, and combine them in an attempt to identify options
for an AAA screening programme in women that would be better than the ones considered so far. Of
particular interest is whether or not any combined options yield an ICER < £20,000 per QALY. We avoid the
possibility of screening at age 75 years, for the reasons given earlier (see Age at screening). We consider
12 options in total, for screening age (either 65 or 70 years), intervention threshold (AAA diameter of 4.5,
5.0 or 5.5 cm) and diagnosis threshold (aortic diameter of either 2.5 cm or 3.0 cm). Surveillance intervals are
set as 3 months for the 1 cm interval below the intervention threshold, 5 years for 2.5–2.9 cm, if applicable,
and 1 year otherwise. Five of the 12 possible options have already been considered in Table 24; results from
the additional seven options are shown in Table 26.
Combined options considered
The results in Table 24 suggest that a favourable combined option might be obtained by screening at
age 70 years, employing an intervention threshold of 5.0 cm and a diagnosis threshold of 2.5 cm. These
options considered singly gave ICERs of £24,000, £28,000 and £25,000, respectively. Combining them is
presented as option 1 in Table 26, and shows increases in both QALYs gained and in incremental costs
compared with both the reference case and the options considered singly (see Table 24). However, the
ICER is estimated as £23,000 per QALY, which represents only a slight improvement in cost-effectiveness.
Given that option 1 did not reduce the ICER to below £20,000 per QALY, all the other additional
combinations were also investigated, being presented as options 2–7 in Table 26. A number of conclusions
can be drawn from the total 12 options considered: (1) many of the options yield very similar ICERs, with,
for example, 9 out of the 12 between £22,500 and £25,000 per QALY; (2) the combinations employing
screening at age 65 years and a diagnosis threshold of 3.0 cm are clearly not the best options; (3) screening
at age 70 years is almost uniformly more cost-effective than screening at age 65 years; (4) a diagnosis
threshold of 2.5 cm is uniformly more cost-effective than one of 3.0 cm; and (5) no option gave an ICER
below £20,000 per QALY.
The best choice of intervention threshold is moot. Except when screening at age 65 years using a 3.0-cm
diagnosis threshold, all three intervention thresholds (4.5 cm, 5.0 cm and 5.5 cm) yield very similar ICERs.
The lower thresholds give rise to greater QALYs gained but also to greater incremental costs from an
increased number of elective operations. However, since the increases in QALYs and costs are proportionally
similar, the ICERs remain similar.
Given the uncertainty in the ICERs, it is not possible to be definitive about which combined option is ‘best’
in terms of cost-effectiveness. However, option 1 gave the lowest ICER estimate and the next to largest
gain in life-years and QALYs. We now examine this option in more detail.
Detailed results for option 1
The numbers of key events for this option, which is the best in terms of overall cost-effectiveness, are
shown in Table 25 (right-hand side). Compared with the reference case, there are fewer AAA ruptures,
emergency operations and AAA deaths due to screening at the higher age of 70 years. The relative
reductions in each of these outcomes in the screening group are 12%, 12% and 8%, compared with
4%, 4% and 3% in the reference case, respectively. However, there are more elective operations in this
screening option than in the reference case, owing to the lower intervention threshold, with a relative
increase of 55% compared with 21%.
The cumulative numbers of elective operations, emergency operations and AAA deaths for option 1 are
shown in Figure 13. Compared with the corresponding figures for the base-case (see Figure 11), the
separation of the lines for the invited and non-invited groups is greater. For emergency operations and
AAA deaths, the separation gradually increases over the whole of the 25-year time course from age
70 to 95 years, with no suggestion, for example, of a marked benefit in the early years after screening.
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TABLE 26 Health economic results for combined screening options for women
Outcome
Option 1 (70 years screening age,
5.0-cm intervention threshold,a
2.5-cm diagnosis threshold)a
Option 2 (70 years
screening age,
5.0-cm intervention
threshold,a
3.0-cm diagnosis
threshold)a
Option 3 (65 years
screening age,
5.0-cm intervention
threshold,a
2.5-cm diagnosis
threshold)a
Option 4 (70 years
screening age,
5.5-cm intervention
threshold,a
2.5-cm diagnosis
threshold)a
Option 5 (70 years
screening age,
5.0-cm intervention
threshold,a
2.5-cm diagnosis
threshold)a
Option 6 (70 years
screening age,
4.5-cm intervention
threshold,a
3.0-cm diagnosis
threshold)a
Option 7 (65 years
screening age,
4.5-cm intervention
threshold,a
2.5-cm diagnosis
threshold)a
No
screening Screeningb Difference Difference Difference Difference Difference Difference Difference
Life-years
Undiscounted 16.4305 16.4353 0.00484 0.00416 0.00465 0.00430 0.00524 0.00450 0.00515
Discounted 11.8599 11.8627 0.00281 0.00246 0.00244 0.00251 0.00303 0.00264 0.00268
Discounted, QA 8.7257 8.7277 0.00200 0.00175 0.00174 0.00178 0.00215 0.00187 0.00192
Costs (£)
Undiscounted 84.53 134.93 50.395 43.584 45.812 44.901 58.111 48.694 51.407
Discounted 52.76 97.83 45.066 40.418 40.954 40.264 52.134 45.491 45.939
ICER (per life-year or QALY) (£)
Undiscounted 10,420 10,480 9842 10,436 11,094 10,830 9977
Discounted 16,016 16,449 16,800 16,072 17,229 17,235 17,126
Discounted, QA 22,540 23,149 23,492 22,615 24,271 24,281 23,972
INMB, discounted, QA (£)
Lambda of
£20,000
–5.08 –5.50 –6.09 –4.66 –9.17 –8.02 –7.61
Lambda of
£30,000
14.91 11.96 11.34 13.15 12.30 10.72 11.55
QA, quality-adjusted.
a Calculated by adding the values in the ‘Difference’ column to the values in the ‘No screening’ column.
b Surveillance intervals of 5 years for 2.5–2.9 cm, if applicable, 3 months for the 1 cm interval below the intervention threshold, and 1 year otherwise.
Note
Lambda: threshold WTP per QALY gained.
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FIGURE 13 Cumulative elective operations, emergency operations, and AAA deaths among 10 million women in
combined screening option 1. (a) Elective operations; (b) emergency operations; and (c) AAA deaths.
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A marked early benefit might be anticipated only if there were a substantial number of women discovered
at screening who were near or over the AAA diameter threshold for considering surgery.
A PSA was carried out for this case, using 1000 runs for different parameter values representing
their uncertainty distributions, each run including 500,000 pairs of women. This involved using the
variance–covariance matrix from the logistic regressions that quantified the relations between age and
AAA diameter on parameters for elective and emergency operations (see Chapter 5). Random draws of
parameter values were taken from the relevant multivariate normal distributions. A normal distribution for
the uncertainty of the altered AAA prevalence estimate (on a logit scale) was used, together with a Beta
distribution for the altered attendance rate. The uncertainty in other parameters was as in the base-case
analysis (see Table 11).
The distribution of incremental costs and QALYs is shown on the cost-effectiveness plane in Figure 14a.
As for the base-case (see Figure 12a), there is a wide spread for incremental QALYs and a lesser spread
for incremental costs. The centre of the distribution lies between the lines representing the thresholds of
£20,000 and £30,000 per QALY. The INMB at a threshold of £20,000 per QALY is –£5.08 (95% uncertainty
interval –£31.53 to £69.98), whereas at a threshold of £30,000 it is £14.91 (95% uncertainty interval
–£25.18 to £135.16). The cost-effectiveness estimate is more favourable than that for the base-case analysis,
there being about a 40% chance that this screening programme would be cost-effective at a threshold of
£20,000 per QALY, as indicated in the CEAC shown in Figure 14b.
Conclusions
Screening women for AAAs might become more cost-effective if one moved away from the options
adopted in NAAASP for men. Screening became more cost-effective if offered at age 70 years. Lowering
the threshold for considering surgery, or lowering the threshold for defining an AAA to a diameter of
2.5 cm, also made AAA screening for women slightly more cost-effective, but none of these changes,
when considered individually, brought the estimated ICER to below £20,000 per QALY gained.
The remaining possibility of finding a more cost-effective screening option for women was to combine the
alternative screening options. All combinations relating to screening age (65 or 70 years), intervention
threshold (4.5 cm, 5.0 cm or 5.5 cm) and diagnosis threshold (2.5 or 3.0 cm) have been investigated in this
chapter. Although many combined options gave similar cost-effectiveness estimates, the numerically best
option involved an invitation to screening at age 70 years, an aortic diameter of 2.5 cm defining an AAA
(with a 5-year surveillance interval for AAAs with a diameter of 2.5- to 2.9-cm AAAs) and consideration for
elective surgery at an AAA diameter of 5.0 cm. The estimated QALY gain was greater than the reference
case analysis (0.00200 vs. 0.00112 QALYs per woman invited). Combined with a greater incremental cost
than the reference case, principally due to an increased number of elective operations, the ICER was
estimated as £23,000 per QALY gained. The corresponding INMB at a threshold of £20,000 per QALY
gained was –£5.08 (95% uncertainty interval –£31.53 to £69.98); especially given the uncertainty in the
cost-effectiveness estimate, this does not provide a sufficient basis to initiate such an AAA screening
programme in women.
The results show that there is little difference, in terms of cost-effectiveness, if elective operations are
considered at 4.5 cm, 5.0 cm or 5.5 cm (except when maintaining screening at age 65 years with a 3.0-cm
diagnosis threshold). Lowering the intervention threshold increases both the QALYs gained and the
incremental costs, but in almost equal proportions. This near equality in cost-effectiveness perhaps
indicates the futility of arguments over which threshold is ‘better’.7,107
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FIGURE 14 Cost-effectiveness from the PSA of combined screening option 1. (a) Results on the cost-effectiveness
plane (the green and blue lines indicate WTP thresholds of £20,000 and £30,000 per QALY, respectively) and
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Chapter 9 Discussion and conclusions
Nationwide screening programmes for AAA in 65-year old men in Sweden108 and the UK109 have beensuccessfully introduced. Nevertheless, the death rate from AAAs has been much higher in England
than in the USA,110 even though only a minority of eligible men in the USA are screened.111 The
comparison of AAA mortality in England and the USA did not provide sex-specific data, but, if aneurysm
death rates are falling in English men, this higher overall mortality rate may imply an even greater disparity
in AAA death rates for women between England and the USA. The prevalence of AAAs is much higher in
smokers than never smokers. Historically, fewer women than men have smoked and women were also
slower to take up smoking than men. Therefore, it is unsurprising that the prevalence of AAAs has been
much lower in women than men. Up to now, this has been assumed to imply that screening women for
AAA would not be cost-effective. However, women have a higher risk of a small AAA rupture than men,
worse outcomes following a ruptured AAA and longer life expectancy; these factors would be favourable
for a screening programme. On the other hand, together with the lower prevalence in women, their lower
attendance rate in the Chichester trial33 and worse outcomes following elective AAA surgery would be
unfavourable for a screening programme. The overall balance in favour or against screening women for
AAA has, thus, been unclear.
Moreover, there may be screening options that would improve the cost-effectiveness of population
screening for AAAs in women. These include increasing the yield of detected AAAs (by screening at a higher
age, or lowering the aortic diameter threshold for defining an AAA in women), reducing the rates of AAA
rupture while under surveillance (by lowering the diameter threshold for considering elective surgery) and
reducing surveillance costs (by using longer surveillance intervals for the smallest AAAs). Another possibility
for reducing AAA deaths in women would be selective screening, for example, of high-risk groups such as
smokers, but this approach was not favoured by our PPI group.
The adoption of NAAASP for men was primarily based on the large MASS randomised screening trial,10
together with health economic modelling based on the trial. The MASS trial10 randomised 68,000 men aged
65–74 years and, ultimately, followed them up for an average of 13 years. The largest trial1 in women was
much smaller (9300 women randomised with follow-up for 5 years). An adequately powered randomised
trial to establish the value of AAA screening in women would have to be substantially larger than the MASS
trial10 with similar follow-up. Such a trial would be enormously expensive to undertake, and is unlikely ever
to be feasible. Given this, a detailed modelling study is the best way to address the uncertainties around
AAA screening in women. Moreover, it provides a way to investigate the relative value of a variety
of screening options, which would not be possible within the fixed protocol of a single randomised trial.
Development work
Discrete event simulation model
The DES model developed for this project was novel in a number of respects. First, in contrast to the
previous multistate Markov model, it modelled the progress of individuals rather than groups. Aortic
diameter expansion could, thus, be more precisely represented, allowing for the substantial heterogeneity
between people in growth rates; avoiding the use of arbitrarily defined categories for aortic diameters and
the awkward, but necessary, introduction of time-dependent transition rates in the multistate model;35 and
better accounting for uncertainty. Moreover, and importantly in the context of investigating AAA screening
for women, the modelling structure allowed the investigation of different screening options, which would
not be feasible in a single multistate model. The downside of individual modelling is the computational
requirements, as enough individuals have to be modelled to ensure that the results obtained are stable
and reliable. The computational demands also increase substantially when undertaking PSAs. This problem
was ameliorated to an important extent by appreciating that only those with an AAA had to be modelled
in detail in order to obtain precise estimates of incremental effects.
DOI: 10.3310/hta22430 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 43
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
The model developed also has potential for further use outside the present work. For example, with
parameters reflecting those for men rather than women, it can be used to investigate alternative screening
options for men, such as the choice of intervention threshold or the inclusion of subaneurysmal men
(aortic diameters of 2.5–2.9 cm) within the surveillance programme. This could suggest ways in which
NAAASP could be improved. The model could also be used for investigating selective screening, for
example, of women smokers, if sufficiently robust data on the parameters for this group could be
obtained. The model also has the potential to be used in other contexts, for example, internationally, by
specifying relevant parameter inputs. In practice, the problem is less in adapting the model, but more in
the likely unavailability of data on relevant parameters in new contexts and the assumptions that might
have to be made.
Prevalence and definition of abdominal aortic aneurysms in women
The systematic review of AAA prevalence was of key importance to this project, but a number of
limitations became apparent. First, the number of data in women was rather limited and complicated
by studies including different age groups being undertaken in different calendar years (so any secular
trends might influence prevalence estimates) and using different screening approaches (population
based, self-referred or physician initiated, and free, self-purchased or reimbursed) and ultrasound
measurement techniques (inner to inner aortic diameter, outer to outer, leading edge to leading edge or
unstated), although nearly all used 3.0-cm diameter as the minimum diameter for definition of an AAA.
Second, except for age and smoking status, rather few characteristics of the women invited (or screened)
were available (e.g. body size or diabetes mellitus, which may influence baseline arterial diameters and
AAA growth rates, respectively). However, it was clear that the prevalence of AAAs was much higher in
current smokers. In the future, it is possible that AAA prevalence in women may increase because of the
historical increase of smoking in women some decades ago.
The usual definition of an AAA in men is either a widest diameter > 50% greater than the suprarenal
aortic diameter or the widely used pragmatic definition of ≥ 3.0 cm. Women have smaller-diameter aortas
than men.21 Most of the screening studies did not hold individual participant data, but these were available
from two modestly sized studies (a Swedish study14 of 5140 women aged 70 years and a Danish study of
570 women aged 67 years), which we used to provide an estimate of the AAA diameter distribution in
women. Analysis of these data indicated that 2.5 cm might be a better minimum threshold diameter for
the definition of an AAA in women. The definition of an AAA in women had considerable impact on both
prevalence and cost-effectiveness estimates.
Data sources analysed
As AAAs have traditionally been considered a male-dominated disorder, female-specific data or inputs
required for the DES model were not readily available and had to be gathered for this project. Estimates
of over 40 female-specific parameters were required (see Tables 1–3). We were fortunate to have access to
several databases that could be explored, including those from the RESCAN study,35 EVAR-138 and other
trials of EVAR versus open repair in the elective setting, and the IMPROVE trial30 for emergency repairs.
Other female-specific input parameters for the model came from exploration of local data sources (e.g.
women dropping out of hospital-based surveillance programmes) or comparative reviews (e.g. proportion
of women at any age accepting invitation to screening, and incidental detection rates). In addition, UK
registries were explored for data about aneurysm repairs, particularly the NVR database and HES: analysis
of such data indicates that EVAR is used preferentially in the older groups and that AAA repair in those
aged > 80 years is now common. However, sadly, they showed that the mortality following elective repair
in women was unacceptably high, particularly for open repair, for which the figure was 8%. We also
obtained international data from the Vascunet collaboration.112
Based on the individual data in the RESCAN study,35 the AAA rupture rate in women increased by about
30-fold as the AAA diameter increased from 3.0 to 5.5 cm, and the AAA rupture risk was about four-fold
higher in women than men at the same AAA diameter. This might naively suggest that an AAA diameter
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threshold of 4.5 cm for considering elective surgery in women would correspond to the same balance
of risks and benefits as the choice of a diameter of 5.5 cm in men. However, because of the worse
elective surgery outcomes in women, there is a trade-off that comes into play, and this is reflected in the
cost-effectiveness analyses.
The analysis of the individual data for women in the NVR26 was important in a number of respects.
First, it substantiated in these recent UK data the overall higher mortalities in women than men for elective
operations, both EVAR and open AAA repair, as found in the systematic review. Second, it showed that the
proportion of patients actually receiving elective EVAR was lower in women than men, which paralleled
the difference in the proportion suitable for EVAR found in the systematic review. Third, it provided
reliable estimates of these parameters for emergency surgery for ruptured AAAs, while the literature review
undertaken for emergency surgery was less detailed and the data sparser than for elective surgery. Fourth,
it allowed the dependence of these parameters on age and AAA diameter for elective operations, and on
age for emergency operations, to be modelled. This was especially important when considering screening
options that changed the age at screening or intervention threshold; using overall figures in these analyses
would have been unrealistic.
In summary, the derivation of the female-specific inputs for the model used a very wide array of sources
and resources; it was a major task, taking over 1 year to complete.
Clinical effectiveness
The systematic reviews of elective AAA operations revealed that all relevant parameters were worse for
women than men. The proportion anatomically suitable for EVAR was lower in women (a disadvantage as
EVAR has a substantially lower operative mortality than open AAA repair), the non-intervention rate was
higher (i.e. more women were either turned down for an operation by the multidisciplinary health-care
team or refused an operation), and the operative mortalities associated with both EVAR and open AAA
repair were higher.
An integral part of screening programmes is the availability of safe treatments to ameliorate the clinical
course of the disease being screened for. In the present case, the aim of screening is to prevent the rupture
of an AAA, which carries an overall mortality of ≥ 80%.113 In men, the requirement for a safe treatment is
met, since the 30-day mortality from either endovascular or open elective repair is < 1% in NAAASP.109
These are excellent results, in part driven by a quality improvement programme for elective aneurysm repair
in the UK, following the information from the Vascunet collaboration27 that operative mortality rates were
higher in the UK than most other countries. Analysis of the Vascunet data112 did not identify sex as being
significantly associated with perioperative mortality in either univariate or multivariate analyses. However, in
this project three separate sources [namely (1) the systematic reviews, (2) NVR and (3) HES] identified
operative mortality after repair of intact aneurysms as being higher in women than men, for both
endovascular and open repair.
These results clearly show the particularly high operative mortality after open repair in women, where an
elective operation kills about 1 in 12 women. This raises the question of whether or not women should be
screened at all if the treatment is associated with such high mortality. There seems little to be gained from
the detection of occult disease if the treatment offered is not as safe as it should be. The observed high
mortality for AAA repair in women arguably fails to meet the criteria for an effective intervention that is
required for the institution of a screening programme in the UK. However, it is notable that perioperative
mortality is lower in men with screen-detected AAA than in men with incidentally detected AAA, and the
same effect may hold for women. Thus, women with screen-detected AAA may have lower perioperative
risk than that presented here, implying that screening should not be ruled out on the basis of perioperative
risk alone.
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Beyond screening, these findings raise important issues regarding AAA surgery. Given that the systematic
review indicated that fewer than half of women evaluated for repair have aortic morphology suitable for
EVAR,37 there currently is no safe treatment for more than half of women considered for elective repair.
Improving endograft technology, such as low-profile device delivery systems, may allow higher proportions
of women to be offered EVAR in the future and go some way to reduce the high non-intervention rate
seen in women.
Overall, in the UK, it is unlikely that screening women for AAAs would be considered clinically effective,
unless a new quality improvement programme can be successfully implemented to reduce the risks of
surgery in women. A quality improvement programme was introduced earlier by the Vascular Society26 to
reduce the operative mortality from elective AAA repair and has been successful in reducing the overall
mortality to < 3.5%. This programme focused on centre volumes and standardised processes (e.g. use of
red blood cell salvage systems) but there was never any attempt to look at sex-specific data. Given that our
systematic review showed 30-day operative mortality as being almost double in women compared with
men, and that the mortality difference between the sexes persisted in the NVR data97 after adjustment for
age and AAA diameter, it might be hypothesised that standard operating processes (e.g. perioperative
management of cardiovascular drugs) might have different physiological effects in older men and women.
If this were true, the centre volume–outcome relationship might be different for women and men. Some
of these considerations are included in the suggestions for further research.
Cost-effectiveness
Base-case and sensitivity analyses
The base-case cost-effectiveness analysis, which adopted the screening options used for men in NAAASP,
showed that the estimated life-years gained per woman invited was very small: 0.00285 life-years or 1.04
life-days. A small average life-years gain is expected in population screening, as the vast majority of those
invited are screened as normal and have no change in life expectancy. Nevertheless, the extremely small gain
in life-years in this base-case analysis is the main reason for the unfavourable cost-effectiveness results. Using
standard discounting for both costs and life-years, the ICER per QALY gained was estimated as £31,000. This
is above the threshold of £20,000 generally used by NICE as a basis for accepting health interventions for use
in the NHS. Moreover, there was considerable uncertainty in this cost-effectiveness estimate: in the PSA, the
INMB estimate of –£12.03 (at a threshold of £20,000 per QALY) had a 95% uncertainty interval of –£27.88
to £22.12. The probability that AAA screening is cost-effective at this WTP threshold is < 20%.
The sensitivity analyses undertaken did not change this conclusion. These also underlined the pivotal role
of AAA prevalence in determining the ICER. When the AAA prevalence was doubled, from 0.43% to
0.86%, the estimated ICER fell below £20,000 per QALY gained. A prevalence of 0.86% is beyond the
upper limit (0.80%) of the 95% CI for women aged 65 years derived from the systematic review. So only
an extreme change in prevalence, beyond what is likely to be compatible with the evidence, could lead to
a conclusion that AAA screening is cost-effective using standard criteria. However, the cost-effectiveness is
also sensitive to the exact shape of the distribution of aortic diameters (not just the prevalence), as shown
by replacing NAAASP-based distribution with one based on the Uppsala14 distribution. This emphasises the
need for better contemporary data on the distribution of aortic diameters in women at ages relevant
to screening.
Screening options in women
Screening women for AAAs might become more cost-effective if one moved away from the options
adopted in NAAASP for men. This was the purpose of the scenario analyses undertaken. As expected,
screening became more cost-effective if offered at age 70 or 75 years. Perhaps surprisingly, it was more
cost-effective at age 75 years than at age 70 years. Thus, the effect of increasing prevalence as age
increased, from 0.43% at age 65 years to 0.70% at age 70 years and 1.15% at age 75 years, outweighed
the more limited life expectancy remaining at older ages. Nevertheless, we adopted a screening age of
DISCUSSION AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
70 years rather than age 75 years in the final combined scenario investigated, for two reasons. First, the
estimated non-intervention rate for elective surgery applied in the model was not dependent on age; this
rate might become unrealistically low at higher ages as surgeons are likely to turn down many elderly
women for elective surgery, especially open AAA repair, for which the risks are substantial. Second, the
estimates for attendance at screening and AAA prevalence become more imprecise and potentially
unreliable at older ages.
Lowering the threshold for defining an AAA to 2.5 cm, lengthening surveillance intervals somewhat for
the smallest AAAs, or lowering the threshold for considering elective surgery to 5.0 or 4.5 cm, made AAA
screening for women slightly more cost-effective, but these changes considered individually did not bring
the ICER down below £20,000 per QALY gained.
The remaining possibility of finding a cost-effective screening option for women was to combine the
alternative screening options. The best one investigated combined invitation to screening at age 70 years,
an aortic diameter of 2.5 cm defining an AAA (with a 5-year surveillance interval for AAAs with a diameter
of 2.5–2.9 cm), and consideration for elective surgery at an AAA diameter of 5.0 cm. The estimated QALY
gain was greater than the base-case analysis (0.00200 vs. 0.00110 per woman invited). Combined with a
greater incremental cost than the base case, principally due to an increased number of elective operations,
the ICER was estimated as £23,000 per QALY gained. In the PSA, the corresponding INMB estimate of
–£5.08, at a threshold of £20,000 per QALY, also had a substantial 95% uncertainty interval of –£31.53
to £69.98.
Conclusion
The conclusion of these analyses is that the accepted criteria for an AAA screening programme in
women are not currently met with respect to either clinical effectiveness (low operative mortality rates)
or cost-effectiveness. We also did not find a combination of screening options for women that would
make population AAA screening cost-effective for the NHS at a WTP threshold of £20,000 per QALY.
Strengths and weaknesses
The study undertaken has a number of strengths. These include the use of individual simulation modelling,
allowing evaluation of multiple screening options; modelling aortic diameter as a continuous variable; use
of women-specific parameters whenever possible; systematic reviews undertaken for key parameters; and
extensive data sources reanalysed, including RESCAN,35 NVR and HES.
The study had some general limitations, including ones shared with many other long-term health economic
evaluations. These include the lack of any specific validation of the model for women against empirical
data; the problem that some parameters were poorly estimated or not specifically available for women;
and the fact that the relevance of some parameter values to current women in the UK was uncertain,
this being an uncertainty that is not fully represented by the PSA.
There are also some specific limitations that can be noted. First, not only is AAA prevalence a key
parameter, but the exact distribution of aortic diameters among women with an AAA is also important.
There was a lack of data on this point. Second, non-AAA mortality was taken to be the same for women
with an AAA as for women without an AAA, despite evidence that they may have a higher cardiovascular
risk.114 A higher cardiovascular risk would increase the effects of competing mortality in women for whom
screening is most beneficial and, therefore, decrease the value of screening overall. However, modelling
would be complex, as the dependence of cardiovascular mortality rates on aortic diameter would have to
be estimated, and no obvious data are available for this. Third, the model assumed that once a decision for
no elective intervention had been made, this would never be reversed in the future. This could be made
more clinically realistic, either in terms of the decision changing as an AAA grew further, or in terms of
the potential for intervention on adverse risk factors to reduce the risk of postoperative mortality so that an
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elective operation could take place later. These subtleties are difficult to model in the absence of relevant
reliable data. Fourth, the QoL adjustment adopted just depended on age and was not based on
contemporary data. More up-to-date information would have been preferable, QoL adjustments for a short
period after surgery could also have been included, and the possible beneficial or deleterious effects on
QoL of invitation to screening, and either subsequent reassurance or surveillance, have been ignored.
Again, there is a lack of robust quantitative evidence on these points.
Research recommendations
Based on our research, we make the following recommendations for future research in priority order:
1. Undertake a large-scale empirical study of the current attendance rate at screening, AAA prevalence and
exact aortic size distribution for women screened at relevant ages. This could include the investigation of
whether or not AAA screening, and positive or negative results, influence QoL.
2. Adapt the DES model to evaluate screening options in men, to assess whether or not NAAASP could
be improved.
3. Investigate why elective operative mortality for AAAs in women is so high and subsequently introduce
any necessary quality improvement programme to lower operative mortality.
4. Make the modelling software program more accessible so that it can be adapted for other contexts,
including internationally.
5. Undertake a comprehensive empirical study of current incidental AAA detection rates for women
(and also for men).
6. Identify relevant parameter estimates specifically for women smokers, and model the cost-effectiveness
of AAA screening in this group.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Patient and public involvement
Introduction
The aims of our PPI activities in this study were to (1) establish a group of women to provide input into
this specific project through reviewing project activities and aiding with the dissemination of project
outputs and (2) ensure that this group became a resource for future research in this area. We chose to use
traditional methods of PPI recruitment and supplement this with the use of social media to enhance PPI
group recruitment, as this approach had proven successful in previous work within the NIHR Leicester
Cardiovascular Biomedical Research Unit.
Generation of a subject-specific patient and public involvement group
Some of the key unknowns surrounding AAA screening for women relate to the acceptability of screening
and likelihood of attending for screening. Although we had access to an existing PPI group with the NIHR
Leicester Cardiovascular Biomedical Research Unit, this forum was deemed unsuitable for the purposes of
this project as the majority of the members were male and, because the group had been established for
nearly 8 years, many of the members were ‘lay experts’ whose opinions may not represent those of women
to be invited for AAA screening. Therefore, we set out to recruit a new, research-naive, group of women.
Recruitment via abdominal aortic aneurysm patient forum
The Leicester Vascular Surgery Unit and the Leicester NAAASP run an annual patient education forum
for men with small AAAs. The aim of this group is to provide information and advice to men with small
AAAs and their partners in order to prepare them for the clinical decision-making process around surgery,
and to provide general health advice. As part of this group, in June 2015, the issue of whether or not to
screen women for AAAs was specifically discussed with the 42 men in attendance. All these men and their
partners were asked if they would be willing to attend a meeting to discuss the issue of AAA screening
for women in more detail. Four men and two women subsequently attended a PPI meeting in July 2015
(see Patient and public involvement meeting 24 July 2015).
Recruitment via media
Because of the poor representation of women in the group recruited via our male patient forum, it was
decided that a more representative PPI group should be recruited. Initial efforts were based on social media
(website, micro-blogging applications, Biomedical Research Unit newsletters) but generated no responses.
Feedback from our existing Biomedical Research Unit PPI group and the PPI group recruited via our patient
forum indicated that this was likely to be due to the limited use of social media in the target group. To address
this, it was decided to engage traditional media outlets in a call for recruitment. Through direct contact with
the Leicester British Broadcasting Corporation (BBC) office, the project was featured on the regional television
news (BBC East Midlands Today) and on local radio (BBC Radio Leicester). The radio interview (two parts) is
available on the project website (www.screeningaaawomen.com/; accessed 1 March 2017). In response to
these activities, expressions of interest were received from 15 women, 11 of whom subsequently attended
and formed the ongoing PPI group for the project.
Patient and public involvement meetings
Patient and public involvement meeting 24 July 2015
The initial PPI meeting for the project was held on 24 July 2015, facilitated by Matthew J Bown. The PPI group
at this time consisted of the four men and two women recruited from the Leicester AAA patient forum. One
of the women was the wife of one of the men, but otherwise the group members were unrelated.
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At this meeting, a presentation was given to those attending detailing the background to the project. This
included the evidence for screening in men and why this evidence was not available for women. Broad
strategies regarding how this evidence may be gathered were discussed, including how to determine if
screening in women would be cost-effective. The concept of asking lay people to assist with the research
project was introduced, using the example of asking how women might respond to being asked to attend
for screening.
The group were specifically asked the following questions:
1. Whether or not women would want to attend screening for AAAs?
2. Is it acceptable to invite only women in high-risk groups?
3. Do women want to be screened?
4. What would prevent them from attending?
5. Would women want an operation to correct an AAA if it was offered, bearing in mind that the
operation is more risky in women than in men?
It was acknowledged by the group that only two women were present and all members had personal
knowledge of the disease. This could lead to the answers not being generalisable to the wider population
of women.
Following a general discussion on all of these points, the group felt that women were more health
conscious and may be more inclined to go for screening if offered. However, there were also mixed
feelings on whether or not women would want to be screened given that they have previously undergone
other forms of screening (they might be ‘fed up’ with screening). Some felt that the detection of an AAA
by screening may cause much anxiety among women, possibly because of the higher risks of treatment
(surgery). The group stated that people generally do not want to know too much about their health,
especially when there may not be a simple treatment for a condition detected by screening.
The group was also asked to consider:
1. What would the public want us to find out from this research project?
2. Is saving lives all that matters?
3. Should financial, personal, or psychological cost be a consideration in AAA screening?
There was a suggestion from the group that screening might be better added to well woman general
practitioner (GP) visits (and health checks for men). Overall, the group felt that if providing screening saved
lives at minimal psychological cost, it would be worthwhile. Financial and personal costs were not thought
to be an issue (but the group stated that this was because AAA screening is so cheap and easy).
The question was raised regarding what is happening in other countries and why can we not simply see if
their programmes work. It was pointed out that the UK is the only country with a national programme for
men and there are not programmes for women anywhere.
Attendees were asked how they find out information on their health in general and AAAs in particular.
Everyone agreed that websites were of some use, as was e-mail, but not many people in this age bracket
would use social media to find out health information.
The general feeling was that there is no media coverage of AAAs and, until you are asked to go for a
screening or are diagnosed with an AAA, you do not know what an aneurysm is. It was suggested that
this be addressed by local media coverage (e.g. local radio or television, church groups, local newspapers).
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Patient and public involvement meeting 12 January 2016
This meeting was the first meeting of the project-specific PPI group that had been recruited through the
radio and television engagement programme. Eleven women attended the meeting, none of whom had
previously been diagnosed with an AAA. Age information was not formally collected. One woman had
a strong family history of AAAs (two first-degree relatives) and one woman’s husband had previously
undergone an AAA repair. The majority (nine women) had family members who had been affected
by AAAs.
The same information was presented to this group as had been presented to the previously convened PPI
group and the group were asked the same set of questions.
The majority of the group thought that women would want to attend for AAA screening if invited.
However, they recognised that this may be a biased response as they all had an interest in this area owing
to having affected family members. The group thought that women were generally more accepting of
screening because they had been used to being screening for other diseases during their lives. They noted
that for the majority of those women screened the reassurance of a negative scan was very important and
well worth the financial cost of screening and the cost to the individual.
The concept of screening only high-risk groups, using the example of tobacco smoking, was the most
contentious area of discussion. Overall, the group thought that this would be unacceptable to the majority
of women, largely because they knew of anecdotal cases in which women had been diagnosed with an
AAA despite being non-smokers. Other high-risk groups, such as those with a family history of disease,
were discussed. The group were surprised that the NHS does not record family history of diseases in any
systematic manner and that this would be unavailable as a method to select women for screening.
The women in attendance were asked about age groups likely to attend for screening. It was proposed
that women would probably be invited for screening between the ages of 65 and 75 years. The group
wanted screening after age 75 years to still be done if the participant wanted this, although they did
recognise that this may not be financially viable.
Barriers to screening were discussed. The group thought the location of screening (especially given the
current model of community screening) was unlikely to have a negative influence on attendance. One
barrier to screening was the lack of knowledge among NHS staff of the possibility of AAAs in women and
that a reluctance of NHS staff to refer for screening, or to exclude women from screening, may have a
negative effect on uptake.
The group were asked about whether or not they would want to undergo AAA repair if this were
indicated, particularly with the knowledge that women have higher perioperative risk than men. The
women thought that, providing the overall risks were considered, most women would want to undergo
AAA repair. The effect of age on perioperative risk was raised by members of the group, who also
suggested that older women may not want screening as they would not want to know or undergo surgery
if diagnosed with an AAA.
Given the failure to engage a suitable group of women for PPI via social media, the use of social media for
PPI and for patient information was discussed. The groups acknowledged that very few people in this age
bracket would use social media to find out health information. There was an acknowledgement that public
awareness of AAAs needs to be improved. The group identified the common scenario in which individuals
know nothing about AAAs until the time of diagnosis. The best way of communicating with the likely
target groups was thought to be through face-to-face meetings, traditional media (local radio/television)
and community groups such as churches.
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Patient and public involvement meeting 15 August 2016
At the time this meeting was held, the project was in a data gathering/processing phase and minimal PPI
relevant updates had been made to project outputs. As one of the aims of the PPI activities for the project
was to set up a PPI group specific to screening women for AAAs, this meeting was used to develop the
discussion in this area. In order to provide a framework for this discussion, the main focus of the meeting
was to discuss a separate study, the Female Aneurysm screening STudy (FAST). FAST is a NIHR Research
for Patient Benefit (RfPB)-funded pilot of AAA screening for high-risk women with the main aims of
determining screening attendance and disease prevalence.
The FAST was presented to the group. In brief, FAST will be based in Leicestershire, Rutland and parts
of Northamptonshire, and will replicate the male screening programme processes. It will use the same
invitation process and information sheets as the male programme. Women will be invited based on their
risk of an AAA, with smokers, ex-smokers and those with a history of coronary artery disease forming the
three groups being assessed. Information on whom to invite will be taken from GP records, but these
records do not show women who have a first-degree relative with an AAA. However, accuracy of GP
records will need to be ascertained, as extracting data from GP records is costly.
The group thought FAST represented the next step in establishing an evidence base for AAA screening in
women, but were disappointed that the study was focused on high-risk groups. They felt that, as AAA
screening was simple and cheap, it should be offered more widely. The group reiterated the positive
psychological effects of a negative scan.
Patient and public involvement meeting 20 March 2017
In preparation for this final meeting, the main issues arising from the previous meetings were summarised.
These were surrounding the acceptability of AAA screening, the positive effects of a negative screen and
targeted screening. The following themes formed the basis for discussion:
l The PPI group’s perception of AAA screening is that it is highly acceptable and there is a good likelihood
that the uptake among women would be at least equivalent to that seen in men, or higher. Very few
physical or logistical barriers to the uptake of screening exist, but the lack of public knowledge regarding
AAAs is a significant area of need that should be addressed, preferably through traditional media outlets.
l One of the main positive aspects of screening for AAAs in women may be the psychological benefit
of a negative screening scan. Although no objective evidence for this effect exists (and, therefore, is a
potential avenue for future investigation), our PPI group felt that this was important. Furthermore, one
of the unifying motivations for the women to attend the PPI group was that they all wanted to be
screened for AAA themselves to obtain this reassurance.
l Targeted screening, particularly if the target group is smokers, is a contentious issue for the public. Given
the simplicity and low cost of AAA screening and positive psychological effect of a negative screen, our
PPI activities suggest that there is a public perception that there is no requirement to target screening.
Key to improving public understanding of AAA screening and/or the acceptability of targeted screening
at high-risk groups will be to provide information regarding the scale of AAA screening and the resultant
effect this has on the overall cost, and cost-effectiveness of AAA screening.
Preliminary discussion of these themes did not raise any additional points. Following this discussion, the
group was presented with the Plain English summary of the project results. The group provided feedback
on the presentation of results and edited the Plain English summary (these edits are incorporated into the
final version presented in this report). The group thought that the individual costs and the overall costs of
screening were important. Comparison of costs for screening with other common NHS interventions would
provide a good reference point for the public. After giving consent, all members present underwent an
aortic screening scan to get direct experience of the procedure.
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Following discussion of the project’s results and having undergone screening, the three themes were
discussed again. In addition, the group were asked to give opinions on what future research should be
performed and what further information the public would want.
All three themes were confirmed by the PPI group. Given the project’s results presented, some women
present thought that targeted screening may be better than no screening at all for women but questioned
the methods for identification of high-risk groups. Many of the women in the PPI group had an interest
in AAA because of a family history or personal knowledge of disease. There was a majority view that
screening based on family history of disease would be important. The group recognised the deficiencies in
clinical systems for recording this type of data. The suggestion was made that when an AAA is diagnosed,
NHS information systems should alert the relatives of the patient. The issues of confidentiality preventing
such a process were discussed. The PPI group felt that alternatives may be to (1) improve public awareness
of the increased risk associated with family history of AAAs and (2) provide information for patients with
an AAA to encourage them to tell their relatives of the diagnosis. The importance of improved QoL was
deemed to be extremely important for the women present. The group thought that the positive effects of
a negative screening scan should be investigated as a research priority going forward.
Summary
The PPI activities for the project achieved their primary aims. A research-naive group of women were
successfully recruited into a new PPI group and became fully engaged with the project. Direct and continual
involvement of the PPI group over the course of the project was maintained, including input into the Plain
English summary and prioritisation of future research. The group has now been established for the future
and is already contributing to the FAST, a NIHR RfPB-funded project focused on AAA screening in women.
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Appendix 2 Additional details for Chapter 2
Details of parameter estimates
Parameter estimates used in the 4-year validation model and 30-year contemporary model for men, and
distributions used for a PSA, are shown in Table 27.
TABLE 27 Parameter estimates used in the 4-year validation model and 30-year contemporary model for men, and
distributions used for a PSA
Parameter
4-year model 30-year contemporary model
Estimate Source Estimate PSA distribution Source
Baseline diameter distribution N/A NAAASP8 N/A N/A NAAASP8
Prevalence: Pr ≥ 3.0 cm at baseline 0.0497 MASS11 0.0134 N/A NAAASP8
Growth model parameters
β0 (log-cm) 1.272 MASS11 1.272 Multivariate normala MASS12
β1 (log-cm per year) 0.058 0.058
σ0 0.176 0.176
σ1 0.036 0.036
ρ 0.426 0.426
σw 0.075 0.075
Rupture model parameters
γ –16.263 MASS11 –16.263 Bivariate normalb MASS12
α 7.210 7.210
Probabilities
Require reinvitation 0.136 MASS11 0.136 Beta(4602,29237) MASS12
Attend screening 0.802 MASS11 0.750 Beta(93170,31022) NAAASP8
Non-visualisation of aorta 0.0121 MASS11 0.0121 Beta(329,26818) MASS12
Non-intervention
(contraindicated)
0.135 MASS11 0.125 Beta(69,481) MASS12
Proportion receiving elective
open vs. EVAR
1 MASS11 0.298 N/A NVR26
Elective open operative
mortality
0.0373
(0.0992c)
MASS11 0.0411 Beta(24,560) EVAR-138
Elective EVAR operative
mortality
N/A N/A 0.0161 Beta(10,612) EVAR-138
Emergency surgery after
rupture
0.441 MASS11 0.368 Beta(193,331) MASS12
Emergency open operative
mortality
0.356 MASS11 0.342 Beta(66,127) MASS12
continued
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Issues related to shrinkage in aortic growth estimates
The DES model has embedded within it a continuous-time linear mixed effects (LME) growth model to allow
individual aortic diameters to grow over time. Parameter estimates for this model are obtained from suitable
data sources (e.g. the MASS trial11,12 when validating the model in men). The LME model parameter estimates
(such as the average log-diameter at baseline, β0, and the average rate of growth on the log-diameter scale, β1)
are relevant to the AAA data used to fit the model. The MASS data used for the validation model in men are
restricted to individuals whose initial diameter is in the range 3.0–5.5 cm.98
The DES model first samples individual observed baseline diameters, γi0, from a relevant population
distribution (e.g. NAAASP) and then samples individual true baseline log-diameters, bi0, and rates of growth,
bi1, conditional on the observed diameter. The individual true baseline log-diameters can either be directly set
to the observed log-diameter (a non-shrunken estimate) or they can be drawn from a conditional normal
distribution based on their posterior distribution (a shrunken estimate). In the latter case, the true diameter is,
TABLE 27 Parameter estimates used in the 4-year validation model and 30-year contemporary model for men, and
distributions used for a PSA (continued )
Parameter
4-year model 30-year contemporary model
Estimate Source Estimate PSA distribution Source
Rates per person-year
Rate of postoperative AAA
deaths following elective open
N/A N/A 0.0007 Gamma(3,0.00023) EVAR-138
Rate of postoperative AAA
deaths following elective EVAR
N/A N/A 0.0077 Gamma(34,0.00023) EVAR-138
Dropout from surveillance 0.082 MASS11 0.057 Gamma(330,0.00017) MASS12
Incidental detection 0.0755 MASS11 0.0459 –4 log(1 – X) where
X∼Beta(19.56,1695.95)
Glover et al.12
Non-AAA death after
contraindication
0.234 MASS11 0.247 Gamma(41,0.006) MASS12
Non-AAA death Age
specific
MASS11 Age
specific
N/A ONS2
Other
µCT (cm) 0.2443 RESCAN
35 0.2443 N/A RESCAN35
σCT 0.190 Singh et al.95 0.190 N/A Singh et al.95
Delay from large AAA scan to
consultation (days)
71 MASS11 71 N/A MASS12
Delay from consultation to
elective surgery
59 MASS11 59 N/A MASS12
N/A, not available.
a PSA realisations generated from back transformation from a multivariate normal distribution with mean vector (β1, β0, log σ1,
log σ0, tanh
–1ρ, log σw ) and associated variance–covariance matrix:
1:99 × 10−6
1:71 × 10−6 3:01 × 10−5
0 0 0:001714
0 0 −1:9 × 10−5 0:000528
0 0 0:000483 4:84 × 10−5 0:002588
0 0 6:8 × 10−5 −1:4 × 10−6 9:26 × 10−6 8:09 × 10−5
0
BBBBBB@
1
CCCCCCA
.
b PSA realisations generated from a bivariate normal distribution with mean vector (α, γ) and associated
variance–covariance matrix:
1:001459
−1:650784 2:758093
 
.
c Via incidental detection.
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on average, shrunk towards the population mean baseline diameter estimated from the LME model, which
will be towards a diameter of > 3.0 cm (for example, the average baseline diameter in the MASS98 AAA
population used to fit the LME model described in Chapter 2, Modelling aortic growth and abdominal aortic
aneurysm rupture, is 3.6 cm). The degree of shrinkage increases for observed baseline diameters that are
further away from the population mean diameter, and so will affect diameters measured < 2.5 cm more than
those that are in the diameter range 3.0–4.4 cm.
Validation of growth model against 4-year Multicentre Aneurysm
Screening Study data
The consequences of using shrunken or non-shrunken baseline diameters in the DES are not entirely
obvious, and investigations of these revealed advantages and disadvantages of both. Based on 105 pairs of
individuals, a DES using non-shrunken baseline diameters resulted in poor 4-year validation performance
(Table 28). This occurs because the DES model and the LME model are now discordant, with the LME
model accounting for shrinkage in its parameter estimates whereas the DES simulation does not. This
results in estimated growth rates (and consequently rupture rates) for diameters observed above the
aneurysmal mean (3.6 cm) being too high. If shrunken estimates are used, then the 4-year validation
results look more reasonable. A third DES model that was investigated shrinks baseline diameters that
measure ≥ 3.0 cm at baseline but not those that measure < 3.0 cm. This model is seen to perform better
than the non-shrunken model and only one key event (number of men contraindicated who are screen
detected) has an E/O ratio of > ± 20%. The reason this third model was investigated is described next
[see Validation of growth model in subaneurysmal (2.6–2.9 cm) diameters].
TABLE 28 Expected/observed rate of events (%) in 4 years of follow-up
Event
E/O ratio (% of MASS98)
Non-shrunken
estimates
Shrunken
estimates
Shrunken estimates if γi0≥ 3.0
Non-shrunken estimates if γi0< 3.0
No screening invitation
Elective operation 106 98 106
Emergency operation 142 111 109
Rupture 136 114 106
AAA death 124 108 102
Non-AAA death 99 99 99
Invited to screening
Elective operation
Resulting from screen detection 121 113 118
Resulting from incidental detection 98 87 93
Emergency operation 109 109 102
Rupture 107 105 96
Contraindicated
Resulting from screen detection 116 131 143
AAA death 106 100 96
Non-AAA death 101 101 100
DOI: 10.3310/hta22430 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 43
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
Validation of growth model in subaneurysmal (2.6–2.9 cm) diameters
The next step was to investigate how different variations of the AAA growth model affected the growth
rates of individuals who have subaneurysmal diameters (2.6–2.9 cm) at baseline, for whom model
extrapolated estimates are used. Data from the Gloucestershire surveillance study115 were available on 1233
individuals with aortic diameters of 2.6–2.9 cm at screening. Figure 15 shows the cumulative incidence of
these individuals progressing to AAAs (diameter of ≥ 3.0 cm) over a 15-year period. Superimposed on the plot
are estimates of the number reaching the diagnosis threshold from the three DES models: (1) using shrunken
estimates of baseline diameters, (2) using non-shrunken estimates and (3) using shrunken estimates only for
baseline diameters measuring ≥ 3.0 cm and non-shrunken estimates otherwise. The model using shrunken
estimates can clearly be seen to overestimate the number of subaneurysmal individuals who progress to the
diagnosis threshold within the first 10 years, with the upwards shrinkage particularly evident at screening,
where > 20% are already presumed to be above the threshold. Meanwhile, the models with no shrinkage
(either for AAAs or aortic diameters measuring < 3.0 cm) give a much better fit to the Gloucestershire data.115
Owing to the poor 4-year validation results of the model that uses non-shrunken estimates throughout,
it was decided to progress with the model that only shrinks baseline diameters that measure ≥ 3.0 cm.
Validation of growth model in all screened normal individuals
A further consideration is the growth of aortic diameters for all screened normal individuals (measuring
< 3.0 cm). Although no direct evidence regarding the progression of these individuals exists, the rupture
rates in screened normal individuals in the MASS trial12 can be used to provide a comparison against the
outputs of the DES model. Figure 16 shows the empirical rupture rates from the MASS trial12 alongside
those estimated from two DES models: (1) a DES model with non-shrunken estimates < 3.0 cm with
growth allowed < 2.0 cm and (2) a DES model with non-shrunken estimates < 3.0 cm with no growth
allowed < 2.0 cm. The model that does not allow aortic diameters to grow < 2.0 cm gives a better fit to
the rupture rates seen in the MASS trial.12 The use of this model is further supported by the cumulative
incidence of those screened as normal progressing to the diagnosis threshold of 3.0 cm (both diagnosed
and undiagnosed AAAs) shown in Figure 17. The model that allows growth < 2.0 cm estimates that 19%
of all 65-year-old men will have an AAA within their lifetimes, compared with 10% using the model that
limits growth. This latter estimate appears to be more reasonable based on prevalence estimates seen in
the literature.
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FIGURE 15 Progression of subaneurysmal (2.6–2.9 cm at baseline) individuals to the diagnosis threshold of 3.0 cm
over a 30-year time horizon, and comparison with data from the Gloucestershire study.115
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Convergence of the incremental cost-effectiveness ratio using selective
versus non-selective sampling
As described in Chapter 2, Convergence, accurate estimates of incremental effects and costs and the derived
ICER and INMB can be obtained by selectively sampling only individuals above the diagnosis threshold.
Figure 18 shows how well this strategy performs. The green line shows the cumulative mean ICER for a DES
model run on 10 million pairs of individuals (using input parameters for women as described in Chapter 7).
Even after 10 million pairs of individuals, the ICER has not converged sufficiently to suggest accuracy of more
than approximately £5000 per QALY. Conversely, the DES model that samples only individuals above the
diagnosis threshold (3.0 cm in this case) converges to within £1000 per QALY after only 1 million pairs of
individuals. Therefore, the decision was taken to run all models described in Chapters 7 and 8 for 10 million
pairs of individuals using the selective sampling approach to get accurate estimates of incremental effects
and costs. When conducting the PSA, it was considered that 500,000 pairs of individuals for each PSA
iteration would be sufficient based on the trace plot shown in Figure 18.
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FIGURE 16 Rupture rates in those screened normal and compared with MASS trial10 data. Two DES models are
investigated: (1) with growth allowed < 2.0 cm; and (2) with no growth allowed < 2.0 cm.
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FIGURE 17 Cumulative incidence of progressing to ≥ 3.0 cm for screened normal individuals using a DES model
with and without growth for individuals who initially measure < 2.0 cm.
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FIGURE 18 Convergence of the ICER in a DES with (black line) and without (green line) selective sampling. The
selective sampling model is run for a total of 1 million pairs of individuals while the no selective sampling model is
run for 10 million pairs of individuals.
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Appendix 3 Additional figures and tables for
Chapter 3
Unique records identified through database
searching and screened
(n = 92)
Potentially relevant articles identified for further
full-text review
(n = 24)
7 articles (from 7 studies) and 1 unpublished
data set included in meta-analysis
Citations excluded based on titles or abstracts
using general criteria
(n = 68)
• Not relevant or not population level, n = 60
• Other publication or study types (editorial,
   review), n = 7
• Full-text unavailable (Japanese article), n = 1
Studies excluded
(n = 17)
• Did not meet inclusion criteria, n = 14
• The AAA detection rates not reported, n = 1
• Incomplete report, n = 1
• Duplicate subjects, n = 1
Articles identified from reference lists, 2
Data set provided by the author, 1 (unpublished)
Studies excluded from meta-analysis
(n = 2)
• Subgroup study, n = 1
• Article reporting minimum prevalence only, n = 1
FIGURE 19 Prevalence review: PRISMA flow chart.
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Unique records identified through database searching
(1 January 2005 to 2 September 2016) and screened
(n = 1591)
Records excluded
(n = 1573)
• Based on screening of titles
   or using general criteria,
   n = 1530
• After reviewing abstracts,
   n = 38
• Other publication or study
   types (review), n = 3
• Foreign language (Polish and
   Chinese), n = 2
Full-text articles assessed for eligibility
(n = 18)
Articles included in quantitative synthesis
(suitability for endovascular repair meta-analysis)
(n = 5)
Articles identified from reference lists
(n = 3)
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Full-text articles excluded
(n = 16)
• No sex-specific data, n = 9
• Fewer than 20 women, n = 4
• Patient selection bias, n = 3
FIGURE 20 Endovascular aneurysm repair suitability review: PRISMA flow chart.
Records excluded
(n = 557)
• Based on screening of titles or using
   general criteria, n = 550
• After reviewing abstracts, n = 7
Full-texta articles assessed for eligibility
(n = 8)
Articles included in quantitative synthesis
(non-intervention rates meta-analysis)
(n = 4)
Articles identified by hand-searching the 2016
abstracts from European Society for Vascular Surgery
(n = 1)
Full-text articles excluded
(n = 5)
• Focused on ruptured aneurysm, n = 3
• Data for men only, n = 1
• Did not provide the denominator
   for women assessed for repair, n = 1
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(n = 565)
In
cl
u
d
ed
El
ig
ib
ili
ty
Id
en
ti
fi
ca
ti
o
n
 a
n
d
sc
re
en
in
g
FIGURE 21 Non-intervention review: PRISMA flow chart. a, One publication65 only available in abstract form.
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Records identified through database searching
(1 January 2009 to 26 August 2016)
(n = 5411)
Records screened
(n = 4063)
Records excluded
(n = 4019)
Common reasons for exclusion:
no sex-specific outcome data,
fewer than 50 women, etc.
• Based on screening of titles
   or using general criteria,
   n = 3644
• After reviewing abstracts,
   n = 343
• Other publication or study
   types (review, letter,
   editorial), n = 32
Full-text articles assessed for eligibility
(n = 51)
Included in quantitative synthesis
(operative mortality meta-analysis)
(n = 8)
Additional records identified through
other sources
(n = 8)
Duplicates removed
(n = 1356)
Articles identified from reference lists
(n = 1)
Full-text articles excluded
(n = 44)
• No sex-specific 30-day
   mortality data, n = 33
• Elective repairs
   contaminated with
   emergency repairs, n = 4
• Study period starts before
   2000, n = 3
• Fewer than 50 women, n = 2
• Duplicate data, n = 2
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from reviews
(n = 7)
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FIGURE 22 Thirty-day operative mortality review: PRISMA flow chart.
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Pooled overall (I 2 = 96.26%)
Forsdahl (2009)49
Hupp (2007)52
Savji (2013)54
Palombo (2010)50
Study ID
Svensjö (2013)14
Ogata (2006)51
Hupp (unpublished)
Bulbulia (2013)53
0.74 (0.53 to 1.03)
1.53 (1.07 to 2.19)
0.94 (0.71 to 1.25)
0.44 (0.43 to 0.45)
1.10 (0.82 to 1.48)
Estimate (95% CI)
0.37 (0.24 to 0.58)
1.46 (0.94 to 2.28)
0.92 (0.63 to 1.32)
0.31 (0.28 to 0.35)
100.00
12.12
12.78
14.11
12.67
% weight
11.23
11.20
12.01
13.88
0.0 0.5 1.0 1.5 2.0
Prevalence (%)
FIGURE 23 Prevalence of AAAs in women aged ≥ 60 years: eight studies with screening performed between 2001
and 2012.
Never smoker
Ever smoker
Subtotal (I 2 = 83.82%)
Svensjö (2013)14
Hupp (unpublished)
Savji (2013)54
Forsdahl (2009)49
Subtotal (I 2 = 86.06%)
Svensjö (2013)14
Hupp (unpublished)
Savji (2013)54
Forsdahl (2009)49
Estimate (95% CI)
0.28 (0.09 to 0.93)
0.03 (0.00 to 0.25)
1.05 (0.50 to 2.18)
0.15 (0.07 to 0.33)
0.52 (0.22 to 1.24)
1.34 (0.82 to 2.19)
0.79 (0.50 to 1.25)
0.88 (0.57 to 1.34)
1.71 (1.34 to 2.19)
2.52 (1.70 to 3.70)
% weight
17.14
28.16
27.69
27.01
23.51
24.20
27.44
24.85
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Prevalence (%)
FIGURE 24 Prevalence of AAAs in women aged ≥ 60 years by smoking status. Derubertis et al.13 reported data on
smoking status in a subgroup of patients from the study by Savji et al.;54 the analysis included 10,012 women, with
a mean age of 69 years, with at least one cardiovascular risk factor screened between 2004 and 2006.
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BOX 1 Search strategy: prevalence review
ti,ab(prevalence OR incidence OR occurence OR frequency)
ti,ab(screening)
MESH.EXACT(“Aortic Aneurysm, Abdominal”)
EMB.EXACT(“abdominal aorta aneurysm”)
ti,ab(abdom[*6] near/5 aort[*2] near/5 (aneurysm[*1] or aneurism[*1]))
MESH.EXACT(“Female”) OR MESH.EXACT.EXPLODE(“Women”) OR MESH.EXACT.EXPLODE
(“Women’s Health”)
EMB.EXACT.EXPLODE(“female”) OR EMB.EXACT(“women’s health”)
ti,ab(female or females or woman or women)
MESH.EXACT(“Sex Factors”) OR MESH.EXACT(“Sex Distribution”) OR MESH.EXACT(“Sex Ratio”) OR
MESH.EXACT(“Sex Characteristics”)
EMB.EXACT(“sex difference”) OR EMB.EXACT(“gender and sex”) OR EMB.EXACT(“gender”) OR EMB.EXACT
(“sex ratio”)
ti,ab(gender or genders or sex)
Limits: start 1 January 2000; end 13 January 2016.
BOX 2 Search strategy: EVAR suitability review
MESH.EXACT.EXPLODE(“Endovascular Procedures”) OR MESH.EXACT.EXPLODE(“Stents”) OR MESH.EXACT
(“Vascular Surgical Procedures”) OR MESH.EXACT(“Blood Vessel Prosthesis”) OR MESH.EXACT(“Blood Vessel
Prosthesis Implantation”) OR MESH.EXACT(“Vascular Grafting”)
EMB.EXACT(“endovascular aneurysm repair”) OR EMB.EXACT(“aortic aneurysm endovascular graft”) OR
EMB.EXACT(“endovascular surgery”) OR EMB.EXACT.EXPLODE(“stent”) OR EMB.EXACT.EXPLODE(“blood
vessel graft”) OR EMB.EXACT(“endoprosthesis”) OR EMB.EXACT.EXPLODE(“vascular stent”) OR EMB.EXACT
(“aneurysm surgery”) OR EMB.EXACT(“vascular surgery”) OR EMB.EXACT.EXPLODE(“blood vessel prosthesis”)
OR EMB.EXACT.EXPLODE(“blood vessel transplantation”)
ti,ab(endovascular or endostent[*4] or stent[*4] or evar or fevar or pevar or endoprosthe[*4] or endograft[*4]
or graft[*4])
incraft or palmaz or zenith or dynalink or hemobahn or luminex* or memotherm or wallstent or viabahn or
nitinol or intracoil or tantalum or powerlink or talent or excluder or aorfix or endologix or anaconda or
triascular or cordis or endurant or quantum or aneurx or ancure or ankura or “e vita” or “e xl” or “endomed
endofit” or fortron or hercules or lifepath or ovation or treovance or ventana or nellix
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MESH.EXACT(“Aortic Aneurysm, Abdominal”)
EMB.EXACT(“abdominal aorta aneurysm”)
ti,ab(abdom[*6] near/5 aort[*2] near/5 (aneurysm[*1] or aneurism[*1]))
ti,ab(aaa or aaas or iaaa or iaaas)
ti,ab(abdom[*6] near/5 aort[*2] near/5 (balloon[*3] or dilat[*6] or bulg[*4] or expan[*6]))
MESH.EXACT(“Female”) OR MESH.EXACT.EXPLODE(“Women”) OR MESH.EXACT.EXPLODE
(“Women’s Health”)
EMB.EXACT.EXPLODE(“female”) OR EMB.EXACT(“women’s health”)
ti,ab(female or females or woman or women)
MESH.EXACT(“Sex Factors”) OR MESH.EXACT(“Sex Distribution”) OR MESH.EXACT(“Sex Ratio”) OR
MESH.EXACT(“Sex Characteristics”)
EMB.EXACT(“sex difference”) OR EMB.EXACT(“gender and sex”) OR EMB.EXACT(“gender”) OR EMB.EXACT
(“sex ratio”)
ti,ab(gender or genders or sex)
MESH(ah) OR MESH(anatom[*6]) OR MESH(morpholog[*6]) OR MESH.EXACT(“Iliac Artery”) OR
MESH(calcification)
EMB(anatom[*6]) OR EMB(morpholog[*6]) OR EMB.EXACT.EXPLODE(“pathological anatomy”) OR EMB.EXACT
(“neck circumference”) OR EMB.EXACT(“artery diameter”) OR EMB.EXACT(“blood vessel diameter”) OR
EMB.EXACT.EXPLODE(“iliac artery”) OR EMB.EXACT(“artery calcification”) OR EMB.EXACT(“calcification”) OR
EMB.EXACT(“blood vessel calcification”)
ti,ab(anatom[*6] or morpholog[*6] or diameter[*1] or circumference[*1] or size[*1] or calcif[*8] or angle[*1] or
angulat[4] or tortuous or tortuosit[*3] or calibre[*1] or calibre[*1] or “access vessel[*1]” or “iliac arter[*3]” or
“ileal arter[*3]” or “ilial arter[*3]” or aortoiliac or “aorto iliac”)
ti,ab(neck[*2] near/5 (aneurysm[*2] or aneurism[*2] or infrarenal or “infra renal” or aortic or proximal or short
or shorten[*2] or favourable or unfavourable or challenging or length[*1] or shape[*1] or hostile)) or ti,ab
(funnel or conical)
ti,ab(“instructions for use” or ifu or ifus)
Limits: start 1 January 2005; end 2 September 2016.
BOX 2 Search strategy: EVAR suitability review (continued)
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BOX 3 Search strategy: non-intervention review
MESH.EXACT.EXPLODE(“Endovascular Procedures”) OR MESH.EXACT.EXPLODE(“Stents”) OR MESH.EXACT
(“Vascular Surgical Procedures”) OR MESH.EXACT(“Blood Vessel Prosthesis”) OR MESH.EXACT(“Blood Vessel
Prosthesis Implantation”) OR MESH.EXACT(“Vascular Grafting”)
EMB.EXACT.EXPLODE(“blood vessel prosthesis”) OR (EMB.EXACT(“aorta graft”) OR EMB.EXACT(“blood vessel
transplantation”)) OR repair OR (endovascular surgery) OR (EMB.EXACT(“endovascular aneurysm repair”)
OR EMB.EXACT.EXPLODE(“aortic aneurysm endovascular graft”) OR EMB.EXACT.EXPLODE(“endovascular
surgery”)) OR (open surgery)
MESH.EXACT(“Aortic Aneurysm, Abdominal”)
EMB.EXACT(“abdominal aorta aneurysm”)
ti,ab(abdom[*6] near/5 aort[*2] near/5 (aneurysm[*1] or aneurism[*1]))
ti,ab(aaa or aaas or iaaa or iaaas)
ti,ab(abdom[*6] near/5 aort[*2] near/5 (balloon[*3] or dilat[*6] or bulg[*4] or expan[*6]))
MESH.EXACT(“Female”) OR MESH.EXACT.EXPLODE(“Women”) OR MESH.EXACT.EXPLODE(“Women’s Health”)
EMB.EXACT.EXPLODE(“female”) OR EMB.EXACT(“women’s health”)
ti,ab(female or females or woman or women)
MESH.EXACT(“Sex Factors”) OR MESH.EXACT(“Sex Distribution”) OR MESH.EXACT(“Sex Ratio”) OR
MESH.EXACT(“Sex Characteristics”)
EMB.EXACT(“sex difference”) OR EMB.EXACT(“gender and sex”) OR EMB.EXACT(“gender”) OR EMB.EXACT
(“sex ratio”)
ti,ab(gender or genders or sex)
(treatment refusal) OR (MESH.EXACT(“Refusal to Treat”)) OR (MESH.EXACT(“Patient Selection”))
COMORBIDITY AND MESH.EXACT(“Comorbidity”) OR (MESH.EXACT(“Risk Factors”)) AND (MESH.EXACT
(“Risk Assessment”))
(MESH.EXACT(“Elective Surgical Procedures”)) or ti,ab(“elective”)
(ti,ab(“treatment refusal” or “undergo treatment”)) OR (MESH.EXACT(“Refusal to Treat”)) OR (MESH.EXACT
(“Patient Selection”)) OR (“turn down” or “turndown”) OR (MESH.EXACT(“Palliative Care”)) OR palliat[*3] OR
(ti,ab(“nonoperated” or “non-operated”))
Limits: start 1 January 2005; end 2 September 2016.
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BOX 4 Search strategy: 30-day operative mortality review
MESH.EXACT.EXPLODE(“Aortic Aneurysm, Abdominal”) OR (abdominal aort*) AND aneurysm*
MESH.EXACT(“Blood Vessel Prosthesis”) OR MESH.EXACT(“Blood Vessel Prosthesis Implantation”) OR
MESH.EXACT(“Vascular Grafting”) OR repair OR (endovascular surgery) OR (open surgery) OR MESH.EXACT
(“Aortic Aneurysm, Abdominal – surgery”)
MESH.EXACT(“Aortic Aneurysm, Abdominal – mortality”) OR MESH.EXACT(“Aortic Aneurysm, Abdominal –
complications”) OR MESH.EXACT(“Hospital Mortality”) OR MESH.EXACT(“Minimally Invasive Surgical
Procedures – mortality”) OR MESH.EXACT(“Vascular Surgical Procedures – mortality”) OR
MESH.EXACT.EXPLODE(“Vascular Surgical Procedures : E.04.100.814 – adverse effects”) OR mortality
MESH.EXACT.EXPLODE(“Treatment Outcome”)
EMB.EXACT.EXPLODE(“abdominal aorta aneurysm”) OR (ti,ab(abdominal aort*) AND aneurysm)
EMB.EXACT.EXPLODE(“blood vessel prosthesis”) OR (EMB.EXACT(“aorta graft”) OR EMB.EXACT(“blood vessel
transplantation”)) OR repair OR (endovascular surgery) OR (EMB.EXACT(“endovascular aneurysm repair”) OR
EMB.EXACT.EXPLODE(“aortic aneurysm endovascular graft”) OR EMB.EXACT.EXPLODE(“endovascular
surgery”)) OR (open surgery)
ti,ab(female or females or woman or women)
MESH.EXACT(“Sex Factors”) OR MESH.EXACT(“Sex Distribution”) OR MESH.EXACT(“Sex Ratio”) OR
MESH.EXACT(“Sex Characteristics”)
EMB.EXACT(“sex difference”) OR EMB.EXACT(“gender and sex”) OR EMB.EXACT(“gender”) OR EMB.EXACT
(“sex ratio”)
ti,ab(gender or genders or sex)
(EMB.EXACT(“cardiovascular mortality”) OR EMB.EXACT.EXPLODE(“surgical mortality”)) OR
EMB.EXACT.EXPLODE(“mortality”) OR mortality
EMB.EXACT(“treatment outcome”)
Limits: start 1 January 2009; end 26 August 2016.
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TABLE 29 Characteristics of the studies included in the suitability for endovascular repair review
Reference,
country Patient base Suitability criteria
N–O
scorea N
Mean age
(years)
Mean aneurysm morphology
EVAR suitable,
n/N (%)
AAA
diameter
(mm)
Neck
diameter
(mm)
Neck
length
(mm)
Neck
angle
(α)a
Iliac or
access
artery
diameter
(mm)
Kristmundsson
2014,56 Sweden
All AAAs with CT scans
2006–7
Within any IFU for
excluder, endurant or
zenith flex grafts
ND 18–32mm
NL ≥ 10mm
NA ≤ 75°
IAD ≥ 7.5mm
3 41 women N/A 58.6 26.8 16.9 30.0 6.4 11/41 (27)
200 men N/A 64.9 27.0 22.8 46.3 8.2 108/200 (54)
Hultgren 2013,57
Sweden
All elective repairs in one
clinic 2006–8
ND ≤ 32mm
NL ≥ 15mm
NA ≤ 60°
≤ 7.5 mm IAD ≤ 20mm
5 32 women 72 56 – – – – 15/32 (47)
140 men 72 65 – – – – 80/140 (57)
Sweet 2011,58 USA All AAAs of> 4.0 cm
with CT scans
1997–2009
18mm ≤ ND ≤ 32mm
NL ≥ 15mm
NA < 60°
5 251 women 77 58 24 15 28 5.6 63/251 (25)
812 men 74 59 25 19 20 7.0 374/812 (46)
Park 2011,59 Korea All AAAs of > 4.0 cm
with CT scan between
2003 and 2010
Within any IFU for
AneuRx, excluder, talent,
or zenith grafts
ND ≤ 32mm
NL ≥ 10mm
NA ≤ 60°
IAD≥ 8mm
4 35 women 73 – – – – – 15/35 (43)
156 men 73 – – – – – 74/156 (47)
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TABLE 29 Characteristics of the studies included in the suitability for endovascular repair review (continued )
Reference,
country Patient base Suitability criteria
N–O
scorea N
Mean age
(years)
Mean aneurysm morphology
EVAR suitable,
n/N (%)
AAA
diameter
(mm)
Neck
diameter
(mm)
Neck
length
(mm)
Neck
angle
(α)a
Iliac or
access
artery
diameter
(mm)
Moise 2006,60 USA Patients evaluated for
EVAR between 2000
and 2003
ND ≤ 29mm
NL ≥ 15mm
NA ≤ 60°
IAD ≥ 7mm
4 41 women N/A – – – – – 15/41 (37)
199 men N/A – – – – – 128/199 (64)
IAD, internal iliac diameter; N–O, Newcastle–Ottawa; N/A, not available; NA, proximal neck angle; ND, proximal neck diameter; NL, proximal neck length.
a N–O score assesses selection, comparability and outcomes, with a maximum score of 10 points.
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TABLE 30 Characteristics of the studies included in the non-intervention review
First author, time period
N–O scorea
(n/8 points) Age information
Non-intervention
rate for men (%)
Non-intervention
rate for women (%)
Whittaker,66 January 2013 to
December 2015
5 N/A 83/389 (21) 24/65 (37)
Scott,64 January 2006 to
April 2012
5 Median overall 73 years 123/516 (24) 15/59 (25)
Gorst,65 July 2007 to
May 2011
5 Mean overall 82 years 58/254 (23) 29/78 (37)
Karthikesalingam,20
January 2008 to
December 2009
5 Mean overall 75 years 16/206 (8) 16/45 (41)
N/A, not available; N–O, Newcastle–Ottawa.
a N–O score for selection and outcome, with a maximum score of 8 points.
Note
All studies were from the UK. Karthikesalingham et al.20 is the only study from a specialist tertiary referral centre.
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TABLE 31 Characteristics of the studies included in the 30-day mortality review, ordered by date of AAA repair
First author,
country Repair date(s) Derivation of cohort Intervention
N–O score
(n/10 points) Women/men (N)
Mean age
(years)
30-day mortality,
EVAR (%)
30-day mortality,
open repair (%)
Nevidomskyte,67
USA
July 2010 to
September 2013
State-wide registry
VI-SCOAP
EVAR, open
repair
6 216 women 73.1 5/160 (3.1) 5/56 (8.9)
848 men 73.0 4/696 (0.6) 4/152 (2.6)
aChung,72 USA June 2003 to July 2012 Single centre EVAR 5 121 women N/Ab 2/121 (1.7) N/A
617 men 11/617 (1.8)
Lo,18 USA 2003–11 VSGNE EVAR, open
repair
7 820 women 75d 5/408 (1.2) 15/412 (3.6)
2777 men 72d 15/1660 (0.9) 19/1117 (1.7)
Mani,69 Sweden 2006–10 Swedvasc EVAR, open
repair
9 765 women N/A 10/329 (3) 17/436 (3.9)
3367 men 39/1669 (2.3) 23/1698 (1.4)
Ramanan,68 USA 2007–9 ACS NSQIP Open repair 7 728 women N/A N/A 34/728 (4.7)
2117 men 61/2117 (2.9)
Mehta,70 USA 2002–9 Single centre EVAR, open
repair
7 553 women N/A 11/344 (3.2) 12/209 (5.7)
1827 men 12/1248 (1.0) 27/579 (4.7)
aPowell,73 five
countriesc
2000–9 EVAR-1,38 ACE,78
DREAM,76 OVER77 RCTs
EVAR, open
repair
9 148 women 75.2 1/77 (1.3) 5/71 (6.9)
2545 men 71.3 15/1312 (1.1) 35/1233 (2.8)
Schermerhorn,71
USA
2008 only Medicare EVAR, open
repair
6 5421 women N/A 77/3657 (2.1) 123/1764 (7.0)
19,705 men 203/15590 (1.3) 214/4115 (5.2)
ACS NSQIP, American College of Surgeons National Surgical Quality Improvement Program; Medicare, national social insurance program; N/A, not available; Swedvasc, Swedish National
Quality Registry for Vascular Surgery; VI-SCOAP, Washington state Vascular-Interventional Surgical Care and Outcomes Assessment Program; VSGNE, Vascular Study Group of New England.
a Reports only asymptomatic intact AAAs.
b Provided only for the whole cohort: women: 77.8 (± 7.6); men: 74.7 (± 8.3), no separate age data for the late era.
c UK, USA, France, the Netherlands/Belgium, only patients operated from 2000 included in the current analysis.
d Median.
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Appendix 4 Additional tables for Chapter 4
TABLE 32 Parameter estimates for the base-case analysis (screening all 65-year-old women) and uncertainty
distributions for the PSA. Gamma(a,b) distribution is parameterised as a= shape and b= rate, with mean a/b
Parameter Source Estimate Distribution
Reinvitation NAAASP8 0.239 None
Attendance Chichester33 0.727 Beta(218,82)
Non-visualisation NAAASP8 0.0035 None
Prevalence Systematic review 60–69 year olds34 0.0043 LogN(–5.451,0.3232)
Aortic size distribution NAAASP (reweighted) See Aortic
diameter
distribution
N/A
AAA growth rates RESCAN (11 studies)35 N(µ,Σ)a
Slope (β1) 0.052
Intercept (β0) 1.33
Slope log-SD [log(σ1)] –3.28
Intercept log-SD [log(σ0)] –1.99
Arctanh correlation [atanh(ρ)] 0.41
Residual log-SD [log(σW)] –2.96
AAA rupture rates RESCAN35
Association with diameter (γ1) 5.47 1:5892 −2:2178
−2:2178 3:1406
 
Intercept (γ0) –12.40
Dropout from surveillance NAAASP8 0.0546 Gamma(1072,19650)
Incidental detection New Zealand study,36 population
data and prevalence estimate
0.0293 Gamma(40,1364)
Time from referral scan to
consultation (days)
NAAASP8 10.6 N/A
Mean difference in CT vs.
ultrasound scan measurement (mm)
RESCAN (4 studies)35 2.44 N/A
Measurement error SD for a CT
scan (mm)
Singh et al.95 1.9 N/A
Decision at consultation: proportion
contraindicated
Four UK hospitals37 0.342 Logit(p) ≈ normal
(–0.654, 0.1352)
Time from consultation to elective
surgery (days)
NAAASP8 70.8 N/A
N/A, not applicable.
a µ = ( 0:052 1:33 −3:28 −1:99 0:41 −2:96 ),
Σ =
0:000015
6:5 × 10−6 0:000568
0:000028 −0:000752 0:009516
0:000186 −0:001364 0:005153 0:011569
−0:000125 −0:000418 −0:000047 0:000843 0:011419
−0:000087 −0:001800 0:002401 0:005566 0:005260 0:013688
0
BBBBBB@
1
CCCCCCA
.
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TABLE 33 Data on invitation and attendance from NAAASP8 for the 2013/14 and 2014/15 cohorts
Number 2013/14 2014/15 Total
Eligible men 304,381 294,253 598,634
Offered an appointment 300,667 293,709 594,376
Declined screening 8738 8620 17,358
Attended after first invite 210,845 205,294 416,139
Who did not attend first appointment 80,463 79,022 159,485
Who attended following DNA 31,829 31,642 63,471
Conclusively tested 235,339 232,183 467,522
With at least one cancelled appointment 621 773 1394
Reinvited 71,725 70,402 142,127
Proportion reinvited 0.2386 0.2397 0.2391
DNA, did not attend.
TABLE 34 Data on visualisation of the aorta from NAAASP8 for the cohorts 2013/14 and 2014/15
Number 2013/14 2014/15 Total
Men visualised at first screen 232,546 231,203 463,749
Men non-visualised at first screen 3803 2979 6782
Men subsequently visualised 2878 2252 5130
Total non-visualised 925 727 1652
Proportion non-visualised 0.0039 0.0031 0.0035
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TABLE 35 Description of studies in the RESCAN study16 that recruited both men and women
Study
Mean
calendar year
at baseline
Threshold for
intervention
(cm)
Measurement
modalities used
Internal/external
diameter
measured
Number,
men/women
Mean follow-up,
men/women
(years)
Number of small
AAA ruptures,
men/women
Crude rupture rate
(per 1000 person-years),
men/women
Chichester, UK 1999 6.0 (later 5.5) Ultrasound only Internal 1405/99 4.45/4.42 43/8 6.88/18.26
Edinburgh, UK NAa 5.5 Ultrasound only External 670/382 2.89/2.42 NA/NA NA/NA
Leeds, UK 2004 5.5 Ultrasound and CT External 220/47 3.27/3.14 NA/NA NA/NA
Manchester,
UK
2005 5.5 Ultrasound only External 837/258 2.41/2.41 6/5 2.97/8.03
Tromsø,
Norway
1995 5.5 Ultrasound only External 179/45 8.59/8.16 2/2 1.30/5.45
PIVOTAL, USA 2007 5.0 Ultrasound and CT External 619/96 0.92/0.96 0/1 0.00/10.84
Propranolol,
Canada
1996 5.0 or 5.5 by
centre
Ultrasound only External 460/88 2.47/2.39 3/0 2.64/0.00
Galdakao,
Spain
2001 5.0 Ultrasound and CT External 859/64 3.93/2.55 5/1 1.47/6.14
Stirling, UK 2003 5.5 Ultrasound and CT No set protocol 331/125 3.08/3.34 4/5 3.92/11.98
Gävle, Sweden 2003 5.0 or 5.5 by
centre
Ultrasound only External 184/59 2.46/2.52 1/0 2.21/0.00
UKSAT, UK 1993 5.5 Ultrasound and CT External 1747/480 2.38/2.65 32/28 7.68/22.00
NA, not available.
a The Edinburgh study provided data only at 6-month intervals with no exact dates.
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TABLE 36 Parameter estimates from mixed-effects growth models for each RESCAN study16 and overall (with SE)
Study β0 β1 log(σ0) log(σ1)] atanh(ρ) log(σW)
Chichester, UK 1.22 0.035 –1.68 –2.73 1.00 –2.21
Edinburgh, UK 1.34 0.074 –1.79 –3.27 0.14 –3.05
Leeds, UK 1.31 0.061 –1.86 –3.92 0.76 –2.43
Manchester, UK 1.37 0.049 –1.84 –3.35 0.49 –3.15
Tromsø, Norway 1.19 0.046 –2.12 –3.54 0.47 –2.94
PIVOTAL, USA 1.47 0.033 –2.98 –3.89 0.76 –3.17
Propranolol, Canada 1.32 0.045 –2.07 –2.97 –0.05 –3.01
Galdakao, Spain 1.32 0.058 –1.82 –3.18 0.74 –2.84
Stirling, UK 1.33 0.054 –1.66 –3.40 0.25 –2.75
Gävle, Sweden 1.37 0.055 –2.15 –3.26 0.13 –3.49
UKSAT, UK 1.42 0.062 –1.96 –3.11 0.39 –3.46
Pooled (two-stage multivariate
meta-analysis)
1.33 (0.02) 0.052 (0.004) –1.99 (0.11) –3.28 (0.10) 0.41 (0.11) –2.96 (0.12)
I2 (%) 98 87 97 85 77 99
TABLE 37 Comparisons between model predicted and empirical probabilities of reaching diagnosis and
intervention thresholds for women in RESCAN35
Baseline size (cm) Proportion reaching 5.5 cm (%)
Observed
range
Diameter for
prediction
Observed in 5 years
(95% CI)
Predicted in
5 years
Observed in 10 years
(95% CI)
Predicted in
10 years
3.0–3.4 3.25 2.1 (0.7 to 6.5) 4.5 33.5 (22.3 to 48.3) 35.6
3.5–3.9 3.75 18.6 (12.4 to 27.4) 25.2 58.7 (42.4 to 75.8) 63.4
4.0–4.4 4.25 48.7 (37.9 to 60.9) 59.2 77.6 (55.1 to 93.8) 84.4
4.5–4.9 4.75 89.1 (77.3 to 96.4) 84.2 a 94.1
5.0–5.4 5.25 a 95.9 a 98.1
a Survival probability not estimated owing to no individuals remaining at risk.
TABLE 38 Characteristics of six RESCAN35 studies that recruited both men and women for analysis of rupture rates
Item Females Males Total
Number of individuals 1071 5358 6429
Number of contributing studies 6 6 6
Number of ruptures (occurring before 5.5-cm threshold) 49 92 141
Length of follow-up to rupture event/censoring date, mean (SD) (years) 3.1 (3.0) 3.4 (3.3) 3.4 (3.3)
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TABLE 39 Pooled estimates obtained from the rupture submodel
Parameter Estimate (SE) I2 Interpretable parameter Value
γ0 –12.40 (1.77) 75% (43, 89) Baseline hazard, per 100 person-years (for a
5.0-cm AAA female)
2.74 (0.94); p= 0.004
γ1 5.47 (1.26) 82% (61, 91) Hazard ratio per 2% increase in AAA diameter 1.11 (0.03); p< 0.001
γ2 –1.46 (0.23) 25% (0, 68) Hazard ratio for males vs. females (reference) 0.23 (0.05); p< 0.001
A method of moments estimator was used to obtain multivariate meta-analysis estimates due to lack of convergence with
restricted maximum likelihood.
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Appendix 5 Additional figures and tables for
Chapter 5
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FIGURE 25 Cumulative hazard of a reintervention after elective EVAR or open AAA repair, based on the EVAR-1
trial:38 men and women combined. Nelson–Aalen estimates of cumulative hazard, with exponential piecewise-
constant survival model fits where time period is split into three epochs (0–30 days, 31–120 days and > 120 days),
with censoring for mortality.
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FIGURE 26 Sex differences in first reintervention rates by operation received, based on the EVAR-1 trial.38
Kaplan–Meier plots with censoring for mortality.
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FIGURE 27 Rate of AAA-related deaths after successful elective EVAR or open repair, based on the EVAR-1 trial:38
men and women combined. Kaplan–Meier plots (95% CIs) with exponential survival model fits, with censoring for
mortality from other causes.
TABLE 40 Parameters (SEs) estimated from logistic regressions for elective AAA repair based on the NVR
Parameter Proportion receiving EVAR
In-hospital operative
mortality after EVAR
In-hospital operative
mortality after open repair
Model (Equation 26), use of the NVR data as a source of parameter estimates in women
Sample size 18,693 11,758 6935
aF 0.348 (0.043) –4.022 (0.210) –2.596 (0.130)
aM 0.205 (0.046) –0.922 (0.241) –0.572 (0.145)
Model (Equation 27), use of the NVR data as a source of parameter estimates in women
Sample size 17,062 10,590 6472
aF 0.702 (0.056) –3.910 (0.217) –2.336 (0.165)
aM 0.529 (0.062) –1.125 (0.264) –0.385 (0.192)
b1F 0.095 (0.007) 0.002 (0.032) 0.064 (0.022)
b1M –0.001 (0.008) 0.089 (0.037) 0.024 (0.024)
b2F –0.303 (0.053) –0.028 (0.257) 0.077 (0.128)
b2M 0.002 (0.055) 0.310 (0.276) 0.043 (0.138)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
TABLE 41 Parameters (SEs) estimated from logistic regressions for emergency AAA repair based on the NVR
Parameter Proportion receiving EVAR
In-hospital operative
mortality after EVAR
In-hospital operative
mortality after open repair
Model (Equation 26), use of the NVR data as a source of parameter estimates in women
Sample size 4552 862 3690
aF –1.599 (0.095) –1.099 (0.201) –0.413 (0.080)
aM 0.173 (0.104) –0.245 (0.221) –0.124 (0.088)
Model (Equation 27), use of the NVR data as a source of parameter estimates in women
Sample size 4549 861 3688
aF –1.548 (0.096) –1.150 (0.211) –0.343 (0.084)
aM 0.289 (0.106) –0.116 (0.231) 0.103 (0.095)
b1F 0.041 (0.014) 0.061 (0.027) 0.033 (0.012)
b1M 0.003 (0.015) –0.011 (0.030) 0.031 (0.013)
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